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  Eagle	  medium	  
HIV:	  human	  immunodeficiency	  virus	  
HSP90:	  heat	  shock	  protein	  90	  




INK4a:	  cyclin-­‐dependent	  kinase	  inhibitor	  
KCl:	  potassium	  chloride	  
KEGG:	  Kyoto	  encyclopedia	  of	  genes	  and	  genomes	  
KO:	  knockout	  
LB:	  Luria	  broth	  
LOF:	  loss	  of	  function	  
loxP:	  locus	  of	  crossover	  in	  P1	  
MADM:	  mosaic	  analysis	  with	  double	  markers	  
Na2HPO4	  ·∙	  7H2O:	  sodium	  phosphate	  dibasic	  eptahydrate	  
NaCl:	  sodium	  chloride	  
NAFBS:	  North	  America	  fetal	  bovine	  serum	  
NG2:	  neuronal-­‐glial	  antigen	  2	  
NP:	  neural	  precursor	  
NPM:	  nucleophosmin	  
NSC:	  neural	  stem	  cell	  
OPC:	  oligodendroglial	  precursor	  cell	  
PcG:	  Polycomb	  group	  	  
PCR:	  polymerase	  chain	  reaction	  
PDGFB:	  platelet	  derived	  growth	  factor	  b	  




PRC:	  Polycomb	  repressive	  complex	  
RIPA:	  radioimmunoprecipitation	  assay	  
RNA:	  ribonucleic	  acid	  
rRNA:	  ribosomal	  RNA	  
RTK:	  receptor	  tyrosine	  kinase	  
SDS:	  sodium	  dodecyl	  sulphate	  
SDS-­‐PAGE:	  SDS-­‐polyacrylamide	  gel	  electrophoresis	  
SET:	  SU(VAR)3-­‐9,	  E(z),	  trx	  	  
SVZ:	  subventricular	  zone	  
TAE:	  Tris	  base,	  acetic	  acid,	  EDTA	  
TAT:	  trans-­‐activator	  of	  transcription	  
TBS-­‐T:	  tris-­‐buffered	  saline	  with	  Tween	  20	  
TCGAN:	  The	  Cancer	  Genome	  Atlas	  Network	  
TE:	  Tris,	  EDTA	  
TPC:	  tumor	  propagating	  cell	  
tRNA:	  transfer	  RNA	  






Gliomas	   represent	   80%	   of	   the	   central	   nervous	   system	   tumors.	   Historically,	   they	   have	   been	  
classified	  by	  the	  World	  Health	  Organization	  according	  to	  their	  supposed	  cell	  of	  origin	  and	  to	  their	  
malignancy	   grade.	   Among	   gliomas,	   astrocytomas	   are	   the	   most	   common	   and	   are	   classified	  
histologically	  with	  a	  four	  grade	  system	  where	  grade	  IV	  corresponds	  to	  the	  most	  malignant	  form,	  
also	   known	   as	   glioblastoma	   multiforme	   (GBM).	   Furthermore,	   in	   recent	   years	   a	   molecular	  
characterization	  has	  been	  defined	  for	  GBM.	  Different	  subtypes	  have	  been	  identified,	  each	  of	  them	  
over	  expressing	  a	  specific	  group	  of	  genes.	  
For	  decades,	   it	  has	  been	  assumed	   that	   cancer	  was	   caused	  only	  by	  genetic	  alterations.	  Now	   the	  
view	   is	   changed	   and	   cancer	   is	   considered	   both	   a	   genetic	   and	   epigenetic	   disease.	   It	   was	  
demonstrated	   indeed	   that	  epigenetic	   silencing	  of	  genes	   through	  DNA	  or	  histone	  methylation	  at	  
their	   promoters	   can	   be	   an	   alternative	   way	   to	   achieve	   their	   loss	   of	   function;	   in	   addition,	   DNA	  
demethylation	  of	   constitutive	  heterochromatin	  can	  promote	  genome	   instability.	   In	   this	   context,	  
we	   refer	   to	   epigenetics	   as	   the	   sum	   of	   heritable	   changes	   in	   phenotype	   and/or	   gene	   expression	  
without	  altering	  the	  primary	  DNA	  sequence.	  	  
Methylation	  of	  lysine	  27	  on	  histone	  H3	  is	  a	  post-­‐translational	  modification	  that	  is	  mediated	  by	  the	  
histone	  methyltransferase	  complex	  known	  as	  Polycomb	  Repressive	  Complex	  2	  (PRC2)	  through	  its	  
active	   subunit,	   Enhancer	   of	   Zeste	   Homolog	   2	   (EZH2).	   This	   facultative	   heterochromatin	   mark	  
promotes	  the	  recruitment	  of	  Polycomb	  Group	  (PcG)	  proteins	  to	  achieve	  gene	  silencing.	  
PcG	  proteins	  have	  been	  shown	  to	  play	  a	  major	  role	  in	  embryonic	  development	  and	  adult	  somatic	  
cell	   differentiation.	   Initial	   studies	   on	   embryonic	   stem	   cells	   (ESCs)	   showed	   that	   Polycomb	  
Complexes	  are	  required	  to	  maintain	  stem	  cell	  identity.	  However	  further	  investigation	  showed	  that	  
this	  process	  is	  much	  more	  elaborated	  and	  the	  current	  model	  proposes	  that	  PcG	  proteins	  function	  
dynamically	  during	  development	  and	  differentiation	  to	   lock	  off	  the	  expression	  of	  alternative	  cell	  
fate	  regulators	  in	  any	  particular	  lineage.	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Moreover	  EZH2	  and	  other	  Polycomb	  members	  have	  been	  found	  to	  be	  dysregulated	  in	  a	  variety	  of	  
cancer	   types.	   EZH2	   is	   overexpressed	   in	   tumors	   like	   prostate,	   breast	   and	   bladder,	   and	   BMI1,	   a	  
member	  of	  Polycomb	  Repressive	  Complex	  1	   (PRC1),	   is	  over	  expressed	   in	  GBM,	  causing	  aberrant	  
expression	  of	  neural	  stem	  cell	  (NSC)	  markers	  and	  preventing	  apoptosis.	  It	  was	  also	  demonstrated	  
that	  genes	  that	  are	  directly	  regulated	  by	  Polycomb	  in	  ESCs	  are	  up	  to	  12-­‐fold	  more	  likely	  to	  have	  
cancer	  specific	  DNA	  hypermethylation	  at	  their	  promoters	  than	  other	  genes.	  
In	   my	   project	   I	   have	   pursued	   two	   main	   questions.	   First,	   I	   wanted	   to	   assess	   whether	   EZH2	   is	  
required	  for	  glioma	  initiation.	  Moreover,	  since	  tumor-­‐initiating	  cells	  have	  been	  found	  also	  in	  GBM,	  
I	  wanted	  to	  check	  if	  EZH2	  is	  required	  to	  maintain	  this	  stem	  cell	  pool.	  	  
In	  order	  to	  address	  those	  questions,	  I	  chose	  a	  well	  established	  animal	  model	  of	  GBM	  which	  relies	  
on	   the	   loss	   of	   Ink4a/Arf	   together	  with	   the	   over	   expression	   of	   EGFRvIII.	   A	   conditional	   knockout	  
allele	  for	  Ezh2	  was	  introduced	  in	  order	  to	  remove	  this	  protein	  at	  different	  stages	  of	  the	  disease.	  
With	   this	   work	   I	   could	   demonstrate	   that	   while	   EZH2	   is	   required	   for	   the	   establishment	   of	   the	  
tumor,	   it	  can	  be	  dispensable	   for	   its	  maintenance.	  The	  Polycomb	  axis	  acts	  early	  on	  during	  tumor	  
formation,	  causing	  the	  relocation	  of	  H3K27me3	  in	  an	  instructive	  manner	  and	  this	  process	  seems	  
to	  be	  fundamental	  in	  order	  to	  achieve	  the	  full	  transformation	  of	  the	  cells.	  I	  was	  able	  to	  show	  that	  
EZH2	  is	  dispensable	  for	  glioma	  maintenance,	  pointing	  to	  a	  unique	  window	  of	  Polycomb	  sensitivity	  
that	   characterizes	   the	  primary	  phase	  of	   gliomagenesis	   prior	   to	   the	  establishment	  of	   the	  glioma	  






Glial	   tumors	   or	   gliomas,	   as	   the	   name	   implies,	   are	   tumors	   thought	   to	   originate	   from	   the	   glial	  
compartment	   of	   the	   brain.	   Gliomas	   represent	   the	  most	   common	   central	   nervous	   system	   (CNS)	  
malignancies	  in	  adults,	  accounting	  for	  about	  80%	  of	  the	  CNS	  cancers.	  They	  include	  astrocytomas,	  
oligodendrogliomas,	   oligoastrocytomas	   and	   ependymomas	   and	   the	   nomenclature	   originally	  
reflected	   the	   morphology	   of	   the	   cells	   found	   in	   the	   tumor	   mass.	   This	   thesis	   is	   focused	   on	  
astrocytomas	  and	  oligodendrogliomas	  and	  I	  do	  not	  discuss	  ependymomas	  further.	  	  
	  
1.1	  Histopathological	  classification	  
The	  first	  comprehensive	  classification	  of	  tumors	  of	  the	  nervous	  system	  dates	  back	  to	  1979,	  when	  
the	   World	   Health	   Organization	   (WHO)	   defined	   the	   guidelines	   for	   the	   histological	   typing	  
[“Histological	  typing	  of	  tumors	  of	  the	  central	  nervous	  system”	  -­‐	  Geneva,	  1979].	  Several	  advances	  
have	  been	  made	  in	  past	  few	  decades,	  including	  immunohistochemical	  typing	  and	  genetic	  profiling	  
but	  also	  epidemiology,	  clinical	  symptoms	  associated	  to	  the	  disease,	   imaging	  data,	  prognosis	  and	  
predictive	  factors	  [Louis	  et	  al.	  2007].	  The	  latest	  edition	  was	  issued	  by	  the	  WHO	  in	  2007.	  	  
Gliomas	   are	   part	   of	   a	   broader	   group	   of	   tumors	   arising	   from	   neuroepithelial	   tissue.	   Historically,	  
they	   have	   been	   classified	   according	   to	   the	   supposed	   cell	   of	   origin	   and	   they	   are	   divided	   into	  
astrocytomas,	   oligodendrogliomas	   and	   oligoastrocytomas	   (table	   1).	   The	   classification	   is	  
accompanied	   by	   a	   grading	   scheme,	   which	   defines	   four	   grades	   of	   malignancy	   (Grade	   I-­‐IV)	   with	  
grade	  I	  being	  the	  least	  and	  grade	  IV	  the	  most	  malignant	  form	  of	  the	  tumor.	  The	  grading	  helps	  in	  
predicting	   the	   behavior	   of	   the	   disease,	   the	   prognosis	   and	   in	   choosing	   the	   most	   appropriate	  























Table	  1.	  WHO	  classification	  and	  grading	  of	  gliomas	  [adapted	  from	  “WHO	  classification	  of	  tumours	  of	  the	  central	  
nervous	  system”	  -­‐	  Lyon,	  2007]	  
	  
Particular	  attention	  has	  been	  dedicated	  at	   the	  grading	  of	  astrocytic	   tumors,	  which	  can	  span	  the	  
entire	  grade	  spectrum.	  This	  special	  attention	  is	  related	  to	  the	  biology	  that	  underlies	  this	  class	  of	  
tumors	   as	   they	   are	   the	  most	   frequent	   form	   of	   glioma.	   Current	  models	   propose	   two	   ontogenic	  
ways	  through	  which	  the	  most	  malignant	  stage,	  also	  known	  as	  glioblastoma	  multiforme	  (GBM),	  is	  
achieved.	   In	   one	   case,	   astrocytomas	   arise	   as	   low	   grade	   tumors	   (grade	   II)	   and	   by	   stepwise	  
accumulation	  of	  genetic	  alterations	  progress	  to	  anaplastic	  astrocytoma	  (grade	  III)	  and	  eventually	  
to	  glioblastoma	   (grade	   IV).	  These	  GBMs	  are	  classed	  as	   secondary	  glioblastomas	  and	  are	   formed	  
within	  5-­‐10	  years	  from	  the	  initial	  astrocytoma	  diagnosis.	  By	  contrast,	  primary	  GBMs	  arise	  without	  
any	  previous	  clinical	  history,	  thus	  it	  is	  likely	  that	  they	  arise	  de	  novo.	  These	  type	  of	  tumors	  usually	  
are	  found	  in	  older	  patients	  compared	  to	  secondary	  GBM	  and	  they	  remain	  clinically	  undetectable	  
until	   the	  massive	  growth	   rate	  causes	   impairment	  of	  brain	  activity	  with	  overt	  neurological	   signs,	  
often	  due	  to	  compression	  of	  adjacent	  anatomical	  structures.	  Primary	  and	  secondary	  GBMs	  show	  
almost	   identical	   histopatological	   features	   and	   are	   both	   characterized	   by	   a	   very	   high	   cell	  





















	   I	   II	   III	   IV	  
Astrocytic	  tumors	   	   	   	   	  
Subependymal	  giant	  cell	  astrocytoma	   x	   	   	   	  
Pilocytic	  astrocytoma	   x	   	   	   	  
Pilomyxoid	  astrocytoma	   	   x	   	   	  
Diffuse	  astrocytoma	   	   x	   	   	  
Pleomorphic	  xanthoastrocytoma	   	   x	   	   	  
Anaplastic	  astrocytoma	   	   	   x	   	  
Glioblastoma	   	   	   	   x	  
Giant	  cell	  glioblastoma	   	   	   	   x	  
Gliosarcoma	   	   	   	   x	  
	   	   	   	   	  
Oligodendrocytic	  tumors	   	   	   	   	  
Oligodendroglioma	   	   x	   	   	  
Anaplastic	  oligodendroglioma	   	   	   x	   	  
	   	   	   	   	  
Oligoastrocytinc	  tumors	   	   	   	   	  
Oligoastrocytoma	   	   x	   	   	  





white	  matter	  tracts	  and	  beneath	  subdural	  sheets.	  The	  invasion	  of	  the	  perivascular	  space	  and	  the	  
sustained	   angiogenesis	   can	   cause	   hemorrhages.	   Patients	   diagnosed	   with	   either	   primary	   or	  
secondary	  GBM	  usually	  die	  within	  12-­‐16	  months	  from	  the	  time	  of	  diagnosis.	  This	  dismal	  prognosis	  
is	  mostly	  due	  to	  the	  lack	  of	  therapies	  that	  can	  eliminate	  residual	  tumor	  infiltration	  after	  surgical	  
resection	  and	  the	  difficulties	  of	  dealing	  with	  a	  tumor	  within	  such	  an	  important	  organ.	  Recurrence	  
of	   the	   tumor	   associated	   with	   high	   resistance	   to	   conventional	   chemotherapy	   and	   radiotherapy	  
strategies	  have	  so	  far	  prevented	  effective	  disease	  control.	  
	  
1.2	  The	  problem	  of	  the	  cell	  of	  origin	  
The	  historical	  classification	  of	  gliomas	  was	  based	  on	  the	  features	  of	  the	  cells	  found	  in	  the	  tumor,	  
which	  were	  considered	  to	  be	  reminiscent	  of	  their	  cell	  of	  origin.	   In	  this	  context,	  the	  term	  “cell	  of	  
origin”	  will	  be	  used	  to	  indicate	  the	  normal	  cell	  in	  which	  transforming	  events	  occur	  that	  will	  finally	  
result	   in	   tumor	   formation.	  Some	  features	  of	  GBMs	  have	   led	   to	   the	  proposal	  of	  a	  more	  complex	  
situation	  in	  which	  cells	  other	  than	  astrocytes	  or	  oligodendrocytes	  could	  act	  as	  initiators.	  First,	  the	  
difference	   between	   primary	   and	   secondary	   GBMs	   (i.e.,	   de	   novo	   versus	   progressive	   disease)	  
opened	   the	  possibility	   that	   two	  different	   cells	   could	  be	   targets	  of	   distinct	   genetic	   or	   epigenetic	  
alterations,	  resulting	  in	  two	  different	  manifestations	  of	  the	  disease.	  Second,	  the	  intra-­‐	  and	  inter-­‐
tumor	  heterogeneity	  of	  GBM,	  in	  which	  mixed	  cytological	  subtypes	  can	  be	  found,	  together	  with	  a	  
non	  uniform	  pattern	  of	  genetic	   lesions	  and	  expression	  profiles,	  reinforced	  the	  debate	  about	  the	  
real	  cell	  of	  origin.	  It	  also	  remains	  unclear	  whether	  the	  cell	  of	  origin	  can	  be	  ascribed	  retrospectively	  
based	   solely	   on	   the	   appearance	   of	   the	   tumor,	   as	   the	   mutations	   and	   changes	   during	   tumor	  
progression	  may	  alter	  the	  cellular	  phenotype.	  
For	  astrocytomas,	  astrocytes	  were	  thought	  to	  originate	  the	  tumor	  since	  they	  were	  believed	  to	  be	  
the	   only	   replicative	   cell	   population	   within	   the	   brain,	   before	   the	   discovery	   of	   neural	   stem	   cells	  
(NSCs).	   Moreover,	   gliomas	   are	   highly	   positive	   for	   glial	   fibrillary	   acidic	   protein	   (GFAP),	   a	   well	  





cells,	   thus	   the	   hypothesis	   of	   astrocytes	   acting	   as	   cell	   of	   origin	   implies	   a	   process	   of	  
dedifferentiation	   through	   which	   fully	   differentiated	   cells	   regain	   immature	   progenitor	   features.	  
One	   study	   in	   particular	   demonstrated	   that	  mouse	   transformed	   cortical	   astrocytes	  were	   able	   to	  
revert	   to	   a	   more	   immature	   state	   [Bachoo	   et	   al.	   2002].	   However,	   one	   difficulty	   has	   been	   the	  
problem	   of	   defining	   astrocyte	   identity	   [Kimelberg	   2004,	   Garcìa-­‐Marqués	   et	   al.	   2012].	   Several	  
types	  of	  astrocytes	  have	  been	  identified	  in	  the	  brain	  and	  it	  is	  possible	  that	  only	  a	  subset	  of	  them	  is	  
able	   to	   go	   back	   to	   former	   stages	   of	   differentiation	   upon	   transformation.	   Another	   problem	   is	  
represented	   by	   the	   GFAP	  marker;	   it	   has	   been	   shown	   that	   also	   adult	   NSCs	   express	   this	   type	   of	  
intermediate	  filament,	  making	  the	  identification	  of	  mature	  astrocytes	  less	  precise	  [Doetsch	  et	  al.	  
1999].	   In	   addition,	   in	   vitro	   cultures	   of	   rodent	   cortical	   astrocytes	   often	   contain	   progenitor	   cells	  
[Laywell	  et	  al.	  2000,	  Sergent-­‐Tanguy	  et	  al.	  2006]	  raising	  the	  hypothesis	  that	  this	  population	  (and	  
not	   astrocytes)	   is	   the	   one	   from	   which	   experimental	   tumors	   originate.	   The	   hypothesis	   of	   adult	  
astrocytes	   acting	   as	   cell	   of	   origin	   for	   brain	   tumors	   is	   therefore	   plausible	   but	   still	   lacks	   proper	  
evidence.	  	  	  
Another	  possibility	  has	  centered	  around	  the	  adult	  NSCs	  of	  the	  subventricular	  zones	  (SVZ)	  or	  other	  
types	  of	  progenitor	  cells	  found	  in	  the	  brain,	  like	  oligodendroglial	  precursor	  cells	  (OPCs).	  With	  two	  
different	  models,	  Bachoo	  and	  Uhrbom	  showed	  that	  not	  only	  astrocytes	  but	  also	  transformed	  NSCs	  
were	  able	  to	  originate	  tumors	  with	  full	  penetrance	  [Bachoo	  et	  al.	  2002,	  Uhrbom	  et	  al.	  2002],	  and	  
their	   findings	   were	   supported	   by	   other	   works	   using	   different	   model	   systems	   [Zhu	   et	   al.	   2005,	  
Kwon	   et	   al.	   2008,	   Zheng	   et	   al.	   2008].	   Emerging	   evidences	   in	   the	   literature	   are	   pointing	   out	   a	  
different	  paradigm	  and	  designate	  OPCs	  as	  the	  ones	  serving	  as	  cell	  of	  origin	  [Lei	  et	  al.	  2011,	  Liu	  et	  
al.	  2011,	  Sugiarto	  et	  al.	  2011].	   Indeed,	   in	  an	  elegant	  experiment,	  using	   the	  mosaic	  analysis	  with	  
double	   markers	   (MADM),	   Liu	   et	   al.	   demonstrated	   that	   the	   cell	   of	   origin	   belonged	   to	   the	   OPC	  
compartment	   [Liu	  et	  al.	  2011].	  Nevertheless,	   some	  problems	  presented	   for	  astrocytes	  exist	  also	  
for	   those	   models.	   Cell	   expressing	   the	   proteoglycan	   NG2	   (neuron-­‐glial	   antigen	   2),	   a	   marker	   for	  
OPCs,	  were	  shown	  to	  generate	  also	  gray	  matter	  astrocytes	  [Zhu	  et	  al.	  2008];	  moreover,	  platelet	  





al.	  2006],	  highlighting	  once	  more	  the	  difficulty	  of	  achieving	  unequivocal,	  prospective	  identification	  
of	  glioma-­‐relevant	  cell	  populations.	  	  
Finally,	   a	   recent	   paper	   by	   Friedmann-­‐Morvinski	   et	   al.	   demonstrated	   that	   gliomas	   can	   originate	  
from	   NSCs,	   astrocytes	   but	   also	   neurons	   [Friedmann-­‐Morvinski	   et	   al.	   2012].	   In	   this	   study	   the	  
authors	   restore	   the	   idea	   of	   dedifferentiation	   of	   terminally	   differentiated	   cells,	   like	   cortical	  
neurons.	   Indeed,	  they	  found	  that	  tumor	  cells	  expressed	  high	  levels	  of	  neural	  stem	  or	  progenitor	  
cells.	   Moreover,	   they	   discovered	   that	   tumors	   originated	   through	   dedifferentiation	   of	  
differentiated	   cells	   (either	   astrocytes	   or	   neurons)	   matched	   to	   the	   mesenchymal	   molecular	  
subtype	   (see	  section	  1.4).	  One	  potential	  explanation	   to	   resolve	   these	  differing	  outcomes	   is	   that	  
GBM,	  as	  is	  now	  realized	  comprises	  several	  distinct	  subtypes.	  Therefore,	  one	  possible	  explanation	  
could	  be	  that	  there	  are	  different	  cell	  of	  origins	  for	  distinct	  subtypes	  of	  the	  disease.	  	  	  	  	  	  
So	   far,	   all	   the	   possibilities	   presented	   by	   several	   studies	   were	   not	   able	   to	   provide	   a	   definitive	  
answer	  about	  the	  real	  cell	  of	  origin.	  All	  hypotheses	  tested	  showed	  some	  still	  unresolved	  caveats,	  
especially	   concerning	   the	   identification	   of	   proper	  markers	   to	   discriminate	   among	   different	   cell	  
population.	  
	  
1.3	  Tumor-­‐	  propagating	  cells	  in	  glioma	  
As	  is	  the	  case	  for	  other	  types	  of	  tumors,	  gliomas	  have	  been	  reported	  to	  harbor	  a	  subpopulation	  of	  
cells	  that	  can	  be	  defined	  as	  “glioma	  stem	  cells”.	  Nevertheless,	  the	  term	  “cancer	  stem	  cells”	  (CSCs)	  
raises	   heated	   debate	   due	   to	   the	   various	   uncertainties	   implicit	   in	   this	   description.	   Since	   the	  
molecular	   mechanisms	   driving	   stem	   cell	   identity	   and	   self-­‐renewal	   are	   still	   being	   elucidated,	   a	  
clearer	  molecular	  definition	   remains	  out	  of	   reach.	   In	  2006	   the	  American	  Association	   for	  Cancer	  
Research	  stated	  that	  CSCs	  are	  a	  subpopulation	  of	  cells	  found	  in	  a	  tumor	  with	  self-­‐renewal	  capacity	  
and	   able	   to	   give	   rise	   to	   the	   heterogeneous	   cell	   composition	   found	   in	   the	   tumor	   [Clarke	   et	   al.	  
2006].	   This	   pool	   of	   cells	   is	   able	   to	   reconstitute	   and	   propagate	   the	   tumor	   and	   is	   considered	   to	  





to	  this	  population	  as	  “tumor-­‐propagating	  cells”	  (TPCs)	  as	  suggested	  by	  several	  reviews	  [Visvader	  
2011,	  Chen	  et	  al.	  2012].	  Several	  studies	  demonstrated	  the	  presence	  of	  TPCs	  in	  gliomas	  [Ignatova	  
et	  al.	  2002,	  Singh	  et	  al.	  2003,	  Hemmati	  et	  al.	  2003,	  Kondo	  et	  al.	  2004,	  Singh	  et	  al.	  2004,	  Yuan	  et	  al.	  
2004,	  Galli	  et	  al.	  2004]	  and	  now	  they	  are	  considered	  to	  be	  a	  faithful	  model	  system	  used	  to	  study	  
this	   type	   of	   tumor	   either	   in	   culture	   or	   in	   xenotransplantation	   experiments.	   Nonetheless,	  many	  
controversies	  affect	  this	  field	  of	  research.	  	  
One	  issue	  is	  the	  way	  in	  which	  the	  tumor	  is	  maintained;	  three	  are	  the	  models	  proposed	  currently	  
[reviewed	  in	  Chen	  et	  al.	  2012]:	  (i)	  the	  classical	  hierarchical	  cancer	  stem	  cell	  model,	  in	  which	  very	  
few	  cells	  inside	  the	  tumor	  are	  endowed	  with	  the	  continuous	  self-­‐renewal	  capacity	  and	  are	  able	  to	  
generate	  other	  different	  cell	   types	  responsible	  for	  the	   intrinsic	  heterogeneity	  of	  this	  disease;	   (ii)	  
the	  stochastic	  model,	  in	  which	  all	  the	  tumor	  cells	  are	  considered	  to	  be	  equivalent	  in	  their	  ability	  to	  
sustain	   the	   tumor	  growth;	   the	  heterogeneity	   in	   this	  case	   is	   justified	  by	  different	  clones	  growing	  
together;	   (iii)	   the	   evolutionary	  model,	   in	  which	   the	   hierarchy	   of	   cancer	   stem	   cells	   is	   constantly	  
evolving	  due	  to	  new	  genomic	  alterations	  that	  confer	  growth	  advantage	  to	  the	  cells	  in	  which	  they	  
occurr.	   In	   this	   view,	  distinct	   subclones	  are	  generated	   through	  a	  Darwinian	  evolutionary	  process	  
within	  the	  tumor.	  
Another	   issue	   regards	   the	   definition	   of	   robust	   and	   reliable	  markers	   that	   univocally	   identify	   the	  
TPC	  population.	  One	  of	  the	  first	  cell	  surface	  markers	  identified	  was	  CD133/prominin	  1	  [Singh	  et	  al.	  
2003,	   Singh	   et	   al.	   2004].	   However,	   it	   is	   now	   clear	   that	   CD133-­‐	   cells	   can	   also	   display	   the	   tumor	  
propagating	   behaviour	   described	   for	   CD133+	   cells.	   Other	  markers	   have	   been	   proposed	   such	   as	  
A2B5	   [Ogden	   et	   al.	   2008,	   Tchoghandjian	   et	   al.	   2010],	   CD15/LeX	   [Son	   et	   al.	   2009]	   and	   integrin	  
alpha-­‐6	  [Lathia	  et	  al.	  2010],	  but	  none	  of	  these	  alone	  is	  able	  to	  unequivocally	  identify	  the	  TPCs.	  In	  
addition,	   the	  patient	   to	  patient	  variability	  and	   the	  variety	  of	  GBM	  subtypes	   further	   complicates	  
the	  situation.	  Similarly	   to	  the	  haematopoietic	   field,	   it	  seems	   likely	   that	  a	   large	  panel	  of	  multiple	  
markers	  is	  the	  only	  robust	  means	  to	  purify	  TPCs.	  	  	  
In	   summary,	   there	   exist	   many	   differences	   among	   gliomas:	   the	   histological	   classification,	   the	  





classification	   (discussed	   in	   the	   following	   section).	   Given	   this	   diversity,	   it	   could	   be	   difficult	   to	  
achieve	  a	  universal	  paradigm,	  supposing	  its	  existence,	  both	  for	  the	  cell	  of	  origin	  and	  for	  the	  cancer	  
stem	  cell	  theory.	  	  
	  
1.4	  Molecular	  classification	  of	  gliomas	  
The	  problem	  of	  heterogeneity	  of	  gliomas	  has	  now	  been	  extensively	  explored	  also	  at	  the	  molecular	  
level.	  
Several	   studies	   have	   tried	   to	   identify	   the	   genetic	   alterations	   involved	   in	   gliomagenesis	   and	   to	  
subclassify	   tumors	   based	  on	   transcriptional	   state.	   Additionally,	   James	   et	   al.	   have	  demonstrated	  
that	  multiple	  genetic	  lesions	  were	  occurring	  non-­‐randomly	  in	  different	  glioma	  samples,	  providing	  
evidence	   that	   the	   genotype,	   rather	   than	   the	   phenotype,	   could	   have	   been	   a	   better	   tool	   to	  
understand	   the	   underlying	  molecular	  mechanisms	   of	   this	   cancer	   [James	   et	   al.	   1988].	  With	   the	  
development	   of	   new	   technologies,	   the	   genomic	   landscape	   has	   been	   explored	   in	   a	   more	  
comprehensive	   manner.	   Two	   complementary	   genome-­‐wide	   studies	   were	   performed	   by	   The	  
Cancer	   Genome	   Atlas	   Research	   Network	   (TCGAN)	   and	   the	   Vogelstein	   Laboratory	   and	   were	  
reported	   in	   landmark	   papers	   in	   2008.	   They	   were	   able	   to	   identify	   the	   most	   significant	   somatic	  
mutations	  occurring	  in	  a	  large	  group	  of	  glioma	  samples,	  such	  as	  Tp53,	  Pten,	  Nf1,	  Egfr,	  Rb	  and	  Pi3k.	  
This	  analysis	  revealed	  the	  presence	  of	  core	  signaling	  pathways	  commonly	  affected	  in	  gliomas:	  the	  
p53	   pathway,	   the	   RB	   pathway	   and	   the	   RTK	   pathway.	   Several	   other	   studies	   provided	   further	  
information	   about	   mutations	   and	   copy	   number	   variations,	   thus	   helping	   to	   discover	   different	  
patterns	   of	   alterations	   and	   their	   incidence.	   Interestingly,	   the	   Vogelstein	   Laboratory,	   due	   to	  
extensive	  exome	  sequencing,	  was	  the	  first	  one	  to	  identify	  the	  mutation	  of	  the	  Idh1	  gene	  that	  are	  
now	  diagnostic	  of	  secondary	  GBM.	  [The	  Cancer	  Genome	  Atlas	  Research	  Network	  2008,	  Parsons	  et	  
al.	  2008].	  
Also	   the	   transcriptome	   of	   gliomas	   has	   been	   widely	   examined,	   revealing	   that	   tumors	   that	   are	  





expression	  profiles	  can	  be	  used	  to	  identify	  multiple	  subtypes	  of	  gliomas	  [Godard	  et	  al.	  2003,	  Shai	  
et	  al.	  2003,	  Liang	  et	  al.	  2005,	  Nigro	  et	  al.	  2005],	  to	  predict	  survival	  [Nutt	  et	  al.	  2003,	  Freije	  et	  al.	  
2004]	  and	  to	  unravel	  the	  differences	  between	  primary	  and	  secondary	  tumors	  [Maher	  et	  al.	  2006,	  
Tso	  et	   al.	   2006].	   In	   the	   last	   years,	   three	  main	   studies	  have	   tried	   to	  accurately	  define	  molecular	  
subtypes	  based	  on	  the	  expression	  profiling	  and	  to	  correlate	  the	  subtypes	  with	  genetic	  alterations,	  
core	   pathways,	   prognosis	   and	   survival	   [Phillips	   et	   al.	   2006,	   Li	   et	   al.	   2009,	   Verhaak	   et	   al.	   2010].	  
More	  recently,	  another	  study	  identified	  six	  biological	  subgroups	  based	  on	  the	  integration	  of	  global	  
DNA	   methylation	   data	   with	   genetic	   alterations,	   expression	   profiling	   and	   clinical	   parameters	  
[Sturm	  et	  al.	  2012].	  Unfortunately	  there	  is	  a	  total	  lack	  of	  consensus	  on	  the	  number	  of	  subgroups	  
and	   on	   the	   features	   characterizing	   each	   of	   them.	   Several	   aspects	   biased	   the	   interpretation	   of	  
expression	  data,	  [reviewed	  in	  Marko	  et	  al.	  2011];	  differences	  in	  the	  sample	  cohort	  chosen	  for	  the	  
analysis,	  sample	  preparation,	  analysis	  technique	  and	  bioinformatics	  and	  statistical	  analysis	  make	  
the	  molecular	  classification	  lacking	  in	  a	  consensus.	  Moreover,	  it	  is	  possible	  a	  lot	  of	  the	  difficulties	  
arise	  from	  the	  intra-­‐tumoral	  heterogeneity,	  with	  multiple	  distinct	  subtypes	  present	  within	  a	  single	  
tumor.	  
Notwithstanding	   this	   blurred	   picture	   arising	   from	   molecular	   studies,	   the	   importance	   of	   their	  
findings	  is	  impacting	  the	  way	  of	  making	  clinical	  diagnosis	  and	  choosing	  therapies.	  Histology	  can	  be	  
flanked	  by	  molecular	  data	  in	  order	  to	  better	  classify	  the	  tumor,	   improving	  the	  diagnosis	  and	  the	  
treatment	  strategy	  applied	  to	  each	  patient	  cohort.	  
	  
2	  Epigenetics	  
2.1	  General	  concepts	  about	  epigenetics	  
The	   evidence	   that	   some	  phenomena	   in	   cells	   or	   organisms	  were	   not	   simply	   relying	   on	   the	  DNA	  
sequence	   came	   already	   in	   the	   40’s.	   The	   first	   one	   arose	   from	   studies	   carried	   out	   by	   several	  
geneticists	  who	  had	  noted	   that	   the	   same	  DNA	   fragment	  could	  generate	  different	  phenotypes	   if	  





Muller	   [Muller	   1938]	   or	   “jumping	   genes”	   discovered	   by	   B.	  McClintock	   [McClintock	   1950]).	   The	  
second	  clue	  came	  from	  developmental	  studies,	  where	  it	  was	  evident	  that	  a	  multicellular	  organism	  
is	  built	  of	  several	  different	  types	  of	  cells,	  all	  coming	  from	  the	  same	  unicellular	  zygote,	  which	  need	  
to	   phenotypically	   diverge	   in	   order	   to	   accomplish	   different	   functions	   in	   the	   complete	   organism.	  
More	  interestingly,	  once	  established,	  those	  differences	  in	  the	  phenotype	  could	  be	  transmitted	  to	  
subsequent	  cell	  generations.	  A	  pioneer	  in	  this	  field	  of	  research	  was	  indeed	  a	  famous	  embryologist	  
and	   geneticist,	   C.H.	   Waddington,	   who	   for	   the	   first	   time	   defined	   the	   concept	   of	   epigentics	  
[Waddington	   1942].	   Work	   from	   J.	   Gurdon	   further	   demonstrated	   that	   during	   development	   all	  
genes	  were	  retained	  in	  somatic	  cells,	  exemplified	  by	  their	  ability	  to	  generate	  the	  entire	  organism	  
following	  nuclear	  transfer.	  The	  genes	  must	  therefore	  be	  turned	  on	  and	  off	  with	  exquisite	  control	  
[Gurdon	   1962].	   After	   almost	   80	   years	   of	   research,	   the	   definition	   of	   epigenetics	   is	   still	   under	  
debate;	  the	  most	  widely	  accepted	  refers	  to	  it	  as	  the	  sum	  of	  the	  changes	  in	  phenotype,	  including	  
gene	   expression,	   that	   can	   be	   mitotically	   and/or	   meiotically	   inherited	   without	   changes	   in	   the	  
underlying	  DNA	  sequence.	  There	  are	  three	  criteria	  used	  to	  define	  a	  molecular	  signal	  as	  epigenetic:	  
(i)	   evidence	   of	   transmission	   (self-­‐sustaining	   transmission	   to	   the	   progeny);	   (ii)	   mechanism	   for	  
propagation	   (how	   the	  mark	   is	  maintained	  after	  DNA	   replication	  and	   cell	   division);	   (iii)	   effect	  on	  
gene	   expression.	   According	   to	   this	   definition,	   two	   are	   the	   bona	   fide	   epigenetic	   marks:	   DNA	  
methylation	   [reviewed	   in	  Bird	  2002]	  and	   trimethylation	  of	   lysine	  27	  on	  histone	  H3	   (H3K27me3)	  
[Hansen	  et	  al.	  2008,	  Margueron	  et	  al.	  2009].	  Despite	  these	  stringent	  criteria	  used	  to	  define	  bona	  
fide	   epigenetic	   marks,	   other	   mechanisms	   are	   known	   to	   affect	   gene	   expression,	   particularly	  
different	  histone	  posttranslational	  modifications,	  nucelosome	  repositioning	  and	  remodelling	  and	  
small	  noncoding	  RNAs.	  	  
	  
2.2	  Histones	  and	  histone-­‐modifications	  
The	  basic	  unit	  of	  chromatin,	  also	  known	  as	  nucleosome,	  consist	  of	  147	  DNA	  base	  pairs	  wrapped	  





core	  histone	  proteins,	  namely	  H2A,	  H2B,	  H3	  and	  H4.	  Histone	  proteins	  are	  highly	  basic	  proteins,	  
composed	  of	  a	  globular	  domain	  and	  a	   tail	   in	   their	   amino-­‐terminal	  portion.	  The	  vast	  majority	  of	  
histone	   posttranslational	   modification	   occurs	   at	   their	   tails,	   which	   stretch	   out	   from	   the	  
nucleosome;	   the	   most	   common	   and	   well-­‐studied	   covalent	   modifications	   include	   methylation,	  
acetylation,	  phosphorylation	  and	  ubiquitylation.	  The	  information	  content	  of	  the	  modifications	  led	  
to	   the	   formulation	   of	   the	   “histone	   code”	   hypothesis	   that	   adds	   another	   control	   level	   to	   the	  
information	   potential	   of	   the	   DNA	   sequence.	   Modifications	   are	   able	   to	   influence	   different	  
processes,	   among	  which	   chromatin	   organization,	   protein	   binding	   and	   transcriptional	   activity.	   It	  
must	  be	  highlighted	  that	  all	  these	  mechanisms	  can	  be	  interconnected	  and	  several	  can	  be	  needed	  
at	  once	  to	  achieve	  the	  final	  output.	  	  
Among	  the	  covalent	  modifications,	  methylation	  is	  considered	  to	  be	  the	  more	  complex.	  Indeed	  it	  
can	  occur	  either	  at	  arginine	  or	  lysine	  residues	  and	  there	  are	  at	  least	  24	  known	  position	  on	  histone	  
tails	  at	  which	  methylation	  can	  be	  established.	  Moreover,	  lysine	  can	  exist	  in	  multiple	  methylation	  
states,	  namely	  unmethylated,	  mono-­‐	  (me1),	  di-­‐	  (me2)	  and	  tri-­‐	  (me3)	  methylated	  and	  arginine	  can	  
be	  unmethylated,	  mono-­‐	  or	  di-­‐methylated.	  A	  further	  level	  of	  complexity	  is	  represented	  by	  the	  fact	  
that,	  differently	  from	  other	  modifications,	  the	  output	  of	  the	  methylation	  can	  be	  either	  an	  active	  
or	  a	  silent	  state	  of	  gene	  expression.	  Paritcularly,	  methylation	  of	  lysine	  (K)	  has	  been	  shown	  to	  play	  
a	   major	   role	   in	   switching	   transcription	   on	   and	   off	   during	   development	   and	   differentiation.	  
Generally,	   methylated	   residues	   linked	   to	   transcriptionally	   active	   regions	   are	   H3K4,	   H3K36	   and	  
H3K79,	  while	  those	  associated	  to	  transcriptionally	  repressed	  regions	  are	  H3K9,	  H3K27	  and	  H4K20.	  
Despite	  this	  categorization,	  recent	  studies	  showed	  that	  marks	  with	  opposing	  effect	  can	  be	  found	  
together	  in	  certain	  chromatin	  regions,	  as	  in	  the	  case	  of	  “bivalent	  domains”	  described	  by	  Bernstein	  
et	  al.	  [Bernstein	  et	  al.	  2006].	  H3K4me3	  and	  H3K27me3	  lay	  together	  in	  these	  domains,	  keeping	  the	  
genes	  expressed	  at	  very	  low	  levels	  and	  poised	  for	  definitive	  activation	  or	  repression,	  introducing	  
an	  extra-­‐layer	  of	  diversification	  for	  the	  control	  of	  the	  biological	  output.	  This	  finding	  was	  confirmed	  
by	  the	  work	  by	  Azuara	  et	  al.	  [Azuara	  et	  al.	  2006].	  Thus,	  a	  complicated	  picture	  has	  emerged	  with	  





2.3	  Polycomb	  mediated	  gene	  repression	  
As	   discussed	   in	   the	   previous	   section,	   the	   observation	   that	   adult	   animals	   were	   constituted	   by	  
several	   hundred	   distinct	   cell	   types	   arising	   from	   one	   cell,	   the	   zygote,	   was	   a	   major	   unresolved	  
problem	   in	   biology.	   It	   became	   clear	   that	   cell	   identity	   and	   function	   was	   maintained	   through	   a	  
specific	  gene	  expression	  profile;	  but	  how	  is	  it	  possible	  to	  tightly	  control	  gene	  expression	  in	  a	  tissue	  
specific	  manner?	  Moreover,	  cells	  are	  able	  to	  rapidly	  respond	  to	  external	  stimuli;	  how	  can	  the	  gene	  
expression	  be	  modified	  precisely,	  robustly	  and	  in	  a	  time	  specific	  manner?	  And,	  how	  is	  it	  possible	  
to	   pass	   the	   established	   pattern	   of	   active	   and	   repressed	   genes	   through	   cell	   division?	   The	   first	  
major	   steps	   to	   addressing	   these	   questions	   came	   from	   classical	   genetic	   studies	   in	   the	   fruit	   fly,	  
Drosophila	  melanogaster,	  and	  where	  then	  confirmed	  also	  in	  mammals.	  	  
In	  their	  lab,	  Pam	  and	  Ed	  Lewis	  identified	  a	  variety	  of	  fly	  mutants	  in	  which	  posterior	  segment	  of	  the	  
abdomen	  showed	  an	  “anteriorized”	  phenotype	   [Lewis	  1978].	   It	   is	  now	  known	  that	   the	  anterior-­‐
posterior	  axis	  development	  of	  the	  body	  plan	  is	  controlled	  by	  expression	  of	  homeotic	  genes,	  also	  
known	   as	   Hox	   genes.	   Hox	   genes	   are	   a	   family	   of	   homeodomain	   transcription	   factors	   that	   are	  
expressed	  in	  a	  specific	  manner	  in	  each	  body	  segment.	  Lewis	  identified	  mutant	  fly	  males	  that	  had	  
extra	   sex	   combs	   also	   on	   the	   second	   and	   third	   pair	   of	   legs,	   while	   wild	   type	   males	   bear	   this	  
structure	   only	   on	   the	   first	   pair	   of	   legs.	   It	   was	   later	   demonstrated	   that	   this	   was	   caused	   by	   a	  
mutation	   in	  a	   trans-­‐acting	   regulator	  of	   the	  Hox	   genes	  and,	  due	   to	   the	   resulting	  phenotype,	   this	  
regulator	   was	   called	   Polycomb.	   Similar	   phenotypes	   were	   obtained	   by	   mutating	   other	   proteins	  
that	  were	  all	  included	  in	  the	  Polycomb	  group	  (PcG).	  It	  was	  demonstrated	  that	  the	  ordered	  pattern	  
of	  the	  anterior-­‐posterior	  axis	  needs	  transcriptional	  repression	  of	  the	  Hox	  genes	  after	  they	  carried	  
out	   their	   function	   in	   a	   time	   and	   space	   specific	   manner.	   PcG	   proteins	   are	   the	   effectors	   of	   this	  
silencing.	  
PcG	  gene	  products	  are	  organized	  in	  two	  different	  multimeric	  protein	  complexes,	  which,	  based	  on	  
their	   function,	  are	  referred	  to	  as	  Polycomb	  Repressive	  Complex	   (PRC)	  1	  and	  2	   [Kuzmichev	  et	  al.	  





initiates	   the	   repression,	   while	   PRC1	   is	   involved	   in	   maintaining	   the	   repressed	   state	   once	  
established	  by	  PRC2.	   The	   core	  proteins	   that	   constitute	   the	  PRC2	   in	  mammals	   (homologs	  of	   the	  
same	  genes	  found	  in	  Drosophila)	  are:	  EED,	  EZH2	  (that	  might	  be	  substituted	  by	  EZH1),	  SUZ12	  and	  
RBAP46/48	   [Muller	   et	   al.	   2002].	   The	   way	   in	   which	   PRC2	   mediates	   gene	   silencing	   is	   through	  
modification	  of	  the	  chromatin;	  indeed,	  the	  complex	  has	  a	  histone	  methyl	  transferase	  activity	  that	  
methylates	  lysine	  27	  of	  histone	  H3,	  and	  to	  a	  lesser	  extent,	  lysine	  9	  [Cao	  et	  al.	  2002,	  Czermin	  et	  al.	  
2002,	   Kuzmichev	   et	   al.	   2002,	   Muller	   et	   al.	   2002].	   Many	   other	   proteins	   associate	   with	   PcG	  
complexes,	   like	   transcription	   factors	   (GAGA	   factors	   [Mulholland	  et	  al.	  2003],	  MYC	   [Ogawa	  et	  al.	  
2002],	  E2F	  [Trimarchi	  et	  al.	  2001,	  Ogawa	  et	  al.	  2002]),	  histone	  deacetylase	  (HDACs)	  [van	  der	  Vlag	  
et	   al.	   1999]	   and	   other	   histone	  methyl	   transferases	   [Sewalt	   et	   al.	   2002].	  When	   PRC2	   is	   initially	  
recruited	  at	  the	  target	  sites,	  it	  associates	  with	  HDACs	  to	  remove	  acetylation	  on	  histone	  H3,	  a	  well-­‐
characterized	   mark	   of	   active	   genes.	   The	   H3	   methyltransferase	   contained	   in	   the	   complex	  
methylates	  H3	  on	  lysine	  27,	  and	  in	  turn	  acts	  as	  docking	  site	  for	  the	  N-­‐terminal	  chromodomain	  of	  
proteins	  assembled	  in	  PRC1.	  	  
	  
3	  Polycomb	  Repressive	  Complexes	  and	  cancer	  
For	  decades,	   it	  has	  been	  assumed	   that	   cancer	  was	   caused	  only	  by	  genetic	  alterations.	  Now	   the	  
view	   is	   changed	   and	   cancer	   is	   considered	   both	   a	   genetic	   and	   epigenetic	   disease.	   It	   was	  
demonstrated	   indeed	   that	  epigenetic	   silencing	  of	  genes	   through	  DNA	  or	  histone	  methylation	  at	  
their	   promoters	   can	   be	   an	   alternative	   way	   to	   achieve	   their	   loss	   of	   function;	   in	   addition,	   DNA	  
demethylation	   of	   constitutive	   heterochromatin	   can	   promote	   genome	   instability.	   Particularly,	  
several	  findings	  linked	  PcG	  proteins	  to	  cancer.	  	  
	  
3.1	  PcG	  proteins	  are	  involved	  in	  malignant	  transformation	  
Ezh2	  and	  Eed	  have	  been	  shown	  to	  be	  targets	  of	  the	  pRB-­‐E2F	  pathway,	  which	  is	  often	  misregulated	  





Weinmann	   et	   al.	   2001].	   It	   is	   known	   that	   the	   integrity	   of	   the	   pRB-­‐E2F	   pathway	   is	   required	   for	  
proper	  differentiation	  and	  embryonic	  development,	  and	  this	  can	  be	  related	  to	  the	  control	  that	  it	  
exerts	   on	   PRC2.	   Another	   important	   evidence	   is	   that	   overexpression	   of	   EZH2	   and	   EED	   shortens	  
G0/G1-­‐S	   phase	   transition,	   conferring	   a	   proliferative	   advantage	   to	   the	   cells,	   which	   is	   a	   typical	  
feature	  of	  many	  tumor	  types	  [Bracken	  et	  al.	  2003].	  
Some	  PcG	  proteins	  have	  been	  shown	  to	  be	  overexpressed	  and/or	  amplified	  in	  variety	  of	  tumors;	  
EZH2	   is	  overexpressed	   in	  metastatic	  prostate	  cancer	  [Varambally	  et	  al.	   	  2002],	  aggressive	  breast	  
cancer	   [Kleer	   et	   al.	   2003,	   Raaphorst	   et	   al.	   2003]	   and	   bladder	   [Arisan	   et	   al.	   2005,	   Raman	   et	   al.	  
2005]	  and	  in	  some	  cases	  the	  overexpression	  might	  be	  due	  to	  amplification	  of	  the	  gene	  [Bracken	  et	  
al.	  2003].	  SUZ12	   is	  overexpressed	   in	  breast	  and	   liver	   tumors	   [Kirmizis	  et	  al.	  2003,	  Kirmizis	  et	  al.	  
2004,	   Kuzmichev	   et	   al.	   2005];	   furthermore,	   it	   is	   regulated	   by	   the	   β-­‐catenin	   pathway,	   which	   is	  
often	  altered	  in	  colon	  cancer,	  thus	  resulting	   in	  Suz12	  upregulation	  [Kirmizis	  et	  al.	  2003].	  Bmi1,	  a	  
member	  of	  the	  PRC1,	  is	  amplified	  in	  haematological	  tumors	  [Bea	  et	  al.	  2001]	  and	  it	  was	  shown	  to	  
cooperate	  with	  RAS	  and	  MYC	  in	  cellular	  transformation	  [Jacobs	  et	  al.	  1999a].	  	  
	  
3.2	  Aberrant	  gene	  regulation	  in	  cancer	  
The	   altered	   expression	   and/or	   activity	   of	   PcG	   proteins	   results	   in	   aberrant	   silencing	   of	   tumor	  
suppressor	   genes	   and	   of	   genes	   that	   control	   differentiation	   and	   restrain	   proliferation.	   Pertinent	  
examples	  of	  this,	  relative	  to	  this	  thesis,	  are	  represented	  by	  the	  control	  of	  the	  Ink4a/Arf	  locus	  and	  
by	  the	  expression	  of	  the	  bone	  morphogenetic	  protein	  receptor	  1b	  (Bmpr1b)	  gene.	  	  
Both	  EZH2	  and	  BMI1	  were	  shown	  to	  directly	  regulate	  the	  silencing	  of	  the	   Ink4a/Arf	   locus,	  which	  
encodes	  for	  two	  proteins,	  p16INK4A	  and	  p14ARF	  [Bracken	  et	  al.	  2007,	  Jacobs	  et	  al.	  1999b].	  These	  two	  
proteins	  control	  cell	  proliferation	  by	  regulating	  the	  pRB-­‐E2F	  pathway	  and	  the	  p53	  pathway,	  two	  of	  
the	  most	  commonly	  mutated	  pathways	  in	  all	  types	  of	  cancer.	  A	  more	  comprehensive	  description	  
of	   p16/p14	   mode	   of	   action	   will	   be	   presented	   in	   the	   next	   section;	   briefly	   they	   inhibit	   RB	  





which	  pRB	  and	  p53	  pathways	  are	  not	  mutated,	  EZH2	  and	  BMI1	  can	  mediate	   Ink4a/Arf	  silencing,	  
leading	  to	  epigenetic	  inactivation	  of	  these	  cell	  cycle	  regulators.	  	  
The	  second	  example	  stems	  from	  the	  finding	  that	  EZH2	  was	  demonstrated	  to	   immunoprecipitate	  
with	  all	  the	  3	  human	  DNA	  methyl	  transferases	  (DNMTs)	  [Vire	  et	  al.	  2006],	  suggesting	  that	  there	  is	  
a	   cooperation	   between	   these	   two	   silencing	   pathways.	   Furthermore,	   PcG	   targets	   in	   embryonic	  
stem	   cells	   are	   12-­‐fold	  more	   likely	   to	   undergo	   DNA	   hypermethylation	   in	   cancer	   and	   H3K27me3	  
(together	  with	  another	  repressive	  histone	  methylation,	  H3K9me2)	  seems	  to	  be	  the	  mark	  required	  
to	  trigger	  DNA	  methylation	  [Ohm	  et	  al.	  2007,	  Schlesinger	  et	  al.	  2007,	  Widschwendter	  et	  al.	  2007].	  
In	  their	  study,	  Lee	  et	  al.	  showed	  that	  a	  subset	  of	  human	  glioma	  stem	  cells	  resemble	  fetal	  neural	  
stem	  cells	  and	  are	  prevented	  from	  differentiating	  by	  DNA	  methylation	  and	  H3K27	  trimethylation	  
occurring	   at	   the	   promoter	   of	  Bmpr1b	   gene.	   This	   gene	   is	   involved	   in	   astroglial	   differentiation	   in	  
normal	   embryogenesis.	   Inhibition	   of	   EZH2	   was	   sufficient	   to	   remove	   the	   superimposed	   DNA	  
methylation,	   restoring	   BMPR1B	   expression	   and,	   consequently,	   the	   astroglial	   differentiation	  
potential	  of	  the	  glioma	  stem	  cells	  [Lee	  et	  al.	  2008].	  	  	  
This	   two	  examples	  highlighted	   two	  different	  mechanism	  of	  action	   through	  which	  Polycomb	  axis	  
can	  facilitate	  tumor	  formation.	  On	  the	  one	  hand,	  it	  can	  cause	  loss	  of	  function	  of	  tumor	  suppressor	  
genes	  by	  epigenetic	  silencing,	  endowing	  cancer	  cells	  with	  growth	  advantage.	  On	  the	  other,	  it	  can	  
overturn	  the	  normal	  gene	  expression	  profile	  of	  the	  cells	  by	  bringing	  them	  back	  to	  and/or	  blocking	  
them	   into	   a	   less	   differentiated	  developmental	   stage.	  Moreover,	   it	   can	   act	   as	   template	   for	  DNA	  
methylation	  which	  has	  been	  demonstrated	  to	  occur	  non-­‐randomly	  but	  rather	  at	  specific	  loci	  in	  an	  
instructive	  manner	  during	  tumor	  formation.	  
	  
4	  Modeling	  glioma	  in	  the	  mouse	  
4.1	  The	  choice	  of	  the	  model	  system	  
There	  are	  many	  murine	  glioma	  models	  described	  in	  literature	  [reviewed	  in	  Hambardzumyan	  et	  al.	  





model	  that	  relies	  on	  the	  orthotopic	  transplantation	  of	  murine	  transformed	  astrocytes	  [Bachoo	  et	  
al.	  2002].	  The	  astrocytes	  are	  derived	  from	  a	  p16INK4a/p19ARF	  double	  knock-­‐out	  (KO)	  strain	  and	  are	  
then	   infected	   in	  order	   to	  overexpress	   the	  mutated	   form	  of	   the	  human	  epidermal	  growth	   factor	  
receptor	   (EGFR)	  known	  as	  EGFRvIII.	   I	  have	  chosen	  the	  Bachoo	  et	  al.	  model	  system	  for	   five	  main	  
reasons.	   First,	   it	   accurately	   recapitulates	   the	   human	   disease,	   both	   at	   the	   genetic	   and	  
histopathological	   level.	   Indeed,	  p16/p19	   loss	  of	  function	  and	  mutation	  of	  Egfr	  are	  two	  signature	  
lesions	  of	  GBM,	  associated	  in	  a	  discrete	  proportion	  of	  gliomas.	  Second,	  this	  study	  demonstrated	  
that	   it	   is	  possible	   to	  establish	   tumors	   from	  either	  astrocytes	  or	  neural	   stem	  cells	   [Bachoo	  et	  al.	  
2002].	   This	   suggests	   that,	   regardless	   of	   the	   cell	   of	   origin	   and	   the	   differentiation	   stage,	   there	   is	  
likely	   to	   be	   a	   convergent	   mechanism	   that	   alters	   the	   gene	   expression	   profile,	   confirming	   the	  
hypothesis	  of	   the	   instructive	  process	   that	   leads	   to	   tumor	   formation.	  Third,	   it	  bears	   the	   intrinsic	  
possibility	  to	  analyze	  cell	  populations	  with	  different	  tumorigenic	  potential,	  enabling	  the	  study	  of	  
their	  transcription	  profiles,	  of	  their	  epigenomes	  and	  how	  the	  first	  varies	  according	  to	  changes	  in	  
the	   latter	   at	   each	   stage	   of	   disease	   progression.	   Fourth,	   the	   KO	   of	   p16/p19	   is	   of	   primary	  
importance	   in	   order	   to	   study	   cancer	   relevant	   developmental	   pathways	   of	   PcG	   aside	   from	   its	  
known	  effect	  on	  INK4a/ARF.	  Finally,	  it	  is	  a	  fully	  penetrant	  modeling,	  with	  associated	  experimental	  
advantages.	  
In	  order	  to	  unravel	  the	  role	  played	  by	  the	  Polycomb	  axis	  during	  gliomagenesis,	  I	  introduced	  in	  the	  
model	  described	  above	  a	  conditional	  allele	  for	  Ezh2	  [Su	  et	  al.	  2003],	  the	  enzymatic	  subunit	  of	  the	  
PRC2.	  	  
	  
4.1.1	  The	  Ink4a/Arf	  locus	  
The	  Ink4a/Arf	  locus	  is	  characterized	  by	  an	  uncommon,	  if	  not	  unique,	  genomic	  structure	  which	  to	  
my	   knowledge	   is	   not	   found	   elsewhere	   in	   the	   mammalian	   genomes.	   This	   segment	   spans	  
approximately	   3	   ×	   104	   bp	   and	   encodes	   for	   two	   different	   proteins	   each	   of	   which	   has	   its	   own	  





third	   are	   shared.	  Despite	   this,	   the	   two	  proteins	  have	  no	   amino-­‐acid	   similarity	   and	   they	   are	  not	  
isoforms.	  
The	   first	   protein	   being	   discovered	   from	   this	   locus	   was	   a	   16	   KDa	   protein	   that	   was	   shown	   to	  
negatively	   modulate	   the	   activity	   of	   cyclin	   dependent	   kinase	   (CDK)	   4	   and	   6,	   hence	   the	   name	  
p16INK4a	   (inhibitor	   of	   CDK4)	   [Serrano	   et	   al.	   1993].	   This	   was	   a	   truncated	   form;	   the	   full	   length	  
contains	  8	  more	  amino-­‐acids,	  for	  a	  total	  of	  156.	  P16	  is	  composed	  of	  4	  ankyrin	  repeat	  (AR)	  motifs	  
linked	   together	  by	   loops	  of	  different	   length;	   the	  second	  and	   third	  AR	  motifs	  are	   responsible	   for	  
binding	  the	  CDKs,	  blocking	  their	  activity.	  Moreover,	  this	  binding	  causes	  the	  shrinkage	  of	  the	  CDK	  
surface	  on	  which	   the	   activator	   of	   the	   kinase,	   cyclin	  D,	   usually	   binds.	   CDK4	   and	  6	   are	   known	   to	  
hyperphosphorilate	  pRB	  in	  the	  late	  G1	  phase,	  causing	  the	  release	  of	  E2F	  transcription	  factors,	  the	  
transcription	  of	  proliferation	  genes	  and	  the	  transition	  to	  the	  S	  phase	  of	  the	  cell	  cycle.	  By	  imparing	  
CDKs	  activity,	  p16	  impedes	  the	  phosphorilation	  of	  pRB,	  which	  sequesters	  E2F	  and	  arrests	  the	  cell	  
cycle	  in	  G1	  phase.	  INK4a	  was	  also	  shown	  to	  be	  involved	  in	  cellular	  senescence	  and	  aging,	  even	  if	  
the	  mechanisms	   are	   still	   not	   fully	   understood.	   Indeed,	  while	   p16	   expression	   level	   is	   low	  during	  
development,	   it	   increases	   during	   aging,	   restricting	   the	   replicative	   potential	   of	   self-­‐renewing	   or	  
progenitor	  populations,	  including	  neural	  progenitor	  cells	  [Molofsky	  et	  al.	  2006,	  Krishnamurthy	  et	  
al.	  2006].	  	  
The	   second	   protein	   was	   discovered	   when	   an	   alternative	   first	   exon	   was	   demonstrated	   to	   be	  
transcribed	  from	  the	  same	  locus,	  producing	  an	  alternate	  reading	  frame	  (ARF,	  also	  known	  as	  p19	  in	  
mouse	   and	   p14	   in	   humans)	   [Quelle	   et	   al.	   1995].	   No	   structural	   motifs	   have	   been	   identified	   in	  
p19ARF;	  of	  the	  169	  amino-­‐acids,	  more	  than	  20%	  are	  arginine	  residues,	  thus	  resulting	  in	  a	  very	  basic	  
and	  hydrophobic	  protein	  which	   is	   localized	   in	   the	  nucleolus	   thanks	   to	   the	  nucleolar	   localization	  
signal	  located	  at	  the	  N-­‐terminal	  portion	  of	  the	  protein.	  Expression	  of	  oncogenes	  upregulates	  p19,	  
inducing	  a	  block	  in	  the	  cell	  cycle	  in	  response	  to	  hyperproliferative	  signals.	  This	  is	  mainly	  due	  to	  the	  
inhibition	  of	  two	  ubiquitin	  ligases,	  MDM2	  and	  ARF-­‐BP1/Mule	  that	  mediate	  ubiquitination	  of	  p53,	  
causing	  its	  nuclear	  export	  and	  proteasomal	  degradation.	  By	  binding	  to	  MDM2,	  p19	  promotes	  the	  





mechanism	  by	  which	  ARF	  is	  able	  to	  restrain	  cell	  growth,	  some	  evidences	  raised	  the	  possibility	  of	  
some	  p53-­‐independent	  mechanism	  of	  action	  of	  p19.	  Indeed,	  it	  was	  shown	  to	  induce	  G1	  arrest	  in	  
cell	   lacking	   p53	   [Weber	   et	   al.	   2000].	   Moreover,	   it	   seems	   to	   reduce	   ribosomal	   biogenesis	   by	  
sequestering	   nucleophosmin/B23	   (NPM)	   in	   the	   nucleolus,	   but	   this	   finding	   is	   still	   under	   debate	  
[Bertwistle	  et	  al.	  2004,	  Itahana	  et	  al.	  2003].	  Finally,	  in	  mouse	  (but	  not	  in	  humans)	  it	  seems	  to	  be	  
involved	  in	  senescence	  [Kamijo	  et	  al.	  1997].	  
The	  Ink4a/Arf	  locus	  therefore	  plays	  a	  central	  role	  in	  controlling	  cellular	  growth,	  particularly	  due	  to	  
malignant	  cues.	  Thus,	  it	  appears	  even	  stranger	  that	  two	  different	  and	  powerful	  tumor	  suppressor	  
mechanisms	  have	  been	  evolutionary	  placed	   in	   the	   same	   locus.	   In	   fact,	   in	  different	   tumor	   types	  
deletion	  or	  mutation	  of	  the	  common	  exons	  often	  lead	  to	  the	  loss	  of	  both	  proteins.	  
	  
4.1.2	  Epidermal	  growth	  factor	  receptor	  vIII	  
Epidermal	  growth	  factor	  receptor	  belongs	  to	  the	  ErbB	  family	  of	  receptors,	  which	  comprises	  four	  
members:	  EGFR	  (also	  known	  as	  ErbB1),	  ErbB2,	  ErbB3	  and	  ErbB4.	  All	  the	  members	  are	  constituted	  
by	  3	  main	  domains:	  an	  extracellular	  domain	  to	  which	  ligands	  bound,	  a	  single	  membrane-­‐spanning	  
region	   and	   an	   intracellular	   domain	   with	   multiple	   tyrosine	   residues	   which	   are	   phosphorylated	  
upon	  ligand	  binding	  and	  receptor	  activation.	  This	  leads	  to	  activation	  of	  downstream	  effectors	  and,	  
ultimately,	  to	  gene	  transcription.	  
Amplification	   of	   the	   EGFR	   gene	  with	   consequent	   over-­‐expression	   is	   the	  most	   common	   genetic	  
alteration	  in	  gliomas,	  occurring	  in	  40-­‐60%	  of	  de	  novo	  GBMs	  [Libermann	  et	  al.	  1984,	  Sugawa	  et	  al.	  
1990,	   Ekstrand	   et	   al.	   1992,	   Jaros	   et	   al.	   1992,	   Wong	   et	   al.	   1992].	   During	   the	   process	   of	  
amplification	  of	   the	  EGFR	   locus,	   some	   amplicons	   undergo	   rearrangements	   resulting	   in	  mutated	  
form	  of	  the	  receptor	  (60-­‐75%	  tumors	  with	  amplified	  EGFR).	  The	  most	  common	  rearrangement	  is	  
the	  deletion	  of	  exons	  2	  to	  7,	  causing	  the	  loss	  of	  267	  aminoacids	  that	  form	  the	  extracellular	  ligand-­‐
binding	  domain	  [Ekstrand	  et	  al.	  1994].	  This	  form	  of	  the	  receptor	  is	  constitutively	  active	  and	  even	  if	  





transplantation	   [Nishikawa	   et	   al.	   1994].	   Several	   studies	   also	   demonstrated	   that	  wild-­‐type	  EGFR	  
amplification	   and	   over-­‐expression	   alone	   is	   quite	   inefficient	   in	   driving	   tumor	   formation,	   even	   in	  
presence	  of	  other	  mutation	  such	  as	  INK4a/ARF	  loss	  of	  function	  (LOF)	  [Lachat	  et	  al.	  2004,	  Zhu	  et	  al.	  
2009].	   EGFRvIII	   alone	   is	   not	   sufficient	   for	   the	   tumorigenic	   process	   [Zhu	   et	   al.	   2009]	   and	   this	  
particular	  mutation	  has	  almost	  always	  been	  found	  in	  association	  with	  INK4a/ARF	  LOF	  [Hayashi	  et	  
al.	  1997,	  Hegi	  et	  al.	  1997],	  while	  it	  is	  mutually	  exclusive	  with	  p53	  LOF	  [Watanabe	  et	  al.	  1996,	  Fulci	  
et	   al.	   2000,	   Labuhn	   et	   al.	   2001].	   Amplification	   of	   EGFR,	   and	   so	   its	   rearrangement,	   seem	   to	   be	  
restricted	   to	   grade	   III	   and	   grade	   IV	   astrocytomas	   [Lieberman	   et	   al.	   1985,	   Wong	   et	   al.	   1987,	  
Ekstrand	  et	  al.	  1992]	  and	  it	   is	   less	  prevalent	   in	  secondary	  GBM.	  The	  mutation	  is	  not	  observed	  in	  
normal	  tissue	  [Garcia	  de	  Palazzo	  et	  al.	  1993,	  Moscatello	  et	  al.	  1995,	  Wikstrand	  et	  al.	  1998]	  and	  its	  
presence	  is	  associated	  with	  poor	  prognosis	  [Furnari	  et	  al.	  2007].	  	  	  
Many	   studies	  have	  attempted	   to	   identify	   the	   function	  of	   EGFRvIII,	   but	   a	   clear	   conclusion	   is	   still	  
missing.	   Several	   studies	   demonstrated	   that	   it	   can	   activate	   the	   PI3K	   pathway	   [Moscatello	   et	   al.	  
1998,	  Choe	  et	  al.	  2003,	  Huang	  et	  al.	  2007],	  which	  is	  associated	  with	  cell	  proliferation,	  survival	  and	  
migration.	  Moreover,	  it	  was	  shown	  to	  upregulate	  Bcl-­‐xl,	  a	  potent	  inhibitor	  of	  apoptosis	  [Nagane	  et	  
al.	   1998],	   and	   to	   cause	   over-­‐expression	   of	   tissue	   factor	   that	   can	   induce	   over-­‐expression	   of	  
angiogenic	  factors	  like	  IL-­‐8	  and	  VEGF,	  leading	  to	  an	  angiogenic	  phenotype	  [Magnus	  et	  al.	  2010].	  
	  
4.1.3	  Enhancer	  of	  Zeste	  homolog	  2	  (Ezh2)	  
EZH2	   is	   the	   active	   subunit	   responsible	   for	   the	   methylation	   of	   K27	   in	   PRC2.	   This	   protein	   is	  
constituted	  of	  746	  amino-­‐acid	  residues	  and	  maps	  to	  chromosome	  6	  in	  mouse	  [Laible	  et	  al.	  1999],	  
close	  to	  Hox	  gene	  cluster.	  
EZH2	  contains	  a	  SET	  domain	  (named	  after	  SU(VAR)3-­‐9,	  E(z)and	  trx,	  the	  founding	  members	  of	  the	  
SET	  domain	  containing	  proteins)	  which	  is	  able	  to	  catalyze	  the	  addition	  of	  methyl	  groups	  to	  the	  ε-­‐
amino	  group	  of	   lysine	   side	   chain.	   Several	   studies	  demonstrated	   that	   complex	   containing	   E(z)	   in	  





et	  al.	  2002,	  Czermin	  et	  al.	  2002,	  Kuzmichev	  et	  al.	  2002,	  Muller	  et	  al.	  2002].	  EZH2	  alone	  is	  not	  able	  
to	  exert	  its	  histone	  methyl	  transferase	  activity;	  it	  requires	  to	  be	  in	  a	  complex	  with	  at	  least	  EED	  and	  
SUZ12,	  which	  are	  thought	  to	  behave	  as	  modulating	  proteins	   [Cao	  et	  al.	  2004,	  Pasini	  et	  al.	  2004,	  
Ketel	   et	   al.	   2005,	  Montgomery	   et	   al.	   2005,	   Nekrasov	   et	   al.	   2005].	  Moreover,	   another	   protein,	  
PHF1	   seems	   to	   interact	   with	   PRC2	   and	   favor	   the	   recruitment	   to	   target	   genes	   and	   the	  
methyltransferase	  activity	  of	  EZH2	  needed	  to	  achieve	  the	  H3K27me3	  [Sarma	  et	  al.	  2008].	  	  
Initial	   studies	  on	  embryonic	  stem	  cells	   (ESCs)	  showed	  that	  Polycomb	  Complexes	  are	  required	  to	  
maintain	   stem	   cell	   identity	   [Boyer	   et	   al.	   2006,	   Lee	   et	   al.	   2006].	   However	   further	   investigation	  
showed	   that	   this	   process	   is	   much	   more	   elaborated	   and	   the	   current	   model	   proposes	   that	   PcG	  
proteins	   function	  dynamically	  during	  development	  and	  differentiation	  to	   lock	  off	   the	  expression	  
of	  alternative	  cell	  fate	  regulators	  in	  any	  particular	  lineage	  [Mohn	  et	  al.	  2008,	  Ezhkova	  et	  al.	  2009].	  
The	   work	   by	   Mohn	   and	   colleagues	   has	   highlighted	   that,	   at	   least	   in	   the	   context	   of	   neural	  
differentiation,	  PRC2	  plays	  a	   role	   in	   the	  whole	  process.	   In	  particular	   this	  work	   shows	   that	  PRC2	  
reaches	  new	  targets	  not	  only	  in	  the	  precocious	  phase	  between	  ES	  cells	  and	  neural	  precursors,	  but	  
also	  at	  a	  later	  stage	  between	  neural	  precursors	  and	  terminal	  differentiated	  neurons	  [Mohn	  et	  al.	  
2008].	   Therefore	   even	   if	   EZH2	   is	   expressed	   at	   low	   level	   in	   late	   stages	   of	   neural	   differentiation	  
[Sher	  et	  al.	  2008,	  Pereira	  et	  al.	  2010],	  it	  appears	  still	   important	  in	  the	  repression	  of	  new	  targets.	  
Hence	   it	   is	   clear	   that	   EZH2	   and	   PRC2	   complex	   have	   a	   function	   at	   all	   stages	   of	   neural	  
differentiation.	   The	   role	   of	   EZH2	   in	   neural	   differentiation	   has	   also	   been	   studied	   in	   vivo	   with	  
contrasting	  results.	  In	  one	  study,	  Ezh2	  was	  deleted	  in	  the	  cortex	  at	  E14.5,	  causing	  impairment	  in	  
the	   neurogenic	   to	   astrogenic	   fate	   switch	   that	   leads	   to	   a	   delay	   in	   the	   appearance	   of	   astrocytic	  
markers	  and	  to	  an	   increased	  numbers	  of	  neurons	   in	  knockout	  cortices	  [Hirabayashi	  et	  al.	  2009].	  
Instead,	   in	  a	   second	  work	  by	  Pereira	  et	  al.	   the	  deletion	  of	  Ezh2	   is	  achieved	  before	   the	  onset	  of	  
neurogenesis	  at	  E12.	  This	  precocious	  absence	  of	  EZH2	  leads	  to	  an	  accelerated	  differentiation	  with	  
an	  earlier	  appearance	  of	  both	  neurons	  and	  astrocytes	  at	  the	  expenses	  of	  neural	  precursors	  that	  





Given	   the	   importance	   of	   EZH2	   during	   the	   CNS	   development,	   it	   appears	   evident	   how	   its	  
disregulation	   that	  often	  happens	   in	   cancer	   can	  affect	   gene	  expression	  and	   the	   “differentiation”	  
state	  of	  a	  cell.	  
Homozygous	   inactivating	  mutations	  of	  Ezh2	   are	  embryonically	   lethal,	  most	  probably	  due	   to	   the	  
lack	  of	  regulation	  of	  Hox	  genes	  expression	  and	  body	  patterning	  formation.	  In	  order	  to	  study	  EZH2	  
effects	  at	  specific	   	  developmental	  stages	  or	  cell	   lineages,	  two	  laboratories	  produced	  two	  slightly	  
different	  conditional	  KO	  alleles	   [Su	  et	  al.	  2003,	  Shen	  et	  al.	  2008].	  A	  conditional	  KO	  allele	  can	  be	  
inactivated	  in	  time	  and/or	  space	  specific	  manner.	  Both	  the	  alleles	  rely	  on	  the	  CRE/loxP	  technology	  
(see	   material	   and	   Methods,	   section	   1.2	   for	   further	   details)	   and	   upon	   exposure	   to	   CRE	  
recombinase	  the	  SET	  domain	  is	  deleted.	  In	  order	  to	  study	  the	  role	  of	  Ezh2	  during	  gliomagenesis,	  I	  




Materials	  and	  Methods	  
1	  Mouse	  strains	  
1.1	  p16/p19-­‐/-­‐	  strain	  	  
INK4a	  (p16)	  and	  ARF	  (p19)	  are	  two	  proteins	  encoded	  by	  the	  same	  locus,	  exploiting	  two	  different	  
promoters	  and	  two	  mutually	  exclusive	  exons	  1,	  namely	  exon	  1α	  for	  p16	  and	  exon	  1β	  for	  p19.	  The	  
other	   two	  exons	  are	   instead	  shared	  between	  the	  two	  proteins.	  Mice	  deficient	   for	  both	  p16	  and	  
p19	  were	  generated	  by	  replacing	  exons	  2	  and	  3	  of	  the	  Ink4a/Arf	  locus	  with	  a	  cassette	  encoding	  for	  











Figure	  1.	   The	   Ink4a/Arf-­‐/-­‐	   locus.	   Schematic	   representation	  of	   the	   Ink4a/Arf	   locus	   (not	   to	   scale).	   a.	   Ink4a	   and	  Arf	   are	  
transcribed	  from	  two	  independent	  promoters.	  Each	  transcript	  has	  a	  specific	  5’	  exon	  (exon	  1α	  for	  p16	  and	  exon	  1β	  for	  
p19)	  which	  is	  spliced	  into	  common	  exons	  2	  and	  3,	  as	  shown	  by	  black	  (p19ARF)	  or	  dashed	  (p16INK4a)	  lines.	  b.	  Mice	  deficient	  
for	   both	   p16INK4a	   and	   p19ARF	   were	   generated	   by	   replacing	   exons	   2	   and	   3	   with	   a	   cassette	   encoding	   for	   neomycin	  
resistance.	  
	  
1.2	  Ezh2	  conditional	  KO	  strain	  	  
Ezh2-­‐/-­‐	   mice	   are	   early	   embryonic	   lethal.	   To	   study	   the	   function	   of	   this	   protein	   I	   employed	   a	  
conditional	  deletion	  strategy.	  Two	  loxP	  sites	  were	  inserted	  in	  the	  Ezh2	  locus.	  Each	  loxP	  site	  is	  a	  Cre	  
(cyclization	   recombination)	   recognition	   element	   of	   34	   base	   pairs	   (bp),	   composed	   of	   two	   13	   bp	  
inverted	  repeats	  flanking	  an	  asymmetrical	  sequence	  called	  spacer.	  If	  the	  spacers	  of	  two	  loxP	  sites	  
are	   oriented	   in	   the	   same	   direction,	   the	   reaction	   will	   result	   in	   the	   excision	   of	   the	   interposed	  







catalytic	  domain	  of	  the	  protein	  (also	  known	  as	  SET	  domain)	  [Su	  et	  al.	  2003].	  Since	  the	  loxP	  sites	  
are	   located	   in	   introns,	   the	   locus	   behaves	   like	   wild-­‐type,	   but,	   upon	   administration	   of	   Cre	  
recombinase,	  this	  portion	  of	  the	  gene	  is	  removed.	  It	  has	  been	  shown	  that	  the	  locus	  encodes	  for	  a	  




Figure	  2.	  The	  Ezh2	  conditional	  allele.	  Part	  of	  the	  Ezh2	  conditional	  allele	  is	  shown	  before	  and	  after	  Cre	  recombination.	  
Green	   boxes	   indicate	   the	   exons	   encoding	   the	   SET	   domain,	   blue	   triangles	   represent	   the	   loxP	   sites.	   Following	   Cre	  
recombination,	  the	  four	  exons	  of	  the	  SET	  domain	  are	  deleted	  and	  the	  exon	   located	  upstream	  can	  be	  spliced	   into	  the	  
exon	  located	  downstream,	  leading	  to	  the	  formation	  of	  a	  truncated	  protein.	  	  	  
	  
1.3	  Rosa26Cre-­‐ERT2	  transgenic	  strain	  
For	   conditional	   activation	   of	   Cre	   we	   made	   use	   of	   a	   tamoxifen	   inducible	   fusion	   protein.	   The	  
transgene	   encoding	   Cre-­‐ERT2	   protein	   was	   inserted	   in	   the	   Rosa26	   locus	   from	   where	   it	   is	  
ubiquitously	   expressed	   [Seibler	   et	   al.	   2003].	   The	   protein	   encoded	   by	   the	   transgene	   is	   a	   Cre	  
recombinase	   fused	   to	  a	  mutated	   form	  of	   the	  estrogen	  binding	  domain	   (EBD).	   In	   the	  absence	  of	  
the	   ligand	   (Tamoxifen),	   the	   EBD	   interacts	   with	   the	   ubiquitous	   heat	   shock	   protein	   90	   (HSP90),	  
keeping	  Cre	  inactive	  in	  the	  cytoplasm.	  Upon	  administration	  of	  Tamoxifen,	  HPS90	  is	  released	  and	  
Cre	   is	  able	  to	  translocate	  to	  the	  nucleus	  where	   it	  catalyses	  the	  recombination	  reaction	  between	  








Figure	  3.	  The	  Rosa26Cre-­‐ERT2	  transgenic	  locus.	  	  
	  
1.4	  Breeding	  strategies	  
1.4.1.Generation	  of	  the	  p16/p19	  KO	  –	  Ezh2	  conditional	  KO	  strain	  
Homozygous	  mice	  from	  both	  parental	  strains	  (p16/p19-­‐/-­‐	  and	  Ezh2	  conditional	  KO)	  were	  bred;	  all	  
the	  pups	  in	  F1	  were	  then	  heterozygous	  for	  both	  mutations.	  By	  breeding	  two	  mice	  from	  F1,	  it	  was	  
possible	   to	   obtain	   in	   F2	  mice	   that	  were	   double	   homozygous	   or	   homozygous	   for	   the	   p16/p19-­‐/-­‐	  
allele	  and	  heterozygous	   for	  Ezh2	   conditional	  allele,	   that	  were	  bred	  together.	   In	   this	  way,	  all	   the	  
mice	  in	  F3	  were	  homozygous	  for	  the	  p16/p19-­‐/-­‐	  	  allele	  and	  either	  homozygous	  or	  heterozygous	  for	  
Ezh2	   conditional	   allele.	   Those	  mice	  were	   used	   to	   derive	   astrocytes	   (see	   paragraph	   2.1);	   double	  
homozygous	   cells	  were	  used	   as	   experimental	   population,	  while	   cells	   heterozygous	   for	   the	  Ezh2	  
conditional	  allele	  were	  used	  as	  controls	  to	  monitor	  Cre	  toxicity.	  
	  
1.4.2.Generation	  of	  the	  Rosa26CreERT2	  –	  Ezh2	  conditional	  KO	  strain	  
Homozygous	   mice	   from	   both	   parental	   strains	   (Rosa26CreERT2	   and	   Ezh2	   conditional	   KO)	   were	  
bred;	  all	  the	  pups	  in	  F1	  were	  then	  heterozygous	  for	  both	  mutations.	  By	  breeding	  two	  mice	  from	  
F1,	  it	  was	  possible	  to	  obtain	  mice	  in	  F2	  that	  were	  double	  homozygous.	  Those	  mice	  were	  bred	  to	  
heterozygous	  mice	  from	  the	  parental	  Ezh2	  conditional	  KO	  strain;	  the	  embryos	  coming	  from	  those	  
breedings	   were	   all	   heterozygous	   for	   the	   Rosa26CreERT2	   allele	   and	   either	   homozygous	   or	  
heterozygous	   for	   the	   Ezh2	   conditional	   allele.	   Those	   embryos	   were	   used	   to	   derive	   neural	  
precursors	   (NPs,	   see	   paragraph	   2.2);	   cells	   homozygous	   for	   the	   Ezh2	   allele	   were	   used	   as	  





2	  Cell	  culture	  
2.1	  Preparation	  of	  astrocytes	  
I	  made	  use	  of	  a	  classic	  protocol	   first	  described	   in	  1980	  [McCarthy	  et	  al.	  1980].	  Five	  to	  7-­‐day-­‐old	  
pups	  were	  sacrificed,	  each	  brain	  was	  removed	  from	  the	  head	  and	  transferred	   into	  a	  cell	  culture	  
dish	   containing	   sterile	   Dulbecco’s	   phosphate	   buffered	   saline	   (DPBS	   –	   Lonza).	   Cerebral	   cortices	  
were	   isolated	   from	   the	   rest	   of	   the	   brain	   and	   placed	   into	   a	   1.5	   ml	   tube	   containing	   0.5	   ml	   of	  
astrocyte	   culture	   medium	   (15%	   North	   American	   fetal	   bovine	   serum,	   NAFBS	   –	   Gibco,	   2	   mM	  
glutamine	  –	  Lonza,	  0.6%	  glucose	  –	  Sigma,	  100	  U/ml	  potassium	  penicillin	  +	  100	  U/ml	  streptomycin	  
sulfate	  –	  Lonza	  in	  Basal	  Medium	  Eagle's,	  BME	  –	  Gibco).	  They	  were	  mechanically	  dissociated	  with	  
scissors	  and	  through	  pipetting;	  the	  dissociated	  tissue	  was	  plated	  into	  a	  T-­‐25	  flask	  and	  incubated	  in	  
a	  humidified	  incubator	  at	  37°C	  with	  5%	  CO2.	  Medium	  was	  changed	  3	  days	  after	  plating	  and	  every	  
other	  day	  thereafter	  until	  day	  9	  of	  culture.	  Cells	  were	  passaged	  every	  4	  to	  5	  days	  starting	  from	  day	  
10	  of	  culture	  at	  a	  1:2	  or	  1:3	  ratio.	  The	  cells	  were	  rinsed	  with	  DPBS	  and	  detached	  in	  trypsin-­‐versene	  
1:10	   (Sigma	   and	   Lonza,	   respectively);	   after	   detachment,	   the	   dissociation	   into	   single	   cells	   was	  
achieved	  through	  pipetting.	  Trypsin	  was	  inactivated	  by	  adding	  fetal	  bovine	  serum	  (FBS	  –	  Gibco,	  1	  
volume	  per	  volume	  of	  trypsin)	  and	  cells	  were	  collected	  by	  centrifugation	  at	  280	  ×	  g	  for	  5	  minutes.	  
The	  cell	  pellet	  was	  resuspended	  in	  fresh	  astrocyte	  medium	  and	  cells	  were	  plated	  in	  6-­‐well-­‐plates.	  
For	   the	   cryopreservation	   of	   astrocytes,	   cells	  were	   harvested	   from	   a	   confluent	  well	   of	   a	   6-­‐well-­‐
plate	  as	  described	  for	  passaging.	  The	  cell	  pellet	  was	  resuspended	  in	  freezing	  medium	  containing	  
50%	  of	  astrocyte	  culture	  medium,	  40%	  of	  FBS	  and	  10%	  of	  dimethylsulfoxide	  (DMSO	  –	  Merck)	  and	  
put	  in	  one	  cryovial.	  After	  2	  days	  at	  -­‐80°C	  in	  a	  cryobox,	  the	  vials	  were	  transferred	  to	  liquid	  nitrogen	  
for	  long	  term	  storage.	  
One	   vial	   of	   frozen	   cells	   was	   quickly	   thawed	   at	   37°C	   in	   a	   circulating	   water	   bath;	   cells	   were	  
transferred	   to	   a	   new	  15	  ml	   tube	   and	   centrifuged	   at	   280	   ×	  g	   for	   5	  minutes.	   The	   cell	   pellet	  was	  
resuspended	  in	  astrocyte	  culture	  medium	  and	  plated	  in	  1	  well	  of	  a	  6-­‐well-­‐plate.	  The	  following	  day	  





2.2	  Preparation	  of	  neural	  precursors	  (NPs)	  
Pregnant	  mice	  were	  sacrificed	  between	  day	  13.5	  and	  14.5	  of	  embryonic	  development.	  The	  uterus	  
was	  extracted	  and	  washed	  in	  Hank’s	  balanced	  salt	  solution	  (HBSS	  –	  Gibco).	  The	  brain	  from	  each	  
embryo	  was	   isolated	  and	  the	  telencephalic	  vesicles	   transferred	  to	  a	  1.5	  ml	   tube	  containing	  10%	  
FBS	   in	   high	   glucose	   Dulbecco’s	  Modified	   Eagle’s	   medium	  with	   GlutaMax™	   (hgDMEM	   –	   Gibco).	  
Tissue	  was	  mechanically	   dissociated	  with	   glass	   pipettes	   rinsed	  with	  medium	  and	   centrifuged	   at	  
280	  ×	  g	  for	  5	  minutes.	  Supernatant	  was	  removed	  and	  the	  cell	  pellet	  washed	  in	  fresh	  media.	  After	  
centrifugation	   (280	   ×	   g	   for	   5	   minutes),	   cells	   were	   resuspended	   in	   B27	   complete	   medium	  
consisting	  of	  1x	  B27	  (Gibco),	  10	  ng/ml	  of	  both	  murine	  epidermal	  growth	  factor	  (EGF	  –	  Peprotech),	  
murine	   fibroblast	  growth	   factor	  2	   (FGF-­‐2	  –	  Peprotech)	  and	  100	  U/ml	  potassium	  penicillin	  +	  100	  
U/ml	   streptomycin	   sulfate	   (Lonza)	   in	  hgDMEM	  with	  GlutaMax™:F-­‐12	  1:1	   (both	   from	  Gibco)	  and	  
plated	  on	  poly-­‐D-­‐lysine	  (PDL	  –	  Sigma)	  precoated	  wells	  of	  24-­‐well	  plates	  at	  the	  density	  of	  5	  ×	  105	  
cells	  per	  well.	  Plates	  were	  placed	  in	  a	  humidified	  incubator	  37°C	  with	  5%	  CO2.	  At	  a	  confluence	  of	  
about	   90%,	   cells	  were	   passaged.	   They	  were	   detached	  with	   trypsin-­‐EDTA	   (Lonza)	   and	   dispersed	  
into	  single	  cells	  by	  gentle	  pipetting.	  Trypsin	  was	  inactivated	  by	  adding	  hgDMEM	  with	  10%	  FBS	  (3	  
volumes	   per	   volume	   of	   trypsin)	   and	   cells	   were	   collected	   by	   centrifugation	   at	   280	   ×	   g	   for	   5	  
minutes.	  The	  cell	  pellet	  was	  resuspended	  in	  fresh	  B27	  complete	  medium	  and	  cells	  were	  plated	  as	  
described	  above.	  
For	  the	  cryopreservation	  of	  neural	  precursors,	  cells	  were	  harvested	  from	  a	  confluent	  well	  of	  a	  24-­‐
well-­‐plate	   as	   described	   for	   passaging.	   The	   cell	   pellet	   was	   resuspended	   in	   freezing	   medium	  
containing	  10%	  DMSO	  in	  B27	  complete	  medium	  and	  put	  in	  one	  cryovial.	  After	  2	  days	  at	  -­‐80°C	  in	  a	  
cryobox,	  the	  vials	  were	  transferred	  to	  liquid	  nitrogen	  for	  long	  term	  storage.	  
One	   vial	   of	   frozen	   cells	   was	   quickly	   thawed	   at	   37°C	   in	   a	   circulating	   water	   bath;	   cells	   were	  
transferred	   to	   a	   new	  15	  ml	   tube	   and	   centrifuged	   at	   280	   ×	  g	   for	   5	  minutes.	   The	   cell	   pellet	  was	  
resuspended	  in	  B27	  complete	  medium	  and	  plated	  in	  1	  well	  of	  a	  24-­‐well-­‐plate.	  The	  following	  day	  





2.3	  Viral	  infection	  of	  cell	  cultures	  	  	  
Epidermal	  growth	  factor	  receptor	  variant	  III	  (EGFRvIII)	  expressing	  retroviral	  particles	  for	  astrocyte	  
infection	   and	   platelet	   derived	   growth	   factor	   beta	   (PDGFB)	   expressing	   retroviral	   particles	   for	  
neural	   precursor	   infection	   were	   generated	   using	   the	   retrovirus	   producer	   cell	   line	   Phoenix-­‐Eco.	  
Phoenix-­‐Eco	  cells	  were	  plated	  one	  day	  before	  transfection	  at	  a	  density	  of	  1.5	  ×	  106	  cells	  per	  10	  cm	  
dish.	  The	  day	  of	  transfection,	  cells	  were	  treated	  with	  25	  µM	  chloroquine	  (Sigma).	  In	  a	  15	  ml	  tube,	  
10	  ng	  of	   retroviral	  vector	   (either	  EGFRvIII	  or	  PDGFB)	  were	  mixed	   to	  a	  250	  mM	  calcium	  chloride	  
(CaCl2,	  VWR)	  solution;	  this	  final	  solution	  was	  added	  dropwise	  to	  bubbling	  2x	  HEPES	  buffered	  saline	  
pH	   7.05	   (HBS;	   50	   mM	   4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	   acid,	   HEPES,	   10	   mM	  
potassium	   chloride,	   KCl,	   12	   mM	   dextrose,	   280	   mM	   sodium	   chloride,	   NaCl,	   1.5	   mM	   sodium	  
phosphate	  dibasic	  heptahydrate,	  Na2HPO4	  ·∙	  7H2O	  –	  all	  from	  VWR).	  After	  15	  minutes	  of	  incubation	  
at	   room	   temperature,	   the	   solution	   was	   added	   to	   the	   cells	   and	   mixed	   by	   rocking	   the	   plate.	  
Supernatants	  were	   collected	   48	   hours	   after	   transfection	   and	   every	   12	   hours	   thereafter	   for	   4-­‐5	  
times.	  
Early-­‐passage	  astrocyte	  cultures	  were	  infected	  using	  the	  viral	  supernatant	  filtered	  through	  a	  0.45	  
µm	  filter.	  Astrocytes	  were	  trypsinized	  as	  described	  before;	  5	  ×	  105	  cells	  were	  resuspended	  in	  3	  ml	  
of	  viral	  supernatant	  supplemented	  with	  8	  µg/ml	  Polybrene®	  (Sigma)	  and	  plated	   in	  a	  well	  of	  a	  6-­‐
well-­‐plate.	   The	   supernatant	   was	   removed	   and	   replaced	   with	   fresh	   supernatant	   at	   each	   new	  
collection.	  
Neural	   precursors	   were	   infected	   using	   ultracentrifugated	   viral	   supernatant.	   After	   the	   last	  
collection,	   all	   the	   supernatant	   was	   filtered	   through	   a	   0.45	   µm	   filter,	   placed	   in	   ultracentrifuge	  
tubes	   and	   ultracentrifugated	   at	   20200	   ×	   g	   for	   2	   hours.	   After	   centrifugation,	   the	   medium	   was	  
removed	  by	  inverting	  the	  tubes	  and	  the	  residual	  few	  microliters	  were	  used	  to	  resuspend	  the	  viral	  
particles	  pelleted	  at	   the	  bottom	  for	  2	  hours	  on	   ice.	  Neural	  precursors	  were	  mixed	  with	  50	  µl	  of	  






2.4	  Derivation	  of	  glioma	  propagating	  cells	  (GPCs)	  
2.4.1	  Derivation	  of	  GPCs	  –	  astrocytoma	  model	  	  
I	  made	  use	  of	  a	  protocol	  that	  allows	  GPC	  culture	  in	  adherent	  conditions	  [Pollard	  et	  al.	  2009].	  Mice	  
injected	  with	  tumorigenic	  astrocytes	  were	  sacrificed	  at	  the	  onset	  of	  neurological	  symptoms.	  The	  
tumor	  mass	  was	  dissected	  from	  the	  brain	  and	  a	  small	  piece	  was	  put	   in	  a	  1.5	  ml	  tube	  containing	  
0.5	  ml	   of	   Accutase	   (Sigma).	   The	   tissue	  was	  mechanically	   dissociated	  with	   scissors	   and	   through	  
pipetting,	  passed	  through	  a	  70	  µm	  cell-­‐strainer	  and	  single	  cell	  suspension	  was	  collected	  in	  a	  50	  ml	  
tube.	  After	  centrifugation	  (300	  ×	  g	  for	  5	  minutes),	  cells	  were	  resuspended	  in	  glioma	  propagating	  
cell	  medium	  (1x	  B27,	  1x	  N2	  –	  Gibco,	  20	  ng/ml	  of	  both	  EGF	  and	  murine	  FGF-­‐2,	  100	  U/ml	  potassium	  
penicillin	  +	  100	  U/ml	   streptomycin	   sulfate	   in	  Neurobasal	  Medium	  –	  Gibco)	  and	  plated	   in	  1	  or	  2	  
wells	  of	  a	  6-­‐well-­‐plate,	   coated	  with	   laminin	   (Roche).	  Plates	  were	  kept	   in	  a	  humidified	   incubator	  
37°C	  with	  5%	  CO2;	  medium	  was	  changed	  2	  days	  after	  plating	  and	  every	  other	  day	  thereafter.	  Cells	  
were	  passaged	  at	  80-­‐90%	  confluence	  at	  a	  ratio	  ranging	  from	  1:3	  to	  1:6.	  They	  were	  detached	  with	  
Accutase	  and	  dispersed	  into	  single	  cells	  by	  gentle	  pipetting;	  after	  centrifugation	  at	  300	  ×	  g	   for	  5	  
minutes,	   cells	   were	   resuspended	   in	   glioma	   propagating	   cell	   medium	   and	   plated	   as	   described	  
above.	  
For	   cryopreservation,	   cells	   were	   harvested	   from	   a	   80-­‐90%	   confluent	   well	   of	   a	   6-­‐well-­‐plate	   as	  
described	   for	   passaging.	   The	   cell	   pellet	   was	   resuspended	   in	   freezing	   medium	   containing	   10%	  
DMSO	   in	   glioma	   propagating	   cell	   medium	   and	   put	   in	   one	   cryovial.	   After	   2	   days	   at	   -­‐80°C	   in	   a	  
cryobox,	  the	  vials	  were	  transferred	  to	  liquid	  nitrogen	  for	  long	  term	  storage.	  
One	   vial	   of	   frozen	   cells	   was	   quickly	   thawed	   at	   37°C	   in	   a	   circulating	   water	   bath;	   cells	   were	  
transferred	   to	   a	   new	  15	  ml	   tube	   and	   centrifuged	   at	   300	   ×	  g	   for	   5	  minutes.	   The	   cell	   pellet	  was	  
resuspended	  in	  glioma	  propagating	  cell	  culture	  medium	  and	  plated	  in	  1	  well	  of	  a	  6-­‐well-­‐plate.	  The	  







2.4.2	  Derivation	  of	  GPCs	  –	  oligodendroglioma	  model	  
Mice	   injected	   with	   tumorigenic	   neural	   precursors	   were	   sacrificed	   at	   the	   onset	   of	   neurological	  
symptoms.	  The	  tumor	  mass	  was	  dissected	  from	  the	  brain	  under	  a	  fluorescence	  steromicroscope	  
(Olympus	   SZX16	   stereomicroscope,	   equipped	  with	   a	   Nikon	   Digital	   Sight	   DS-­‐5Mc	   RGB	   8-­‐bit	   CCD	  
camera,pixel	  size	  7.5	  µm;	  images	  were	  acquired	  with	  NIS	  Element	  software	  by	  Nikon	  and	  analyzed	  
with	  ImageJ	  software)	  partially	  dissociated	  with	  forceps	  and	  put	  in	  a	  15	  ml	  tube	  containing	  10	  mM	  
HEPES	   in	  HBSS.	  After	  centrifugation	   (280	  ×	  g	   for	  5	  minutes),	   supernatant	  was	  removed,	   trypsin-­‐
EDTA	  was	  added	  to	  the	  tube	  and	  incubated	  for	  15	  minutes	  at	  37°C.	  Trypsin	  was	  blocked	  by	  adding	  
hgDMEM	  with	   10%	   FBS	   and	   the	   tumor	  mass	  was	  mechanically	   dissociated	  with	   Pasteur’s	   glass	  
pipettes	  rinsed	  with	  medium.	  The	  single	  cell	  suspension	  was	  centrifuged	  at	  280	  ×	  g	  for	  5	  minutes;	  
the	   cell	   pellet	  was	   resuspended	   in	   B27	   complete	  medium	   and	   plated	   on	  Matrigel™	  matrix	   (BD	  
Biosciences)	   precoated	  wells	   of	   6-­‐well	   plates	   at	   the	  density	   of	   1-­‐1.5	   ×	   106	   cells	   per	  well.	   Plates	  
were	  kept	  in	  a	  humidified	  incubator	  37°C	  with	  5%	  CO2;	  medium	  was	  changed	  2	  days	  after	  plating	  
and	  every	  other	  day	  thereafter.	  Cells	  were	  passaged	  at	  80-­‐90%	  confluency	  at	  a	  ratio	  ranging	  from	  
1	   to	   3	   to	   1	   to	   6.	   They	   were	   detached	   with	   Accutase	   and	   dispersed	   into	   single	   cells	   by	   gentle	  
pipetting;	  after	  centrifugation	  at	  280	  ×	  g	  for	  5	  minutes,	  cells	  were	  resuspended	  in	  B27	  complete	  
medium	  and	  plated	  as	  described	  above.	  
For	   cryopreservation,	   cells	   were	   harvested	   from	   a	   80-­‐90%	   confluent	   well	   of	   a	   6-­‐well-­‐plate	   as	  
described	   for	   passaging.	   The	   cell	   pellet	   was	   resuspended	   in	   freezing	   medium	   containing	   10%	  
DMSO	  and	  10%	  FBS	  in	  B27	  complete	  medium	  and	  put	   in	  one	  cryovial.	  After	  2	  days	  at	   -­‐80°C	   in	  a	  
cryobox,	  the	  vials	  were	  transferred	  to	  liquid	  nitrogen	  for	  long	  term	  storage.	  
One	   vial	   of	   frozen	   cells	   was	   quickly	   thawed	   at	   37°C	   in	   a	   circulating	   water	   bath;	   cells	   were	  
transferred	   to	   a	   new	  15	  ml	   tube	   and	   centrifuged	   at	   280	   ×	  g	   for	   5	  minutes.	   The	   cell	   pellet	  was	  
resuspended	   in	  B27	  complete	  medium	  and	  plated	   in	  1	  well	  of	  a	  6-­‐well-­‐plate.	  The	   following	  day	  






2.5	  Cell	  treatment	  with	  Cre	  recombinase	  
2.5.1	  Cre-­‐mediated	  recombination	  in	  astrocytes	  and	  in	  corresponding	  GPCs	  
To	  induce	  Cre-­‐mediated	  recombination	  in	  astrocytes	  carrying	  the	  conditional	  allele	  for	  Ezh2,	  the	  
cells	   were	   treated	   with	   a	   Cre	   recombinase	   fused	   with	   Human	   Immunodeficiency	   Virus	   (HIV)	  
Transactivator	  of	  Transcription	   (TAT)	  protein	   [Peitz	  et	  al.	  2002].	  Astrocyte	  or	  GPC	  cultures	  were	  
washed	   3	   times	   with	   DPBS.	   For	   transduction,	   purified	   TAT-­‐Cre	   protein	   was	   diluted	   in	   1	   ml	   of	  
HyClone	   animal	   derived	   component	   free	   (ADCF)-­‐MAb™	   medium	   (Thermo	   Scientific).	   After	   3	  
hours,	   medium	   was	   replaced	   with	   fresh	   astrocyte	   culture	   medium	   or	   glioma	   propagating	   cell	  
culture	  medium.	  The	  treatment	  was	  repeated	  every	  day	  for	  5	  to	  7	  consecutive	  days.	  To	  confirm	  
that	   recombination	   had	   occurred,	   genomic	   DNA	   was	   extracted	   from	   cells	   and	   tested	   both	   by	  
polymerase	  chain	  reaction	  (PCR)	  and	  copy-­‐number	  TaqMan®	  assay	  (assay	  ID:	  Mm00178344_cn	  –	  
Applied	  Biosystems).	  
	  
2.5.2	  Cre-­‐mediated	  recombination	  in	  neural	  precursors	  and	  in	  corresponding	  GPCs	  
Neural	  precursors	  were	  derived	  from	  a	  mouse	  strain	  carrying	  both	  the	  conditional	  allele	  for	  Ezh2	  
and	   the	   Cre-­‐ERT2	   transgene	   under	   the	   control	   of	   the	   Rosa26	   promoter.	   To	   activate	   the	   Cre	  
recombinase	  either	   in	   the	  NPs	  or	   in	   the	  corresponding	  GPCs,	  1	  µM	  4-­‐hydroxytamoxifen	   (4-­‐OHT,	  
Sigma)	  was	  added	  to	  the	  culture	  medium	  every	  day	  for	  4	  to	  5	  consecutive	  days.	  To	  confirm	  that	  
recombination	  had	  occurred,	  genomic	  DNA	  was	  extracted	  from	  cells	  and	  tested	  both	  by	  PCR	  and	  
copy-­‐number	  TaqMan®	  assay	  (assay	  ID:	  Mm00178344_cn	  –	  Applied	  Biosystems).	  
	  
2.6	  Protein	  staining	  and	  analysis	  
2.6.1	  Immunofluorescence	  (IF)	  on	  cultured	  cells	  
To	  perform	  immunofluorescence	  on	  cultured	  cells,	  the	  cells	  were	  plated	  either	  on	  glass	  coverslips	  





Nunc).	  After	  removing	  the	  culture	  medium,	  cells	  were	  fixed	  with	  4%	  paraformaldehyde	  (PFA)	  for	  
15	   minutes	   at	   room	   temperature,	   washed	   3	   times	   with	   DPBS,	   incubated	   in	  
permeabilization/blocking	   buffer	   (2%	   bovine	   serum	   albumin,	   BSA	   –	   Sigma,	   0.1%	   Triton	   X-­‐100	   –	  
VWR	   in	  DPBS)	   for	  15	  minutes	  at	   room	  temperature	  and	  washed	  again	  3	   times	   in	  DPBS.	  Primary	  
antibodies	  were	  diluted	  in	  2%	  BSA	  DPBS	  according	  to	  manufacturer	  indications	  and	  incubated	  in	  a	  
humidified	  chamber	  at	  4°C	  overnight.	  Cells	  were	  washed	  3	  times	  in	  DPBS,	  incubated	  with	  specie-­‐
specific	   secondary	   antibodies	   conjugated	   to	   FITC	   and	   Cy3	   (Jackson	   ImmunoReserch),	   washed	  
again	  3	   times	   in	  DPBS	  and	   finally	   incubated	  with	  DAPI:water	  1:5000.	  Slides	  were	  mounted	  with	  
Mowiol®	   (Calbiochem).	   The	   cells	   were	   imaged	   with	   an	   Olympus	   AX70	   upright	   microscope	  
equipped	  with	  a	  Photometrics	  Coolsnap	  EZ	  b/w	  12-­‐bit	  CCD	  camera	  (pixel	  size	  6.45	  µm)	  with	  the	  
software	   MetaVue	   7.5.6.0	   (Molecular	   Devices).	   Image	   analysis	   was	   performed	   with	   ImageJ	  
software.	  
Antibody	   Working	  dilution	   Supplier	   Species	   Clonality	   Code	  
GFAP	   1:500	   DAKO	   Rabbit	   Polyclonal	   Z	  0334	  
Nestin	   1:500	   Millipore	   Mouse	   Monoclonal	   MAB353	  
OLIG2	   1:150	   Millipore	   Rabbit	   Polyclonal	   AB9610	  
	  
Table	  2.	  Antibodies	  used	  in	  immunofluorescence	  
	  
2.6.2	  Fluorescence	  Activated	  Cell	  Sorting	  (FACS)	  
Cells	  were	  harvested	  as	  described	  for	  passaging.	  Cells	  that	  were	  infected	  with	  fluorescent-­‐protein	  
expressing	   viruses	   were	   fixed	   in	   4%	   PFA	   for	   15	   minutes	   at	   room	   temperature	   and	   directly	  
analyzed;	   in	   the	   case	   of	   sorting,	   the	   fixation	   step	  was	   omitted.	   To	   stain	   surface	   antigens,	   cells	  
were	  washed	  in	  DPBS,	  pelleted	  by	  centrifugation	  (280	  ×	  g	  for	  5	  minutes)	  and	  resuspended	  in	  2%	  
BSA	  in	  DPBS.	  Primary	  purified	  antibodies	  were	  added	  according	  to	  manufacturer	  instructions	  and	  
allowed	  to	  bind	  for	  1-­‐2	  hours	  on	  ice.	  Cells	  were	  then	  pelleted	  by	  centrifugation,	  washed	  3	  times	  in	  
DPBS	   (each	   step	   at	   280	   ×	   g	   for	   5	   minutes)	   and	   resuspended	   in	   2%	   BSA	   in	   DPBS.	   They	   were	  
incubated	  with	  secondary	  antibodies	  conjugated	  to	  FITC	  and	  Cy3,	  washed	  again	  3	  times	  in	  DPBS	  





population	  analysis,	  while	  FACSAria	  (Becton	  Dickinson)	  was	  used	  to	  sort	  different	  populations	  of	  
cells.	  Data	  were	  analyzed	  with	  FlowJo®	  software	  (Tree	  Star	  inc.).	  	  	  	  
Antibody	   Working	  dilution	   Supplier	   Species	   Clonality	   Code	  
A2B5	   1:200	   Millipore	   Mouse	   Monoclonal	   MAB312R	  
CD133	   1:100	   eBioscience	   Rat	   Monoclonal	   13-­‐1331	  
	  
Table	  3.	  Antibodies	  used	  for	  FACS	  
	  
2.6.3	  Immunoblotting	  	  
The	   cells	  were	   harvested	   as	   described	   for	   passaging.	   After	   centrifugation,	   the	   supernatant	  was	  
removed,	   cell	   pellet	   was	   lysed	   in	   an	   appropriate	   volume	   of	   radio-­‐immuno-­‐precipitation	   assay	  
buffer	  (RIPA	  buffer,	  150	  mM	  NaCl,	  1%	  Triton	  X-­‐100,	  0.5%	  sodium	  deoxycholate,	  0.1%	  SDS,	  50	  mM	  
Tris	  pH	  8)	  supplemented	  with	  protease	   inhibitors	  (2	  µg/ml	  aprotin,	  5-­‐10	  µg/ml	   leupeptin,	  1	  mM	  
PMSF)	   and	   then	   sonicated	   in	   a	   4°C	  water-­‐bath	   sonicator	   (Bioruptor®	  Diagenode,	   high	   power,	   3	  
cycles	  of	  30	  s	  pulse	  and	  1	  minute	  pause	  each)	  to	  achieve	  complete	  lysis	  of	  the	  cells	  and	  to	  shear	  
genomic	  DNA.	  Protein	  concentration	  was	  determined	  by	  a	  Bradford	  assay	  using	  BSA	  as	  a	  protein	  
standard;	   2	   µl	   of	   lysate	   were	   diluted	   in	   800	   µl	   of	   water	   plus	   200	   µl	   of	   Bio-­‐Rad	   Protein	   Assay	  
(Biorad)	  and	  the	  absorbance	  at	  595	  nm	  was	  measured	  with	  the	  spectrophotometer.	  Proteins	  were	  
separated	   according	   to	   their	   molecular	   weight	   by	   sodium	   dodecyl	   sulfate	   polyacrylamide	   gel	  
electrophoresis	  (SDS-­‐PAGE).	  Fifty	  ng	  of	  proteins	  mixed	  with	  6x	  Laemmli	  buffer	  (375	  mM	  Tris	  HCl	  
pH	  6.8,	  9%	  SDS,	  50%	  glycerol,	  9%	  beta-­‐mercaptoethanol	  ,	  0.03%	  bromophenol	  blue)	  were	  boiled	  
at	   95°C	   for	   5	   minutes	   to	   achieve	   denaturation	   and	   loaded	   on	   a	   gel;	   run	   was	   performed	   in	   a	  
standard	   migration	   buffer	   (25	   mM	   Tris	   base,	   190	   mM	   glycine,	   0.1%	   SDS).	   Proteins	   were	  
transferred	  to	  a	  nitrocellulose	  membrane	  using	  a	  standard	  transfer	  buffer	  (25	  mM	  Tris	  base,	  190	  
mM	   glycine,	   20%	  methanol).	   Efficiency	   of	   the	   transfer	  was	   checked	   by	   staining	   the	  membrane	  
with	  Ponceau	  red	   (VWR);	   the	  membrane	  was	  blocked	   in	  5%	   (w/v)	   skimmed	  milk	  powder	   in	  Tris	  
buffered	  saline	  with	  0.1%	  Tween	  20	  (TBS-­‐T,	  25	  mM	  Tris,	  150	  mM	  NaCl,	  2	  mM	  KCl)	  for	  one	  hour	  at	  





milk	  solution	  and	  allowed	  to	  bind	  overnight	  at	  4°C	  under	  agitation.	  The	  day	  after,	  the	  membrane	  
was	  washed	  3	  times	  for	  5	  minutes	  in	  TBS-­‐T;	  the	  secondary	  antibody	  was	  then	  added	  in	  a	  fresh	  5%	  
milk	   solution	   and	   allowed	   to	   bind	   for	   1	   or	   2	   hours	   at	   room	   temperature.	   The	  membrane	   was	  
washed	  again	  3	  times	  for	  5	  minutes	  in	  TBS-­‐T	  and	  bands	  were	  detected	  with	  ECL	  (GE	  Amersham).	  
Radiographic	  films	  were	  used	  to	  image	  the	  bands.	  
Antibody	   Working	  dilution	   Supplier	   Species	   Clonality	   Code	  
EGFR	   1:1000	   Home	  made	   Rabbit	   Polyclonal	   -­‐	  
EZH2	   1:1000	   Home	  made	   Mouse	   Monoclonal	   -­‐	  
Vinculin	   1:5000	   Sigma	   Mouse	   Monoclonal	   V	  9131	  
	  
Table	  4.	  Antibodies	  used	  in	  immunoblotting	  
	  
3	  DNA	  methods	  
3.1	  DNA	  extraction	  
3.1.1	  Isolation	  of	  genomic	  DNA	  from	  mouse	  tails	  	  
I	  made	  use	  of	  a	  classic	  protocol	  described	  in	  1991	  [Laird	  et	  al.	  1991].	  Tail	  biopsies	  were	  taken	  from	  
pups	  at	  weaning	  age	  by	  the	  IFOM-­‐IEO	  Animal	  House	  facility	  staff.	  They	  were	  incubated	  in	  0.5	  ml	  of	  
lysis	  buffer	  (100	  mM	  Tris-­‐HCl,	  pH	  8.5	  –	  VWR,	  5	  mM	  EDTA	  –	  VWR,	  0.2%	  SDS	  –	  BDH,	  200	  mM	  NaCl	  –	  
VWR	  and	  100	  µg/ml	  proteinase	  K	  –	  Sigma)	   in	  a	  thermomixer	  at	  37°C,	  800	  rpm	  for	  3	  to	  6	  hours.	  
Lysate	  was	  centrifuged	  at	  16000	  ×	  g	  for	  1	  minute	  in	  order	  to	  remove	  non-­‐digested	  tissue;	  half	  of	  
the	  lysate	  was	  put	  in	  a	  new	  tube	  and	  one	  volume	  of	  isopropanol	  (Sigma)	  was	  added	  to	  precipitate	  
DNA.	   After	   centrifugation	   at	   16000	   ×	   g	   for	   10	  minutes,	   the	   DNA	   pellet	   was	   washed	   with	   70%	  
ethanol	   (Sigma)	   and	   centrifuged	   again.	   Finally,	   the	   dried	   DNA	   pellet	   was	   resuspended	   in	   an	  
appropriate	  volume	  of	  water	  or	  1x	  Tris-­‐EDTA	  buffer	  (TE,	  10	  mM	  Tris-­‐HCl	  pH	  8.0,	  1	  mM	  EDTA).	  The	  
remaining	  half	  of	  the	  lysate	  was	  put	  at	  94°C	  for	  10	  minutes	  to	  heat-­‐inactivate	  the	  proteinase	  K.	  1	  







3.1.2	  DNA	  purification	  using	  phenol-­‐chloroform	  extraction	  
To	   remove	  protein	   contaminants	   and	   to	  obtain	   high-­‐molecular	  weight	  molecules,	  DNA	   samples	  
were	  purified	  by	  means	  of	  phenol-­‐chloroform	  extraction.	  An	  equal	  volume	  of	  phenol	  was	  added	  
to	   the	   lysate	   (generally	  obtained	   from	  cell	  pellets,	  using	   the	  same	   lysis	  buffer	  described	  before)	  
and	   the	   phases	  were	  mixed	   by	   vortexing.	   After	   centrifugation	   at	   16000	   ×	   g	   for	   5	  minutes,	   the	  
aqueous	   upper	   layer	   containing	   DNA	   was	   transferred	   to	   a	   new	   tube.	   An	   equal	   volume	   of	  
phenol:chloroform	  1:1	  was	  added,	  mixed	  by	  vortexing	  and	  centrifugated	  as	  in	  the	  previous	  step.	  
The	  aqueous	  phase	  was	  transferred	  to	  a	  new	  tube	  and	  one	  volume	  of	  chloroform:isoamyl	  alcohol	  
24:1	   was	   added	   to	   remove	   any	   trace	   of	   phenol.	   After	   mixing	   and	   centrifugation,	   the	   aqueous	  
phase	  was	  transferred	  to	  a	  new	  tube	  and	  DNA	  was	  precipitated	  by	  ethanol	  precipitation.	  NaCl	  was	  
added	   to	   the	   aqueous	   solution	   to	   a	   final	   concentration	   of	   200	   mM;	   2	   volumes	   of	   cold	   100%	  
ethanol	  were	  added	  and	  mixed	  by	  inversion.	  	  After	  centrifugation	  at	  16000	  ×	  g	  for	  10	  minutes	  at	  
4°C,	   the	   DNA	   pellet	  was	  washed	  with	   70%	   ethanol	   and	   centrifuged	   again.	   The	   DNA	   pellet	  was	  
resuspended	   in	   an	   appropriate	   volume	   of	  water	   or	   TE	   buffer	   and	   quantified	   using	   a	  Nanodrop	  
(Thermo	  Scientific).	  
	  
3.1.3	  DNA	  purification	  using	  Qiagen	  DNeasy®	  blood	  and	  tissue	  kit	  	  
Samples	   were	   first	   lysed	   using	   proteinase	   K.	   Buffering	   conditions	   were	   adjusted	   to	   provide	  
optimal	   DNA	   binding	   conditions	   and	   the	   lysate	   was	   loaded	   onto	   the	   column.	   During	  
centrifugation,	  DNA	  was	   selectively	  bound	   to	   the	  membrane	   in	   the	   column	  while	   contaminants	  
passed	   through.	  Remaining	   contaminants	   and	  enzyme	   inhibitors	  were	   removed	   in	   two	  efficient	  
wash	   steps	   and	  DNA	  was	   then	   eluted	   in	  water	   or	   buffer,	   ready	   for	   use.	   (Adapted	   from	  Qiagen	  








3.2	  Polymerase	  chain	  reaction	  (PCR)	  
3.2.1	  Genotyping	  PCR	  
PCR	   reactions	  were	  usually	   carried	  out	   in	   a	   total	   volume	  of	  25	  µl	  with	  0.8	  mM	  dNTPs	   (0.2	  mM	  
each),	   2	   µM	   of	   each	   primer,	   0.02	   U/µl	   DNA	   polymerase,	   DNA	   template	   (in	   different	   amount	  
depending	   on	   the	   source)	   and	   the	   appropriate	   buffer	   provided	   by	   the	   supplier.	   The	   reaction	  
conditions	  varied	  among	  the	  experiments,	  but	  generally	  followed	  this	  cycling	  steps:	  3	  minutes	  of	  
initial	   denaturation	   at	   95°C,	   35	   cycles	   each	   of	   which	   consisting	   of	   30	   seconds	   denaturation	   at	  
95°C,	  30	  seconds	  of	  annealing	  (temperature	  optimized	  for	  each	  primer	  combination)	  and	  variable	  
extension	   time	   according	   to	   amplicon	   length	   at	   72°C	   and,	   after	   the	   last	   cycle,	   a	   final	   extension	  
step	  of	  7	  minutes	  at	  72°C.	  	  
PCR	  products	  were	   run	  on	  agarose	   gels	   containing	  0.5	  µg/ml	   ethidium	  bromide	   in	   Tris-­‐acetate-­‐
EDTA	  (TAE)	  buffer.	  	  
Gene/Locus	   Primer	  name	   Primer	  sequence	  (5’-­‐3’)	  
Ezh2F	   TTATTCATAGAGCCACCTGG	  
Ezh2	  
Ezh2R	   CTGCTCTGAATGGCAACTCC	  
RosawtF	   AAAGTCGCTCTGAGTTGTTAT	  
RosawtR	   GGAGCGGGAGAAATGGATATG	  Rosa26CreERT2	  
RosacreR	   CCTGATCCTGGCAATTTCG	  
19C10	   TTAACAGCGGAGCTTCGTACA	  
20C10	   CTGCACCGTAGTTGAGCAGAA	  Ink4a/Arf	  
2B2	   GCCTACCCGCTTCCATTGCT	  
	  
Table	  5.	  Primers	  used	  for	  genotyping	  
	  
3.2.2	  Quantitative	  PCR	  for	  copy	  number	  assay	  
10	   ng	   of	   genomic	   DNA	   was	   amplified	   in	   a	   reaction	   volume	   of	   15	   µl	   containing	   the	   following	  
reagents:	  7.5	  µl	  of	  TaqMan®	  PCR	  Mastermix	  2x	  No	  UNG	  (Applied	  Biosystems),	  0.75	  µl	  of	  TaqMan®	  
Copy	  Number	  Assay	  20x	   (Applied	  Biosystems)	  and	  0.75	  µl	  of	  TaqMan®	  Copy	  Number	  Reference	  
Tert	  20x	  (Applied	  Biosystems).	  Real-­‐time	  PCR	  was	  carried	  out	  on	  the	  ABI/Prism	  7900	  HT	  Sequence	  





cycles	   of	   15	   seconds	   at	   95°C	   and	   60	   seconds	   at	   60°C.	   Data	  were	   analyzed	  with	   CopyCaller	   1.0	  
software	  (Applied	  Biosystems).	  
	  
3.3	  Plasmid	  preparation	  
3.3.1	  Bacterial	  transformation	  by	  heat	  shock	  
Chemically	  competent	  bacteria	  (DH5-­‐alpha	  E.	  Coli)	  were	  thawed	  on	  ice.	  25	  ng	  of	  DNA	  were	  added	  
to	  the	  cells	  and	  the	  tube	  was	  incubated	  on	  ice	  for	  30	  minutes.	  The	  tube	  was	  then	  transferred	  to	  a	  
preheated	  42°C	  circulating	  water	  bath,	  incubated	  for	  exactly	  90	  seconds	  and	  rapidly	  moved	  to	  an	  
ice	   bath,	   allowed	   to	   cool	   for	   1-­‐2	  minutes.	   Eight	   hundreds	  µl	   of	   Luria	   Broth	   (LB)	  medium	  were	  
added	  to	  the	  tube	  and	  the	  culture	  was	  then	  kept	  at	  37°C	   for	  45	  minutes	  under	  gentle	  agitation	  
(225	   rpm).	   Hundred	   µl	   of	   transformed	   cells	   were	   then	   plated	   on	   agar-­‐LB	   containing	   the	  
appropriate	  antibiotic;	  plates	  were	  inverted	  and	  incubated	  over	  night	  at	  37°C.	  
	  
3.3.2	  Plasmid	  preparation	  using	  Qiagen	  QIAprep®	  Spin	  Miniprep	  kit	  (miniprep)	  
The	  QIAprep	  miniprep	  procedure	  uses	   the	  modified	  alkaline	   lysis	  method	  of	  Birnboim	  and	  Doly	  
[Birnboim	   et	   al.	   1979].	   Bacteria	   were	   lysed	   under	   alkaline	   conditions,	   and	   the	   lysate	   was	  
subsequently	   neutralized	   and	   adjusted	   to	   high-­‐salt	   binding	   conditions.	   The	   columns	  use	   a	   silica	  
membrane	   for	   selective	   adsorption	   of	   plasmid	   DNA	   in	   high-­‐salt	   buffer	   and	   elution	   in	   low-­‐salt	  
buffer.	   Endonucleases	   and	   salts	   were	   efficiently	   removed	   by	   a	   brief	   wash	   step.	   High-­‐quality	  
plasmid	  DNA	  was	  then	  eluted	  from	  the	  column	  with	  appropriate	  buffer	  or	  water.	  (Adapted	  from	  
Qiagen	  QIAprep	  Miniprep	  kit	  handbook,	  12/2006)	  
	  
3.3.3	  Plasmid	  preparation	  using	  QIAGEN®	  Plasmid	  Purification	  kit	  (maxiprep)	  
Plasmid	   purification	   protocol	   is	   based	   on	   a	   modified	   alkaline	   lysis	   procedure	   as	   described	   for	  





salt	  and	  pH	  conditions.	  RNA,	  proteins,	  dyes,	  and	  low-­‐molecular-­‐weight	  impurities	  were	  removed	  
by	  a	  medium-­‐salt	  wash.	  Plasmid	  DNA	  was	  eluted	  in	  a	  high-­‐salt	  buffer	  and	  then	  concentrated	  and	  
desalted	  by	   isopropanol	  precipitation.	   (Adapted	   from	  Qiagen	  Plasmid	  Purification	  kit	  handbook,	  
11/2005)	  
	  
4	  RNA	  methods	  
4.1	  RNA	  extraction	  
4.1.1	  Total	  RNA	  extraction	  with	  TRIzol®	  Reagent	  
Cell	  pellets	  were	   lysed	  by	  adding	  1	  ml	  of	  TRIzol®	  Reagent	   (Life	  Technologies)	   to	  5-­‐10	  x	  106	  cells	  
and	   incubated	   for	  5	  minutes	  at	   room	   temperature.	  0,2	  ml	  of	   chloroform	  were	  added	  per	  ml	  of	  
TRIzol®	  Reagent,	  mixed	  vigorously	  and	  the	  samples	  were	  incubated	  at	  room	  temperature	  for	  2	  to	  
3	   minutes.	   After	   centrifugation	   at	   12000	   ×	   g	   for	   10	   minutes	   at	   4	   °C,	   the	   upper	   phase	   was	  
transferred	  to	  a	  new	  tube.	  0.5	  ml	  of	  isopropanol	  per	  ml	  of	  TRIzol®	  Reagent	  were	  added,	  samples	  
were	   incubated	   at	   room	   temperature	   for	   5	  minutes	   and	   then	   centrifuged	   at	   12000	   ×	   g	   for	   10	  
minutes	  at	  4	   °C.	   Supernatant	  was	  discarded	  and	   the	  RNA	  pellet	  was	  washed	  with	  75%	  ethanol;	  
after	  centrifugation	  at	  7500	  ×	  g	  for	  5	  minutes	  at	  4	  °C,	  ethanol	  was	  discarded	  and	  the	  pellet	  dried	  
for	  2-­‐3	  minutes.	  The	  RNA	  pellet	  was	  resuspended	  in	  30	  µl	  of	  RNAse-­‐free	  water.	  
	  
4.1.2	  Total	  RNA	  extraction	  with	  Qiagen	  RNeasy®	  Plus	  Mini	  kit	  
Biological	   samples	   were	   first	   lysed	   and	   homogenized	   in	   a	   highly	   denaturing	   guanidine-­‐
isothiocyanate–containing	   buffer,	   which	   immediately	   inactivates	   RNases	   to	   ensure	   isolation	   of	  
intact	  RNA.	  The	  lysate	  was	  then	  passed	  through	  a	  genomic	  DNA	  eliminator	  column.	  This	  column,	  
in	   combination	  with	   the	   optimized	   high-­‐salt	   buffer,	   allowed	   efficient	   removal	   of	   genomic	  DNA.	  
Ethanol	  was	  added	   to	   the	   flow-­‐through	   to	  provide	  appropriate	  binding	  conditions	   for	  RNA,	  and	  





contaminants	  are	  efficiently	  washed	  away.	  High-­‐quality	  RNA	  was	  then	  eluted	  in	  water.	  With	  this	  
procedure,	  all	  RNA	  molecules	   longer	   than	  200	  nucleotides	  are	   isolated.	  The	  procedure	  provides	  
an	   enrichment	   for	  mRNA,	   since	  most	   RNAs	   <200	  nucleotides	   (such	   as	   5.8S	   rRNA,	   5S	   rRNA,	   and	  
tRNAs,	  which	   together	   comprise	   15–20%	  of	   total	   RNA)	   are	   selectively	   excluded.	   (Adapted	   from	  
Qiagen	  RNeasy®	  Plus	  Mini	  kit	  handbook,	  09/2010)	  
	  
4.2	  cDNA	  synthesis	  	  
cDNA	  synthesis	  was	  performed	  according	   to	  SuperScript®	  VILO™	  cDNA	  Syntesis	   kit	   according	   to	  
the	  instructions	  of	  the	  manufacturer.	  Briefly,	  the	  following	  components	  were	  combined	  in	  a	  tube:	  
4	  µl	   of	   5X	   VILO™	   reaction	  mix	   (which	   includes	   random	   primers,	   MgCl2	   and	   dNTPs	   in	   a	   buffer	  
formulation	   optimized	   for	   qRT-­‐PCR),	   2	   µl	   of	   10X	   SuperScript®	   enzyme	   mix	   (which	   includes	  
SuperScript®	   III	   reverse	   transcriptase,	   RNaseOUT™	   recombinant	   ribonuclease	   inhibitor	   and	   an	  
helper	  protein),	  RNA	  up	  to	  2.5	  µg	  (generally	  1	  µg)	  and	  water	  up	  to	  20	  µl.	  Tubes	  were	  incubated	  at	  
25°C	   for	   10	  minutes,	   at	   42°C	   for	   60	  minutes	   and	   finally	   at	   85°C	   for	   5	  minutes	   to	   terminate	   the	  
reaction.	  cDNA	  can	  be	  used	  diluted	  or	  undiluted	  in	  qPCR	  analysis.	  
	  
4.3	  Quantitative	  real-­‐time	  PCR	  (qRT-­‐PCR)	  
4.3.1	  qRT-­‐PCR	  with	  TaqMan®	  assay	  
cDNA	  was	   diluted	   to	   achieve	   a	   concentration	   equivalent	   of	   starting	  with	   100	   ng	   of	   RNA	   in	   the	  
reverse	  transcription	  reaction.	  Five	  ng	  of	  cDNA	  was	  amplified	  (in	  triplicate)	  in	  a	  reaction	  volume	  of	  
15	  µl	  containing	  the	  following	  reagents:	  7.5	  µl	  of	  TaqMan®	  PCR	  Mastermix	  2x	  No	  UNG	  (Applied	  
Biosystems),	  0.75	  µl	  of	  TaqMan®	  Gene	  Expression	  Assay	  20x	  (Applied	  Biosystems).	  Real-­‐time	  PCR	  
was	  carried	  out	  on	  the	  ABI/Prism	  7900	  HT	  Sequence	  Detector	  System	  (Applied	  Biosystems),	  using	  
a	  pre-­‐PCR	  step	  of	  10	  min	  at	  95°C,	  followed	  by	  40	  cycles	  of	  15	  seconds	  at	  95°C	  and	  60	  seconds	  at	  





controls.	   Samples	  were	  amplified	  with	   specific	  primers	   for	  each	  gene	  and	  TATA	  binding	  protein	  
(Tbp)	   as	   housekeeping	   gene.	   Each	   sample	   was	   analyzed	   in	   triplicate	   and	   normalized	   to	   Tbp.	  
Expression	   level	  for	  each	  gene	  is	  calculated	  using	  the	  comparative	  cycle	  threshold	  method	  (ΔCt)	  
and	  relative	  mRNA	  amount	  is	  reported	  as	  2-­‐ΔCt.	  
Gene/Locus	   TaqMan®	  assay	  ID	  
Aldh1l1	   Mm00550947_m1	  
Aqp4	   Mm00802131_m1	  
Ezh2	   Mm00468464_m1	  
Gfap	   Mm01253033_m1	  
Mbp	   Mm01266402_m1	  
Nestin	   Mm00450205_m1	  
Pdgfra	   Mm00440701_m1	  
Slc12a5	   Mm00803929_m1	  
Slc1a3	   Mm00600697_m1	  
Snap25	   Mm00456921_m1	  
Sox10	   Mm01300162_m1	  
Syt1	   Mm00436858_m1	  
Tbp	   Mm00446973_m1	  
	  
Table	  6.	  TaqMan®	  assays	  used	  in	  qRT-­‐PCR	  
	  
5	  Hi-­‐throughput	  experiments	  
5.1	  Chromatin	  immunoprecipitation	  followed	  by	  deep-­‐sequencing	  (ChIP-­‐seq)	  
5.1.1	  ChIP-­‐seq	  	  
Cells	   were	   cross-­‐linked	   with	   1%	   formaldehyde	   in	   DPBS	   for	   10	   minutes	   at	   room	   temperature.	  
Fixation	  was	  quenched	  by	  addition	  of	  glycine	  to	  a	  final	  concentration	  of	  0.125	  M	  for	  5	  minutes	  at	  
room	   temperature.	  Cells	  were	  washed	  2	   times	   in	  DPBS	  and	   then	  harvested	   in	  SDS	  buffer	   (0.5%	  
SDS,	  50	  mM	  Tris	  HCl	  pH8.1,	  100	  mM	  NaCl,	  5	  mM	  EDTA	  pH	  8,	  0.02%	  NaN3)	  with	  protease	  inhibitors	  
(2	   µg/ml	   aprotin,	   5-­‐10	   µg/ml	   leupeptin,	   1	   mM	   PMSF).	   After	   centrifugation	   at	   2000	   rpm	   for	   6	  
minutes,	  cells	  were	  resuspended	  in	  3	  ml	  of	  SDS	  buffer:Triton	  Dilution	  buffer	  1:0.5	  (Triton	  Dilution	  
buffer:	  5%	  Triton	  X-­‐100,	  100	  mM	  Tris	  HCl	  pH	  8.6,	  100	  mM	  NaCl,	  5	  mM	  EDTA	  pH	  8,	  0.02%	  NaN3)	  
and	  sonicated	  on	  ice	  with	  a	  large	  tip	  in	  a	  Branson	  Sonifier	  (20-­‐30	  seconds	  with	  2-­‐3	  minutes	  rest	  in	  





4°C	  and	  protein	  content	  is	  quantified	  using	  Bradford	  assay	  (see	  paragraph	  2.6.3).	  Hundred	  µg	  are	  
diluted	   in	   1	   ml	   of	   SDS	   buffer:Triton	   Dilution	   buffer	   1:0.5;	   10	   µl	   are	   taken	   to	   be	   used	   as	   total	  
control	  (1%	  input).	  	  
Primary	  antibodies	  were	  added	  according	  to	  manufacturer	   instructions	  and	   incubated	  overnight	  
at	  4°C	  on	  a	  rotating	  wheel.	  ChIP	  complexes	  were	  collected	  by	  incubating	  with	  40	  µl	  of	  protein	  A	  
sepharose	  beads	  (GE	  Healthcare)	  for	  2-­‐4	  hours	  at	  4°C	  on	  a	  rotating	  wheel;	  ChIP-­‐bead	  complexes	  
were	   pelleted	   2000	   rpm	  and	  washed	   3	   times	   in	   150	  mM	  NaCl	  Wash	  buffer	   (150	  mM	  NaCl,	   1%	  
Triton	  X-­‐100,	  20	  mM	  Tris	  HCl	  pH	  8.0,	  0.1%	  SDS,	  2	  mM	  EDTA	  pH	  8)	  and	  1	   time	   in	  500	  mM	  NaCl	  
Wash	  buffer	  (500	  mM	  NaCl,	  1%	  Triton	  X-­‐100,	  20	  mM	  Tris	  HCl	  pH	  8.0,	  0.1%	  SDS,	  2	  mM	  EDTA	  pH	  8).	  
ChIP-­‐bead	  complexes	  and	  the	  1%	  input	  were	  incubated	  in	  120	  µl	  of	  1%	  SDS,	  0.1	  M	  NaHCO3	  at	  65°C	  
overnight	   to	   reverse	   crosslink	   of	   proteins	   to	   DNA.	   DNA	   was	   purified	   with	   the	   QIAquick	   PCR	  
purification	   kit	   (Qiagen)	   following	   manufacturer	   instructions	   and	   eluted	   in	   100	   µl	   of	   provided	  
buffer	  EB.	  	  
Antibody	   Working	  dilution	   Supplier	   Species	   Code	  
H3K27me3	   2,7	  µg	  /	  100	  µg	  of	  chromatin	   Cell	  Signaling	   Rabbit	  (M)	   9733	  
H3	   2	  µg	  /	  100	  µg	  of	  chromatin	   Abcam	   Rabbit	  (P)	   ab1791	  
IgG	   1	  µg	  /	  100	  µg	  of	  chromatin	   Sigma	   Rabbit	   I8140	  
	  
Table	  7.	  Antibodies	  used	  in	  chromatin	  immunoprecipitation	  (M:	  monoclonal,	  P:	  polyclonal).	  
	  
For	   the	   sequencing,	   samples	  were	  quantified	   and	   given	   to	   the	   Illumina	   facility	   of	   the	   IFOM-­‐IEO	  
Campus	  which	  performed	  the	  following	  part	  of	  the	  protocol;	  the	  starting	  amount	  of	  DNA	  was	  10	  
ng.	  The	  overhangs	  of	  the	  DNA	  fragments	  were	  converted	   into	  phosphorylated	  blunt	  ends,	  using	  
T4	   DNA	   polymerase,	   E.	   coli	   DNA	   polymerase	   I	   large	   fragment	   (Klenow	   polymerase),	   and	   T4	  
polynucleotide	  kinase.	  The	  3'	  to	  5'	  exonuclease	  activity	  of	  these	  enzymes	  removed	  3'	  overhangs	  
and	  the	  polymerase	  activity	  filled	  in	  the	  5'	  overhangs.	  A	  single	  ‘A’	  nucleotide	  was	  added	  to	  the	  to	  
the	  3'	  end	  of	  the	  blunt	  phosphorylated	  DNA	  fragments,	  using	  the	  polymerase	  activity	  of	  Klenow	  
fragment	  (3'	  to	  5'	  exo	  minus).	  This	  prepared	  the	  DNA	  fragments	  for	  ligation	  to	  the	  adapters,	  which	  





fragments,	  preparing	  them	  to	  be	  hybridized	  to	  a	  flow	  cell.	  DNA	  was	  run	  on	  a	  TAE	  2%	  agarose	  gel	  
to	   remove	   excess	   adaptors	   and	   selects	   a	   size	   range	   of	   templates;	   a	   gel	   slice	   containing	   the	  
material	  in	  the	  200±25	  bp	  range	  was	  cut	  from	  the	  gel	  and	  purified	  with	  QIAquick	  Gel	  Extraction	  Kit	  
(Qiagen)	   according	   to	   manufacturer	   instructions.	   The	   adapter-­‐modified	   DNA	   fragments	   were	  
enriched	   by	   PCR	   amplification	   using	   the	   gel-­‐extracted	   DNA.	   (Adapted	   from	   ChIP-­‐seq	   Sample	  
Preparation	  Guide	   2007,	   Illumina).	   Sequencing	  was	   performed	   on	   Illumina	  Genome	  Analyzer	   II,	  
using	  36	  bp	  paired	  end	  reads.	  	  	  	  
	  
5.1.2	  Bioinformatic	  analysis	  of	  ChIP-­‐seq	  
Raw	   data	   from	   the	   sequencing	   experiments	   were	   aligned	   to	   the	   reference	   mouse	   genomic	  
sequence	   (NCBI37/mm9,	   July	  2007)	  with	  BowTie	  v.0.12.7	   [Langmead	  et	  al.	  2009]	  allowing	  up	  to	  
two	  mismatches	  per	  read	  and	  discarding	  multiply-­‐aligning	  reads.	  To	  identify	  enriched	  domains	  we	  
used	   MACS	   v.1.4.0	   [Zhang	   et	   al.	   2008]	   which	   estimates	   the	   enrichment	   of	   the	   specific	   signal	  
against	  a	  noise	  signal	   (input).	  Enriched	  regions	  were	  assigned	  to	  genes	  by	  determining,	   for	  each	  
RefSeq	   transcript,	   whether	   an	   enriched	   domain	   overlapped	   with	   a	   +/-­‐5kb	   region	   around	   the	  
transcription	  start	  site	  (TSS).	  
	  
5.2	  Whole	  Transcriptome	  Shotgun	  Sequencing	  
5.2.1	  RNA-­‐seq	  	  
Total	  RNA	  was	  extracted	  with	  the	  Qiagen	  RNeasy®	  Plus	  Mini	  kit	  (see	  paragraph	  4.1.2).	  	  
The	  following	  part	  of	  the	  protocol	  was	  performed	  by	  the	  Illumina	  facility	  of	  the	  IFOM-­‐IEO	  Campus;	  
the	   starting	   amount	   of	   total	   RNA	   was	   4	  µg.	   From	   the	   total	   RNA,	   the	   poly-­‐A	   containing	  mRNA	  
molecules	   were	   purified	   using	   poly-­‐T	   oligo	   attached	   magnetic	   beads	   using	   two	   rounds	   of	  
purification.	   During	   the	   second	   elution	   of	   the	   poly-­‐A	   RNA,	   the	   RNA	  was	   also	   fragmented	   using	  





hexamers.	 The	   primed	   and	   cleaved	   RNA	   fragments	   were	   reverse	   into	   first	   strand	   cDNA	   using	  
reverse	  transcriptase	  and	  random	  primers.	  The	  RNA	  template	  was	  removed	  with	  RNase	  H	  and	  a	  
replacement	  strand	  was	  synthesized	  with	  DNA	  Polymerase	  I	  to	  generate	  double-­‐strand	  (ds)	  cDNA.	  
Beads	  (AMPure	  XP	  beads)	  are	  used	  to	  separate	  the	  ds	  cDNA	  from	  the	  second	  strand	  reaction	  mix.	  
Overhangs	  resulting	  from	  fragmentation	  were	  converted	  into	  blunt	  ends	  using	  an	  End	  Repair	  Mix:	  
the	  3'	  to	  5'	  exonuclease	  activity	  of	  this	  mix	  removes	  the	  3'	  overhangs	  and	  the	  polymerase	  activity	  
fills	  in	  the	  5'	  overhangs.	  A	  single	  ‘A’	  nucleotide	  was	  added	  to	  the	  3'	  ends	  of	  the	  blunt	  fragments	  to	  
prevent	  them	  from	  ligating	  to	  one	  another	  during	  the	  adapter	  ligation	  reaction.	  A	  corresponding	  
single	  ‘T’	  nucleotide	  on	  the	  3'	  end	  of	  the	  adapter	  provided	  a	  complementary	  overhang	  for	  ligating	  
the	  adapter	  to	  the	  fragment.	 This	  strategy	  ensures	  a	  low	  rate	  of	  chimera	  (concatenated	  template)	  
formation.	  Multiple	   indexing	  adapters	  were	   ligated	  to	  the	  ends	  of	   the	  ds	  cDNA,	  preparing	  them	  
for	  hybridization	  onto	  a	   flow	  cell.	  PCR	  was	  used	   to	  selectively	  enrich	   those	  DNA	   fragments	   that	  
have	  adapter	  molecules	  on	  both	  ends	  and	  to	  amplify	  the	  amount	  of	  DNA	  in	  the	  library.	  Fragments	  
with	   only	   one	   or	   no	   adapters	   on	   their	   ends	   are	   by-­‐products	   of	   inefficiencies	   in	   the	   ligation	  
reaction.	  Neither	  species	  can	  be	  used	  to	  make	  clusters,	  as	  fragments	  without	  any	  adapters	  cannot	  
hybridize	  to	  surface-­‐bound	  primers	   in	   the	   flow	  cell,	  and	  fragments	  with	  an	  adapter	  on	  only	  one	  
end	   can	   hybridize	   to	   surface	   bound	   primers	   but	   cannot	   form	   clusters.	   The	   PCR	  was	   performed	  
with	  a	  PCR	  primer	  cocktail	  that	  anneals	  to	  the	  ends	  of	  the	  adapters.	  (Adapted	  from	  TruSeq®	  RNA	  
Sample	  Preparation	  v2	  Guide	  05/2012,	  Illumina).	  Sequencing	  was	  performed	  on	  Illumina	  I-­‐seq	  2K,	  
using	  50	  bp	  paired	  end	  reads.	  
	  
5.2.2	  Bioinformatic	  analysis	  of	  RNA-­‐seq	  
Raw	   data	   from	   the	   sequencing	   experiments	   were	   aligned	   to	   the	   reference	   mouse	   genomic	  
sequence	  (NCBI37/mm9,	  July	  2007)	  with	  TopHat-­‐CuffLink	  software	  pipeline	  [Trapnell	  et	  al.	  2012].	  
TopHat	  is	  a	  program	  that	  aligns	  RNA-­‐Seq	  reads	  to	  a	  genome	  in	  order	  to	  identify	  exon-­‐exon	  splice	  





reads	   to	   the	   genome,	   TopHat	   identifies	   potential	   exons,	   since	   many	   RNA-­‐Seq	   reads	   will	  
contiguously	   align	   to	   the	   genome.	   Using	   this	   initial	   mapping	   information,	   TopHat	   builds	   a	  
database	  of	  possible	  splice	  junctions,	  and	  then	  maps	  the	  reads	  against	  these	  junctions	  to	  confirm	  
them.	  Short	   read	   sequencing	  machines	   can	  currently	  produce	   reads	  100bp	  or	   longer,	  but	  many	  
exons	   are	   shorter	   than	   this,	   and	   so	  would	   be	  missed	   in	   the	   initial	  mapping.	   TopHat	   solves	   this	  
problem	   by	   splitting	   all	   input	   reads	   into	   smaller	   segments,	   and	   then	   mapping	   them	  
independently.	  The	  segment	  alignments	  are	  "glued"	  back	  together	  in	  a	  final	  step	  of	  the	  program	  
to	  produce	  the	  end-­‐to-­‐end	  read	  alignments.	  	  
The	  alignment	  is	  then	  revised	  by	  the	  software	  Cufflink,	  which	  generated	  enrichment	  maps	  used	  to	  
quantify	   the	   abundance	   of	   the	   transcripts.	   Cufflinks	   assembles	   transcripts,	   estimates	   their	  
abundances,	   and	   tests	   for	  differential	   expression	  and	   regulation	   in	  RNA-­‐Seq	   samples.	   It	   accepts	  
aligned	   RNA-­‐Seq	   reads	   and	   assembles	   the	   alignments	   into	   a	   parsimonious	   set	   of	   transcripts.	  
Cufflinks	   then	  estimates	  the	  relative	  abundances	  of	   these	  transcripts	  based	  on	  how	  many	  reads	  
support	  each	  one,	  taking	  into	  account	  biases	  in	  library	  preparation	  protocols.	  Replicates	  (e.g.:	  all	  
the	   data	   from	   different	   samples	   of	   astrocytes)	   were	   analyzed	   together	   and	   a	   p-­‐value	   was	  
associated	   at	   each	   transcript;	   the	   lower	   the	   p-­‐value,	   the	   more	   expression	   values	   were	   similar	  
among	  the	  samples.	  After	  this	  first	  step,	  through	  the	  CuffDiff	  plug-­‐in,	  different	  group	  of	  samples	  
were	  compared	  (e.g.:	  astrocytes	  versus	  gliomas)	  and	  a	  second	  p-­‐value	  was	  generated;	  the	  lower	  
the	  p-­‐value,	  the	  more	  expression	   levels	  were	  different	  between	  the	  groups.	  Data	  on	  differential	  
expression	  were	  then	  validated	  by	  qRT-­‐PCR.	  	  
	  
5.3	  Functional	  Annotation	  Analysis	  (FAA)	  
5.3.1	  Gene	  Ontology	  analysis	  
Cytoscape	   software	   and	   the	   BiNGO	   plugin	   [Maere	   et	   al.	   2005]	   were	   used	   to	   analyze	   Gene	  
Ontology	  terms,	  particularly	  biological	  processes	  and	  molecular	  functions,	  significantly	  associated	  





P	   values	   were	   corrected	   using	   FDR	   procedure.	   All	   terms	   with	   a	   FDR	   <0.05	   were	   considered	  
associated.	  	  
5.3.2	  Analysis	  of	  KEGG	  pathway	  enrichment	  
DAVID	  online	  analysis	  tools	  [Huang	  et	  al.	  2009]	  were	  used	  to	  interrogate	  KEGG	  database	  in	  order	  
to	  find	  annotated	  pathways	  significantly	  associated	  to	  the	  various	  gene	  sets.	  The	  enrichment	  for	  
each	   term	   was	   tested	   using	   hypergeometric	   test	   and	   P	   values	   were	   corrected	   using	   FDR	  
procedure.	  All	  the	  pathways	  with	  a	  FDR	  <0.05	  were	  considered	  associated.	  
	  
6	  Stereotaxic	  injection	  
Tumor	  initiation	  assays	  were	  carried	  out	  using	  stereotaxic	  apparatus	  to	  inject	  cells	  into	  the	  brain	  
of	  immunocompromised	  recipient	  mice	  (CD1®	  nude	  HO	  –	  Charles	  River).	  Cells	  were	  harvested	  as	  
described	   for	   passaging.	  Astrocytes	   and	  GICs	  were	   counted	  with	   a	  hemocytometer,	   pelleted	  by	  
centrifugation	  and	   resuspended	   in	  an	  appropriate	   volume	  of	  DPBS	   in	  order	   to	  have	  2-­‐2.5	  ×	  104	  
cells	  per	  microliter.	  NPs	  were	  counted	  with	  an	  hemocytometer	  under	  a	  fluorescence	  microscope	  
(Olympus	   IX81	   inverted	  microscope,	  equipped	  with	  a	  Photometrics	  Coolsnap	  EZ	  b/w	  12-­‐bit	  CCD	  
camera,	  pixel	  size	  6.45	  µm;	  images	  were	  acquired	  with	  MetaMorph	  7.5.6.0	  software	  by	  Molecular	  
Device	  and	  analyzed	  with	  ImageJ	  software)	  in	  order	  to	  determine	  the	  percentage	  of	  infected	  cells;	  
after	  centrifugation,	  cells	  were	  resuspended	  in	  an	  appropriate	  volume	  of	  DPBS	  in	  order	  to	  have	  5	  
×	   103	   infected	   cells	   per	   microliter.	   Each	   animal	   was	   anaesthetized	   by	   intraperitoneal	  
administration	  of	   tri-­‐bromo-­‐ethanol	   (avertin)	  at	   the	  concentration	  of	  0.25-­‐0.5	  mg/g.	  The	  mouse	  
was	   then	   placed	   into	   a	   stereotaxic	   frame	   to	   determine	   the	   exact	   coordinates	   for	   the	   site	   of	  
injection	   on	   the	   3	   axis	   (x,y,z),	   as	   represented	   in	   Figure	   4.	   The	   skin	   of	   the	   head	  was	   cut	  with	   a	  
scalpel	   and	   the	   needle	   tip	   (gauge	   26s,	   point	   style	   2)	   of	   a	   Hamilton	   syringe	  was	   aligned	   to	   the	  
bregma;	  the	  x	  and	  y	  coordinates	  were	  measured	  and	  in	  that	  point	  a	  hole	  was	  drilled	  in	  the	  skull	  
with	   a	   dentist	   drill.	   The	   syringe	  was	   loaded	  with	   cells	   resuspended	   in	  DPBS	   (3	   to	   5	  µl)	   and	   the	  





steps	  (half	  of	  the	  volume	  at	  each	  step),	  with	  a	  1	  minute	  pause	  in	  between.	  One	  minute	  after	  the	  
second	  step,	  the	  needle	  was	  pulled	  up	  by	  half	  of	  the	  z	  coordinate	  and	  after	  3	  more	  minutes	  it	  was	  
pulled	  out	  from	  the	  skull.	  The	  wound	  of	  the	  skin	  was	  sealed	  with	  a	  surgical	  clip.	  
	  
Figure	  4.	  Determination	  of	  stereotaxic	  coordinates.	  	  
	  
7	  Histopathology	  
7.1	  Brain	  processing	  
7.1.1	  Paraffin-­‐embedding	  of	  adult	  brain	  
Mice	  were	   sacrificed	   at	   the	  onset	   of	   frank	  neurological	   symptoms.	   The	  brain	  was	   taken,	   rinsed	  
quickly	  in	  PBS	  to	  remove	  blood	  and	  then	  put	  overnight	  in	  formalin	  for	  fixation.	  The	  following	  day,	  
it	  was	  cut	  in	  1	  mm-­‐	  thick	  slices	  which	  were	  in	  turn	  placed	  in	  histological	  cassettes.	  The	  tissue	  was	  
processed	   in	   an	   automatized	   tissue	   processor.	   After	   processing,	   the	   slices	   were	   embedded	   in	  
paraffin	  and	  stored	  at	   room	  temperature;	  paraffin	  blocks	  were	  cut	  with	  a	  microtome	  (Leica	  RM	  
1450	  S)	  in	  4	  µm	  thick	  sections	  that	  were	  attached	  onto	  glass	  slides	  for	  further	  analysis.	  
	  
7.1.2	  OCT-­‐	  embedded	  brain	  
Mice	  were	  sacrificed	  at	  the	  onset	  of	  frank	  neurological	  symptoms.	  The	  brain	  was	  taken	  and	  rinsed	  
quickly	  in	  DPBS	  to	  remove	  blood	  and	  then	  put	  overnight	  in	  PFA	  for	  fixation.	  The	  following	  day,	  the	  





then	  transferred	  into	  a	  15	  ml	  tube	  and	  incubated	  in	  a	  1:1	  mixture	  of	  OCT	  and	  30%	  (w/v)	  sucrose	  
on	  a	  rotating	  wheel	  at	  room	  temperature	  for	  one	  hour.	  The	  brain	  was	  then	  embedded	  and	  frozen	  
in	  OCT	  on	  dry-­‐ice	  and	  placed	  at	  -­‐80	  °C	  for	  long	  term	  storage.	  The	  night	  before	  cutting	  the	  brain,	  it	  
was	  moved	  to	  -­‐20	  °C	  to	  equilibrate	  the	  OCT	  at	  the	  cutting	  temperature.	  12	  µm	  thick	  sections	  were	  
cut	  with	  a	  Leica	  cryostat	  and	  placed	  onto	  SuperFrost®	  Microscope	  Slides	   (Thermo	  Scientific)	   for	  
further	  analysis.	  	  	  
	  
7.2	  Staining	  
7.2.1	  Hematoxylin	  –	  eosin	  staining	  
Hematoxylin	   –	   eosin	   staining	  was	   performed	   in	   the	   Anatomo-­‐pathology	  Unit	   of	   the	   S.	   Raffaele	  
Institute	  using	  an	  automated	  colorator	  (Leica	  ST	  5020).	  Briefly,	  glass	  slides	  with	  paraffin	  sections	  
were	   deparaffinized,	   re-­‐hydrated,	   coloured,	   de-­‐hydrated	   and	   finally	   mounted	   with	   a	   toluemic-­‐
based	   non-­‐aqueous	   glue.	  Glass	   slides	  were	  washed	   for	   3	  minutes	   in	   Bioclear	   (Bio	  Optica)	   for	   4	  
times	  to	  achieve	  deparaffinization;	  they	  were	  then	  soaked	  in	  a	  descending	  alcohol	  scale,	  2	  times	  
in	   99%	   ethanol,	   2	   times	   in	   95%	   ethanol	   and	   1	   time	   in	   70%	   ethanol,	   1.5	  minutes	   for	   each	   step	  
followed	  by	  a	   longer	  step	  of	  3	  minutes	   in	  70%	  ethanol.	  Slides	  were	  moved	   into	  hematoxylin	   for	  
1.5	   minutes,	   allowed	   to	   change	   colour	   for	   5	   minutes	   in	   water	   and	   stained	   with	   eosin	   for	   3	  
minutes.	  De-­‐hydration	  was	  performed	  by	  soaking	  the	  slides	  once	   in	  95%	  ethanol	  and	  2	  times	   in	  
99%	  ethanol,	  each	   step	   lasting	  1.5	  minutes.	  To	  clarify	   the	   staining,	  2	   steps	  of	  1.5	  minutes	  were	  
performed	  in	  Bioclear.	  After	  the	  staining,	  slides	  are	  mounted	  with	  Mowiol	  by	  an	  automated	  glass-­‐
mounter	  Leica	  CV	  5030.	  	  
	  
7.2.2	  Immunohistochemistry	  
Paraffin-­‐embedded	   sections	   were	   cut	   as	   previously	   described.	   Sections	   were	   washed	   in	   Xylol	  





95%	  and	  70%	  ethanol	  (10	  minutes	  for	  each	  step).	  The	  antigen	  is	  unmasked	  in	  Tris-­‐EDTA	  pH	  9	  in	  a	  
water-­‐bath	   at	   97°C	   for	   30	   minutes;	   endogenous	   peroxidase	   is	   inhibited	   with	   3%	   hydrogen	  
peroxide	   (H2O2)	   for	  5	  minutes.	   Sections	  were	   then	   incubated	   in	  blocking	  buffer	   for	  10	  minutes;	  
primary	   antibodies	   were	   diluted	   in	   2%	   BSA	   in	   DPBS	   and	   allowed	   to	   bind	   for	   1	   hour	   at	   room	  
temperature.	   After	   washing,	   sections	   are	   incubated	   with	   the	   secondary	   antibodies	   for	   half	   an	  
hour	  at	  room	  temperature.	  Staining	  is	  contrasted	  by	  hematoxylin	  staining	  (10	  s);	  sections	  are	  then	  
de-­‐hydrated	  (95%	  and	  99%	  ethanol,	  10	  minutes	  each)	  and	  glass	  are	  mounted	  with	  90%	  glycerol	  in	  
DPBS.	  
Antibody	   Working	  dilution	   Supplier	  
Ezh2	   1:500	   Novocastra	  
Ki-­‐67	   1:500	   DAKO	  
	  
Table	  8.	  Antibodies	  used	  in	  immunohistochemistry	  
	  
7.2.3	  Immunofluorescence	  
Paraffin-­‐embedded	   sections	   were	   cut	   as	   previously	   described.	   Sections	   were	   washed	   in	   Xylol	  
(Sigma)	  for	  30	  minutes	  to	  remove	  paraffin	  and	  hydrated	  in	  a	  descending	  alcoholic	  scale	  with	  99%,	  
95%	  and	  70%	  ethanol	  (10	  minutes	  for	  each	  step).	  The	  antigen	  is	  unmasked	  in	  Tris-­‐EDTA	  pH	  9	  in	  a	  
water-­‐bath	   at	   97°C	   for	   30	   minutes.	   Sections	   were	   then	   incubated	   in	   blocking	   buffer	   for	   10	  
minutes;	  primary	  antibodies	  were	  diluted	   in	   2%	  BSA	   in	  DPBS	  and	  allowed	   to	  bind	   for	  1	  hour	  at	  
room	   temperature.	   Sections	   were	   washed	   and	   incubated	   with	   specie-­‐specific	   secondary	  
antibodies	   conjugated	   to	   Alexa	   fluor	   555	   or	   488.	   Nuclei	   are	   stained	  with	   DAPI	   and	   glasses	   are	  
mounted	  with	  90%	  glycerol	  in	  DPBS.	  Imaging	  was	  done	  as	  described	  for	  immunofluorescence	  (see	  
paragraph	  2.6.1).	  
Antibody	   Working	  dilution	   Supplier	  
Ezh2	   1:500	   Novocastra	  
	  






7.3	  Histopathological	  classification	  
Tumors	  were	  classified	  according	  to	  the	  World	  Health	  Organization	  (WHO)	  classification	  following	  






1.	  The	  Ink4a/Arf-­‐/-­‐/EGFRvIII	  overexpression	  tumor	  model	  
The	  first	  model	   I	  exploited	  to	  pursue	  the	  objectives	  of	  my	  project	   is	  a	  well	  established	  model	  of	  
gliomagenesis,	  that	  relies	  on	  the	  loss	  of	  Ink4a/Arf	  combined	  with	  the	  over	  expression	  of	  EGFRvIII	  
[Bachoo	  et	  al.	  2002].	  The	  EGFRvIII	  is	  vital,	  as	  it	  has	  been	  demonstrated	  that	  p16INK4a/p19ARF-­‐/-­‐	  mice	  
develop	  spontaneous	  sarcomas	  and	  lymphomas,	  but	  this	  mutation	  alone	  is	  not	  sufficient	  to	  drive	  
glioma	   [Serrano	  et	   al.	   1996].	   This	  model	   recapitulates	  well	   the	  human	  counterpart,	  both	  at	   the	  
genetic	  and	  histological	  level,	  since	  the	  association	  of	  those	  two	  mutations	  is	  frequent	  in	  human	  
gliomas	  [von	  Deimling	  et	  al.	  1992,	  Hayashi	  et	  al.	  1997,	  Hegi	  et	  al.	  1997,	  TCGAN	  2008].	  Moreover,	  
the	   combination	   of	   these	   mutations	   was	   shown	   to	   provoke	   high-­‐grade	   gliomas	   with	   100%	  
penetrance.	  	  
	  	  	  	  
1.1	  Characterization	  of	  astrocyte	  cultures	  
I	   started	   off	   by	   validating	   the	   set	   up	   of	   the	   experimental	   system.	   For	   this	   purpose	   p16/p19-­‐/-­‐	  
cortical	  astrocytes	  were	  derived	  from	  pups	  5	  days	  after	  birth	  following	  the	  same	  protocol	  used	  in	  
the	  original	  study	  by	  Bachoo	  et	  al.	  (see	  Material	  and	  Methods	  for	  detailed	  description)	  [McCarthy	  
et	  al.	  1980].	  Cultures	  were	  characterized	  by	  checking	  the	  expression	  at	  the	  mRNA	  level	  of	  several	  
markers	  that	  were	  shown	  to	  be	  specific	  for	  different	  central	  nervous	  system	  cell	  types	  [Cahoy	  et	  
al.	   2008].	   I	   assessed	   expression	   of	   four	   astrocyte-­‐specific	   (Gfap,	   Aqp4,	   Aldh1l1,	   Slc1a3),	   three	  
neuronal-­‐specific	  (Syt1,	  Slc12a5,	  Snap25),	  three	  oligodendroglial-­‐specific	  markers	  (Pdgfra,	  Sox10,	  
Mbp)	  and	  Nestin	  (Figure	  5).	  Astrocyte	  markers	  are	  highly	  expressed	  indicating	  that	  the	  majority	  of	  
the	   cells	   in	   culture	   belong	   to	   the	   astroglial	   lineage,	   but	   also	  Pdgfra	   (oligodendrocyte	   precursor	  







Figure	  5.	  Astrocyte	  specific	  markers	  are	  highly	  expressed	  by	  the	  cells	  in	  culture.	  TaqMan	  assay	  on	  4	  different	  astrocytic	  
cell	   lines	   revealed	   that	   cells	   in	   culture	   are	   expressing	   high	   levels	   of	   astrocyte-­‐specific	   genes	   (Gfap,	   Aqp4,	   Aldh1l1,	  
Slc1a3)	   and	   low	   levels	   of	  Pdgfra	   (marker	  of	   oligodendrocyte	  precursors)	   and	  Nestin.	  Other	  oligodendrocytic	  markers	  
corresponding	   to	   a	   more	   differentiated	   stage	   (i.e.	   myelinating	   oligodendrocytes)	   and	   neuronal	   markers	   are	   not	  
expressed.	  mRNA	  levels	  are	  calculated	  for	  each	  gene	  using	  the	  comparative	  cycle	  threshold	  method	  (ΔCt)	  and	  relative	  
mRNA	  amount	  compared	  to	  Tbp	  is	  reported	  as	  2-­‐ΔCt.	  Bars	  represent	  the	  positive	  standard	  deviation	  (S.D.).	  	  
	  
Astrocyte	  cultures	  showed	  a	  mild	  grade	  of	  heterogeneity	  in	  the	  morphology	  of	  the	  cells	  (figure	  6,	  
a,	   c,	   e).	   This	  was	   not	   completely	   unexpected	   since	  maturation	  of	   astrocytes	   in	   vivo	   is	   achieved	  
towards	   the	   4th	   week	   after	   birth	   [Baumann	   et	   al.	   2001]	   and,	   with	   this	   protocol,	   I	   derived	   cells	  
within	   the	   1st	   week	   after	   birth.	   In	   order	   to	   characterize	   my	   cultures,	   I	   performed	  
immunocytochemistry	  for	  glial	  fibrillary	  acidic	  protein	  (GFAP),	  nestin	  and	  OLIG2	  (figure	  6,	  b,	  d,	  f).	  
OLIG2	   is	   a	   transcription	   factor	   required	   for	   oligodendrocyte	   differentiation	   that	   is	   expressed	   in	  
oligodendrocyte	   precursors	   [Lu	   et	   al.	   2000,	   Zhou	   et	   al.	   2000].	   Nestin	   is	   a	   member	   of	   type	   VI	  
intermediate	  filament	  (IF)	  protein	  family	  [Lendhal	  et	  al.	  1990].	  It	  starts	  being	  expressed	  in	  neural	  
stem	   cells	   throughout	   the	   developing	   neuraxis	   during	   embryonic	   development	   and	   it	   is	   down-­‐
regulated	  postnatally,	  when	  it	  is	  replaced	  by	  cell-­‐type	  specific	  IFs.	  Specifically,	  during	  gliogenesis	  it	  
is	  gradually	  replaced	  by	  GFAP,	  a	  type	  III	  IF	  protein.	  Nestin	  is	  currently	  used	  as	  a	  neural	  stem	  cell	  or	  
neural	  progenitor	  marker,	  while	  GFAP	   identifies	  astroglial	   and	   radial	   glial	   cells.	   In	  my	  cultures	  a	  





nestin+	   or	   OLIG2+	   cells.	   It	   was	   previously	   shown	   that	   nestin+	   neural	   progenitors	   are	   found	   in	  
astrocyte	   cultures	   established	   from	   newborn	   rodent	   cortices	   [Sergent-­‐Tanguy	   et	   al.	   2006].	   In	  
addition,	  OLIG2	  is	  expressed	  in	  immature	  cortical	  astrocytes	  during	  early	  postnatal	  stages	  [Cai	  et	  












Figure	  6.	  The	  astrocyte	  culture	  is	  mildly	  heterogeneous.	  Morphologically,	  the	  astrocyte	  culture	  appears	  to	  own	  a	  minor	  
level	  of	  heterogeneity.	  Astrocytes	  (a),	  stained	  for	  GFAP	  (b),	  represent	  the	  most	  abundant	  population.	  Sparse	  clusters	  of	  
immature	   cells	   from	  which	  more	   differentiated	   cells	   are	   spreading	   out	   (c)	   are	   identified	   through	   nestin	   staining	   (d;	  
nestin:	   red,	  GFAP:	   green).	  Oligodendrocyte	   precursors	   (e,	   arrows)	   and	  OLIG2+	   cells	   (f)	   are	   also	   found.	   (10x	   in	   all	   the	  
panels	  except	  for	  panel	  e,	  20x)	  
	  
1.2	  Orthotopic	   transplantation	  of	  astrocytes	   into	   immunocompromised	  mice	  and	   tumor	  
formation	  
In	   order	   to	   introduce	   the	   second	   alteration	   upon	   the	   constitutive	   p16/p19	   knockout	   to	   fully	  
transform	   astrocytes,	   cells	  were	   infected	  with	   a	   retroviral	   vector	   encoding	   the	  mutant	   form	   of	  















Figure	   7.	   EGFRvIII	   is	   highly	   expressed	   in	   astrocyte	   cultures	   upon	   infection.	   Western	   Blot	   analysis	   on	   4	   different	  
astrocytic	   cell	   lines	   (Astro	   1-­‐4)	   showed	   that	   hEGFRvIII	   is	   expressed	   upon	   infection	   (HeLa	   extract	   is	   used	   as	   positive	  
control	  for	  the	  detection	  of	  human	  EGFR).	  	  
	  
In	  order	  to	  assess	  the	  tumorigenicity	  of	  the	  transformed	  astrocytes,	  I	  transplanted	  them	  into	  the	  
brain	  of	  recipient	  immunocompromised	  mice.	  These	  animals	  lack	  the	  thymus	  and	  therefore	  fail	  to	  
generate	  mature	  T-­‐cells.	  Being	  unable	  to	  mount	  a	  proper	  immune	  response,	  they	  are	  prevented	  
from	   rejecting	   xenografts.	   The	   day	   of	   injection,	   cells	   were	   harvested,	   counted	   with	   an	  
hemocytometer	  and	  resuspended	  in	  DPBS	  in	  order	  to	  have	  a	  concentration	  of	  2-­‐2.5	  ×	  104	  cells	  per	  
µl.	  Nude	  mice	  were	  anaesthetized,	  placed	  in	  the	  stereotaxic	  frame	  and	  injected	  with	  5	  ×	  104	  to	  1	  ×	  
105	  transformed	  astrocytes	  using	  stereotaxic	  coordinates	  corresponding	  to	  a	  posterior	  portion	  of	  
the	   caudate	   (0.7	   mm	   back,	   3	   mm	   left	   and	   3.5	   mm	   deep	   from	   the	   bregma).	   At	   the	   onset	   of	  
neurological	  symptoms,	  mice	  were	  sacrificed	  and	  brains	  were	  isolated	  from	  the	  head	  for	  further	  
analyses.	  I	  confirmed	  that	  this	  model	  was	  fully	  penetrant	  as	  I	  obtained	  lethal	  tumors	  from	  all	  the	  
mice	  I	  injected	  (n=29).	  Tumors	  were	  obvious	  and	  had	  glioma	  like	  appearance	  at	  the	  macroscopic	  



















Figure	  8.	  Tumors	  are	   identified	  at	  macroscopic	   level.	  a,	  b.	  Swollen	  hemorrhagic	   lesion	  typical	  of	  high	  grade	  gliomas.	  
The	  injected	  hemisphere	  (left,	  L)	  appears	  enlarged	  compared	  to	  the	  right	  (R)	  counterpart,	  both	  in	  the	  freshly	   isolated	  
brain	  (c)	  and	  in	  the	  fixed	  brain	  (d,	  hematoxylin-­‐eosin	  staining).	  In	  the	  close-­‐ups	  (10x)	  a	  comparison	  is	  made	  between	  the	  
left	  and	  the	  right	  parenchyma,	  the	  first	  one	  showing	  hypercellularity	  and	  a	  complete	  invasion	  by	  tumor	  cells.	  	  	  
	  
1.3	  Histopathological	  analysis	  and	  classification	  of	  the	  tumors	  
Tumors	   were	   processed	   according	   to	   standard	   procedures	   used	   for	   histopathological	   analysis.	  
They	   were	   independently	   classified	   following	   the	   World	   Health	   Organization	   guidelines,	   in	  
collaboration	   with	   Dr.	   Doglioni	   and	   Dr.	   Terreni	   from	   the	   Anatomo-­‐pathology	   Unit	   of	   the	   San	  
Raffaele	  Hospital	   in	  Milan.	   Some	  of	   the	   tumors	   clearly	   showed	   glioblastoma	  multiforme	   (GBM)	  
features	  such	  as	  pseudopalisading	  necrosis,	  neoangiogenesis	  and	  a	  high	  mitotic	  index	  (Figure	  9,	  a-­‐
b).	  In	  addition,	  a	  thorough	  histological	  classification	  pointed	  out	  distinct	  variants	  of	  these	  gliomas,	  
such	  as	  oligodendrogliomas,	  oligoastrocytomas	  and	  gliosarcomas	  (Figure	  9,	  d-­‐e;	  Table	  10,	  a)	  were	  
also	  generated.	  Nevertheless,	  the	  majority	  of	  tumors	  showed	  a	  high	  malignancy	  grade	  (Table	  10,	  
b),	  in	  accordance	  with	  the	  phenotype	  described	  for	  this	  model.	  In	  certain	  cases	  the	  subcutaneous	  
layer	  was	  also	  infiltrated	  (Figure	  9,	  c).	  The	  heterogeneity	  in	  tumor	  types	  can	  be	  explained	  by	  the	  
heterogeneity	  of	  the	  starting	  astrocyte	  cultures.	  These	  results	  are	  in	  line	  with	  those	  obtained	  by	  
a	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Bruggeman	  et	  al.	   [Bruggeman	  et	  al.	  2007]	   in	  their	  study:	  using	  the	  same	  model,	   they	  could	  also	  
generate	  different	  types	  of	  gliomas	  but	  all	  characterized	  by	  a	  high	  grade	  of	  malignancy.	  
	  
Figure	  9.	  High	  malignancy	  features	  are	  identified	  in	  histopathological	  analysis	  of	  tumors.	  a.	  Pseudopalisade	  necrosis	  
(indicated	  by	  arrows)	  b.	  New	  vessels	   formed	  during	  tumor	  development	  (indicated	  by	  arrows).	  c.	  Subcutaneous	   layer	  
invasion.	  Representative	  examples	  of	  different	   tumor	   types	  are	   shown;	  d:	  oligodendroglioma,	  e:	  oligoastrocytoma,	   f:	  
gliosarcoma.	  (Hematoxylin-­‐eosin	  staining	  in	  all	  the	  panels,	  10x).	  
	  
	  
Table	   10.	   Histopathological	   classification	   of	   the	   tumors	   according	   to	   the	   World	   Health	   Organization	   system.	   a.	  
Histolgical	   classification	   of	   tumors.	   “NA”:	   not	   assigned.	   b.	   Malignancy	   grade	   were	   defined	   for	   all	   categories	   except	  
“Others”	  and	  “NA”.	  	  
	  
1.4	  Derivation	  and	  characterization	  of	  glioma	  propagating	  cells	  (GPCs)	  
The	   cancer	   stem	   cell	  model	   proposes	   the	   existence	   of	   a	   pool	   of	   cells	   that	   is	   able	   both	   to	   self-­‐
renew	  and	   to	  maintain	   and	  expand	   the	  bulk	  of	   the	   tumor.	   In	  order	   to	   confirm	   the	  presence	  of	  
such	   cells	   in	  my	  model	   system,	   a	   portion	   of	   the	   tumor	  mass	  was	   isolated	   from	  each	   brain	   and	  












an	  average	  efficiency	  of	  50%.	  Traditionally,	  GPCs	  were	  cultured	  as	  non-­‐adherent	  spheroids,	  also	  
known	  as	  neurospheres	  [Galli	  et	  al.	  2004,	  Singh	  et	  al.	  2004].	  However,	  the	  condensed	  structure	  of	  
the	  neurosphere	  hampers	  the	  diffusion	  of	  growth	  factors	  at	  the	  innermost	  cells,	  causing	  cell	  death	  
and	  differentiation	   [Woolard	  et	   al.	   2009].	   Therefore,	   I	   decided	   to	  grow	  GPCs	  on	   laminin-­‐coated	  
dishes	   as	   adherent	   cultures	   [Pollard	   et	   al.	   2009];	   in	   these	   conditions,	   all	   the	   cells	   can	   equally	  
access	   growth	   factors	   and	   the	   culture	   can	   be	   expanded	   homogeneously	   without	   spontaneous	  
differentiation.	  The	  morphology	  of	  GPCs	  varied	  among	  different	  samples,	  as	  shown	  in	  Figure	  10.	  
Despite	  grown	  in	  adherent	  conditions,	  one	  line	  never	  managed	  to	  attach	  to	  the	  plate	  and	  formed	  
floating	  neurospheres.	  No	  correlation	  was	  found	  between	  the	  tumor	  type	  and	  the	  morphology	  of	  
the	  GPCs.	  
	  
Figure	  10.	  GPC	  lines	  showed	  different	  morphology.	  a-­‐c:	  phase	  contrast	  image	  of	  different	  GPC	  lines	  (10x).	  As	  shown	  in	  
the	  right	  panel,	  one	  line	  never	  attached	  to	  the	  plate	  and	  grew	  forming	  floating	  neurospheres.	  	  
	  
GPCs	   derived	   from	   human	   brain	   tumors	   express	   markers	   associated	   with	   neural	   stem	   and	  
progenitor	  cells,	   like	  CD133	  and	  A2B5	  [Singh	  et	  al.	  2004,	  Ogden	  et	  al.	  2008,	  Tchoghandjian	  et	  al.	  
2010].	  Flow	  cytometry	  analysis	   showed	   that	  GPCs	  obtained	   in	  my	  experiments	  were	  A2B5+,	  but	  
CD133-­‐	  (Figure	  11).	  	  
	  
	  






Figure	   11.	   Glioma	   initiating	   cells	   express	   A2B5	   but	   not	   CD133.	   Flow	   cytometry	   analysis	   of	   GPCs	   showed	   a	   high	  
positivity	   for	   A2B5,	   while	   CD133	   was	   almost	   absent.	   In	   each	   graph,	   red	   and	   green	   curves	   represent	   two	   different	  
samples,	  while	  the	  black	  curve	  represent	  the	  negative	  control.	  
	  
Since	  serial	  orthotopic	  transplantations	  represent	  the	  best	  functional	  test	  to	  evaluate	  self-­‐renewal	  
and	   tumor	   propagation,	   I	   re-­‐injected	   5	   ×	   104	   GPCs	   per	  mouse	   as	   described	   for	   astrocytes	   into	  
secondary	   hosts	   (n=10).	   I	   obtained	   secondary	   tumors	   with	   100%	   penetrance.	   Moreover,	   the	  
development	  of	  these	  tumors	  was	  faster	  compared	  to	  primaries,	  with	  an	  average	  survival	  of	  32.5	  
days	  (Figure	  12).	  
	  
Figure	   12.	   Glioma	   initiating	   cells	   generate	   secondary	   tumors	  with	   a	   shorter	   latency.	   Kaplan-­‐Meyer	   curves	   showing	  
mice	  survival	  rate	  for	  primary	  tumors	  (n=5,	  average	  =	  53.2	  days,	  median	  =	  67	  days)	  and	  secondary	  tumors	  (n=5,	  average	  
=	  32.5	  days,	  median	  =	  32	  days).	  P	  value	  =	  0.0027	  (Log-­‐rank	  test)	  
	  
2.	  Analysis	  of	  EZH2	  function	  in	  gliomagenesis	  
In	   order	   to	   assess	   the	   role	   of	   EZH2	   during	   gliomagenesis,	   I	   chose	   a	   conditional	   mutagenesis	  
approach.	  Indeed,	  straight	  Ezh2	  KO	  causes	  embryonic	  lethality.	  By	  employing	  a	  conditional	  allele,	  





manner.	   The	   astrocytes	   used	   for	   this	   experiment	   carried	   a	   conditional	   allele	   of	  Ezh2	   (hereafter	  
referred	   to	   as	   Ezh2flox),	   in	   which	   the	   SET	   domain	   can	   be	   removed	   by	   Cre	   recombinase	  
administration,	  causing	  the	   loss	  and/or	  truncation	  of	  EZH2	  [Su	  et	  al.	  2003].	  Despite	  the	  possible	  
formation	  of	  a	  truncated	  form	  of	  the	  protein,	  the	  lack	  of	  the	  catalytic	  domain	  allows	  to	  consider	  
this	  as	  a	  bona	  fide	  KO.	  As	  Polycomb-­‐mediated	  silencing	  of	  the	  Ink4a/Arf	  locus	  can	  occur	  in	  cancer	  
[Bracken	  et	  al.	  2003,	  Sparmann	  et	  al.	  2006,	  Bracken	  et	  al.	  2007],	  the	  model	  I	  chose	  bypasses	  the	  
problem	   of	   a	   potential	   restored	   expression	   of	   the	   same	   locus	  when	  Ezh2	   is	   deleted.	  With	   this	  
strategy,	   it	   is	   possible	   to	   study	   pathways	   that	   are	   relevant	   for	   glioma	   development,	   that	   are	  
regulated	  by	  PcG	  but	  that	  are	  independent	  of	  its	  effect	  on	  this	  locus.	  
	  
2.1	  Assessing	  the	  role	  of	  EZH2	  in	  glioma	  formation	  
2.1.1	  Ezh2	  expression	  during	  gliomagenesis	  
I	  measured	  the	  expression	  of	  Ezh2	   in	   the	  astrocytes	  and	   in	  cultured	  GPCs	  samples	   (primary	  and	  
secondary)	  by	  qRT-­‐PCR.	  Ezh2	  is	  increased	  in	  tumors	  compared	  to	  astrocytes	  (Figure	  13).	  
	  
Figure	   13.	   Ezh2	   is	   increased	   in	   tumors.	  a.	   TaqMan	   assay	   on	   different	   cell	   populations.	   Astrocytes	   (A)	  with	   different	  
tumorigenic	  potential	  (one	  wild	  type	  -­‐	  wt,	  two	  p16/p19-­‐/-­‐	  -­‐	  KO,	  5	  p16/p19-­‐/-­‐	  overexpressing	  EGFRvIII	  –	  K/E),	  two	  primary	  
GPCs	  (PT)	  and	  two	  secondary	  GPCs	  (ST)	  revealed	  that	  Ezh2	  is	  more	  expressed	  in	  tumors	  compared	  to	  astrocytes.	  mRNA	  
levels	  are	  calculated	  using	  the	  comparative	  cycle	  threshold	  method	  (ΔCt)	  and	  relative	  mRNA	  amount	  compared	  to	  Tbp	  






Since	  it	  is	  known	  that	  gliomas	  are	  highly	  proliferative,	  I	  combined	  the	  analysis	  of	  EZH2	  with	  Ki-­‐67	  
by	  immunohistochemical	  staining	  on	  subsequent	  slices	  of	  tumor	  samples.	  Ki-­‐67	  is	  a	  well	  defined	  
marker	  that	  identifies	  proliferating	  cells.	  It	  is	  expressed	  during	  G1,	  S,	  G2	  and	  M	  phases	  of	  the	  cell	  
cycle	  but	  not	  in	  G0.	  My	  data	  revealed	  a	  spatial	  co-­‐localization	  between	  Ki-­‐67	  and	  EZH2,	  while	  the	  
two	  proteins	  were	  almost	  absent	  in	  the	  normal	  brain	  parenchyma	  (Figure	  14).	  Thus,	  EZH2	  appears	  
to	   be	   selectively	   over-­‐expressed	   in	   the	   tumor	   regions	   characterized	   by	   a	   higher	   proliferative	  
index.	  	  
	  
Figure	   14.	   Co-­‐localization	   of	   EZH2	   and	   Ki-­‐67	   in	   the	   tumor	   mass.	   a-­‐b.	   Haematoxylin/eosin	   staining.	   c-­‐d.	   EZH2	  
immunostaining;	   in	  the	  normal	  parenchyma	  EZH2	  is	  almost	  absent	  (panel	  c,	  arrow),	  while	  it	   is	  highly	  expressed	  in	  the	  
tumor	  mass.	  e-­‐f.	  Ki-­‐67	  immunostaining.	  (10x	  magnification	  in	  all	  the	  panels).	  
	  
2.1.2	  Deletion	  of	  Ezh2	  by	  administration	  of	  Cre	  recombinase	  
After	  demonstrating	  that	  Ezh2	   is	  expressed	  at	  high	   levels	  both	  primary	  and	  secondary	  gliomas,	   I	  
proceeded	  to	   inactivate	   the	  Ezh2	  gene	  by	  administration	  of	   the	  cell-­‐permeable	  Cre	  protein	   (Cre	  
fused	   to	   the	  HIV-­‐derived	  TAT	  peptide).	   In	  order	   to	   check	   for	  Cre-­‐mediated	   toxicity	   in	  Ezh2flox/flox	  
cells	  (hereafter	  called	  “experimental”	  or	  “Astrodel/del”),	  I	  used	  as	  controls	  Ezh2flox/+	  cells	  (hereafter	  
called	  “controls”	  or	  “Astrodel/+”).	  This	  control	   is	  useful	   for	  assessing	  Cre	  toxicity	  while	  having	  the	  
recombinase	   activity	   readout	   of	   the	   deletion	   of	   the	   floxed	   allele.	   The	   deleted	   allele	   will	   be	  











define	  the	  optimal	  conditions	  of	  TAT-­‐Cre	  treatment;	   I	  tried	  the	  following	  3	  different	  regimens	  in	  
parallel:	  
i. 50	  µg/ml	  of	  TAT-­‐Cre	  with	  overnight	  incubation	  in	  2	  ml	  of	  medium,	  one	  pulse;	  
ii. 100	  µg/ml	  of	  TAT-­‐Cre	  with	  3	  hours	  incubation	  in	  2	  ml	  of	  medium,	  one	  pulse;	  
iii. 15	  µg/ml	  of	  TAT-­‐Cre	  with	  3	  hours	  incubation	  in	  2	  ml	  of	  medium,	  one	  pulse	  per	  day	  for	  3	  
consecutive	  days;	  
The	   first	   two	   protocols	   showed	   a	   high	   degree	   of	   acute	   toxicity	   with	   massive	   cell	   death.	   In	  
particular,	  the	  death	  in	  the	  controls	  treated	  according	  to	  the	  first	  protocol	  was	  so	  high	  that	  it	  was	  
impossible	   to	  rescue	  the	  cell	   line.	  The	  experimental	  counterpart	  was	  also	  extremely	  affected	  by	  
the	  treatment,	  but	  I	  could	  retrieve	  enough	  cells	  to	  perform	  injections	  in	  mice	  (n=3).	  Despite	  those	  
cells	   had	   an	   in	   vivo	   performance	   in	   line	   with	   the	   other	   2	   experimental	   sets	   of	   cells	   treated	  
according	   to	   the	   second	   and	   third	   protocol,	   the	   results	   are	   never	   included	   in	   the	   subsequent	  
analysis	   because	   of	   the	   lack	   of	   the	   proper	   control.	   I	   assessed	   the	   level	   of	   deletion	   in	   the	   cells	  
treated	  according	  to	  the	  second	  and	  third	  regimens	  of	  TAT-­‐Cre	  by	  genomic	  qPCR	  with	  a	  TaqMan®	  
assay	  designed	  on	  the	  SET	  domain.	   In	  both	  cases	  and	  for	  both	  genotypes	  the	  efficiency	  was	  low	  
(Figure	  15).	  	  
	  
Figure	  15.	  Ezh2	  SET	  domain	  deletion	  in	  astrocytes	  was	  inefficient.	   	  qPCR	  analysis	  of	  the	  Cre-­‐mediated	  Ezh2	  deletion;	  
the	   efficiency	   was	   sub-­‐optimal	   in	   both	   genotypes	   (expected	   results:	   50%	   and	   0%	   for	   Astrodel/+	   and	   Astrodel/del,	  





2.1.3	  Injection	  of	  TAT-­‐Cre	  treated	  astrocytes	  in	  nude	  mice	  and	  tumor	  formation	  
After	  the	  TAT-­‐Cre	  treatment,	  Astrodel/del	  and	  Astrodel/+	  were	   injected	   in	  nude	  mice	  to	  assess	  their	  
tumorigenic	  capacity	  as	  indicated	  in	  the	  table	  below	  (Table	  11).	  	  
	  
Table	  11.	  Panel	  of	  injections	  of	  tumorigenic	  astrocytes	  .	  	  	  	  
	  
The	   two	   cohorts	   showed	   a	   nearly	   twofold	   difference	   in	   survival,	   with	   a	  mean	   of	   42.4	   days	   for	  
control	  animals	  and	  of	  73.1	  days	  for	  the	  experimental	  animals	  (Figure	  16).	  	  
	  
	  
Figure	  16.	  EZH2	  loss	  in	  tumorigenic	  astrocytes	  increases	  survival	  of	  recipient	  mice.	  Kaplan-­‐Meyer	  curves	  showing	  mice	  
survival	  rate.	  Animals	  receiving	  Astrodel/del	  (experimental,	  n=8,	  average	  =	  73.1	  days,	  median	  =	  66.5	  days)	  survived	  longer	  
than	  animals	  receiving	  Astrodel/+	  (controls,	  n=8,	  average	  =	  42.4	  days,	  median	  =	  40	  days).	  P	  value	  <	  0.0001	  (Log-­‐rank	  test).	  
	  
Although	  tumor	  development	  was	  severely	  delayed,	  the	  full	  penetrance	  of	  tumorigenesis	  even	  in	  
mice	  injected	  with	  the	  Astrodel/del	  was	  at	  odds	  with	  the	  hypothesis	  that	  EZH2	  is	  required	  for	  glioma	  
initiation	  and	  suggested	  two	  alternative	  scenarios:	  whether	  EZH2	  loss	  is	  negatively	  selected	  during	  





between	  these	  two	  hypotheses,	  I	  performed	  a	  copy	  number	  assay	  on	  genomic	  DNA	  purified	  from	  
from	   GPCs	   derived	   from	   both	   control	   and	   experimental	   tumors.	   Though	   TAT-­‐Cre	   treatment	  
showed	   a	   certain	   level	   of	   deletion	   on	   both	   populations	   before	   injection,	   results	   on	   GPCs	   DNA	  
showed	   that	  experimental	   gliomas	  were	   composed	  only	  of	   cells	   that	  had	  escaped	  Cre-­‐deletion,	  
thus	   indicating	   a	   massive	   counterselection	   for	   the	   loss	   of	   Ezh2	   during	   primary	   gliomagenesis	  
(Figure	  17).	  This	   in	  vivo	   competition	  experiment	   suggests	   that	   cells	   retaining	  Ezh2	  might	  have	  a	  
proliferative	  advantage	  over	  cells	  that	   lost	   it;	  this	  could	  explain	  why	  mice	  eventually	  succumbed	  
to	  tumors.	  
	  
Figure	  17.	  GPCs	  from	  primary	  tumors	  are	  Ezh2	  proficient.	  PTs	  are	  primary	  glioma	  initiating	  cells	  derived	  from	  tumors	  
generated	  with	  the	  respective	  astrocyte	  populations.	  In	  tumors	  derived	  from	  Astrodel/del	  (PT3	  and	  PT4)	  there	  is	  a	  strong	  
counter	   selection	   for	   cells	   that	   lost	   Ezh2.	   Astrodel/+	   and	   Astrodel/del	   data	   representing	   the	   deletion	   in	   transformed	  
astrocytes	   treated	  with	  15	  µg/ml	  of	  TAT-­‐Cre	  with	  3	  hours	   incubation	   for	  3	   consecutive	  days	  are	   reported	   for	   clarity.	  
Results	  are	  expressed	  as	  percentages	  compared	  to	  wild-­‐type,	  that	  represents	  100%.	  
	  
	  2.2	  Assessing	  the	  role	  of	  EZH2	  in	  tumor	  maintenance	  
2.2.1	  Generation	  of	  Ezh2-­‐proficient	  GPCs	  
To	  test	  whether	  EZH2	  is	  required	  for	  the	  maintenance	  of	  the	  tumor,	  I	  generated	  primary	  tumors	  





injection.	  This	  allowed	  me	  to	  obtain	  primary	  GPC	  cell	  lines	  that	  were	  still	  proficient	  for	  Ezh2	  but	  in	  
which	  the	  allele	  could	  be	  deleted	  afterwards.	  GPCs	  were	  treated	  in	  culture	  with	  15	  ng/ml	  TAT-­‐Cre	  
for	   3	   hours	   for	   3	   consecutive	   days	   to	   remove	   Ezh2	   SET	   domain.	   Secondary	   hosts	   receiving	  
experimental	  primary	  GPCs	   treated	  with	  Cre	  recombinase	   (GPCdel/del;	  5	  ×	  104	  cells/mouse)	  didn’t	  
show	   any	   difference	   in	   the	   survival	   rate	   from	   those	   injected	   with	   untreated	   primary	   GPCs	  
(GPCflox/flox;	  5	  ×	  104	  cells/mouse),	  as	  shown	  in	  Figure	  18.	  	  
	  
Figure	   18.	   Secondary	   tumors	   are	   not	   affected	   by	   Ezh2	   loss.	   In	   secondary	   tumor	   formation,	   there	   is	   no	   difference	  
between	  the	  survival	  of	  experimental	   (n=5,	  average	  =	  34.2	  days,	  median	  =	  32	  days)	  and	  control	   (n=5,	  average	  =	  30.8	  
days,	  median	  =	  32	  days)	  mice.	  P	  value	  =	  0.7012	  (Log-­‐rank	  test).	  
	  
I	  checked	  for	  Ezh2	  deletion	  using	  the	  copy	  number	  assay,	  but	  in	  this	  case	  no	  counter	  selection	  was	  
seen	  in	  GPCs	  derived	  from	  secondary	  tumors	  (Figure	  19).	  GPCdel/del	  were	  able	  to	  form	  the	  tumor	  to	  
the	   same	  extent	  as	   the	  GPCflox/flox.	   Together,	   these	  experiments	   suggest	   that	  while	  EZH2	  plays	  a	  






Figure	  19.	  GPCs	  derived	  from	  secondary	  tumors	  are	  deleted	  for	  Ezh2.	  Copy	  number	  assay	  on	  genomic	  DNA	  show	  no	  
positive	  selection	  for	  cells	  Ezh2	  proficient	  in	  secondary	  tumors	  (ST).	  Results	  are	  expressed	  as	  percentages	  compared	  to	  
wild-­‐type,	  that	  represents	  100%.	  
	  
3.	  Validation	  of	  the	  results	  in	  the	  model	  of	  PDGFB-­‐dependent	  gliomagenesis	  
As	   discussed	   earlier,	   gliomas	   are	   associated	   with	   a	   range	   of	   distinct	   genetic	   lesions.	   For	   this	  
reason,	  I	  wanted	  to	  validate	  my	  results	  in	  a	  distinct	  model	  of	  this	  tumor.	  This	  was	  done	  in	  order	  to	  
determine	  if	  the	  role	  of	  EZH2	  is	  consistent	  among	  different	  tumor	  driving	  mutations	  and	  signaling	  
pathways	  or	  if	  it	  is	  specific	  for	  the	  one	  I	  used	  previously.	  The	  second	  model	  I	  adopted	  relies	  on	  the	  
overexpression	   of	   PDGFB	   in	   cortical	   neural	   progenitor	   cultures	   prepared	   from	   embryonic	  
telencephalic	  explants	  	  [Appolloni	  et	  al.	  2009].	  	  
	  
3.1	  Setup	  of	  the	  PDGFB	  glioma	  model	  
Also	  the	  second	  model	  I	  decided	  to	  exploit	  is	  a	  well	  eastablished	  model	  with	  100%	  penetrance.	  In	  
the	   classical	   version,	   the	   transformed	   neural	   progenitors	   (NPs)	   obtained	   from	   C57	   mice	   are	  
infected	  in	  order	  to	  overexpress	  PDGFB	  and	  then	  transplanted	  into	  singenic	  C57	  mice.	  The	  neural	  





background;	   nevertheless,	   they	  were	   transgenic	   for	   the	   Cre-­‐ERT2	   gene,	   ubiquitously	   expressed	  
through	  the	  Rosa26	  promoter.	  I	  first	  wanted	  to	  assess	  if	  this	  transgenic	  protein	  could	  have	  been	  
recognized	   as	   non-­‐self,	   causing	   immune	   rejection	   in	   recipient	   C57	   mice	   and	   thus	   preventing	  
tumor	   formation.	   I	   performed	   a	   pilot	   experiment	   injecting	   transformed	  NPs	   in	   C57	  mice,	   nude	  
mice	   and	   SCID	   beige	   mouse	   (n=3	   for	   each	   strain).	   All	   mice	   developed	   tumors	   within	   a	   similar	  
timeframe;	  thus	  I	  decided	  to	  perform	  all	  following	  experiments	  in	  C57	  mice.	  
	  
3.2	  Setting	  up	  the	  experiment	  
The	   retroviral	   vector	   used	   to	   overexpress	   PDGFB	   encodes	   also	   for	   a	   fluorescent	   protein,	   either	  
dsRED	   or	   GFP.	   I	   decided	   to	   use	   both	   vectors	   to	   infect	   Ezh2flox/flox	   and	   Ezh2flox/+	   cells	   with	   two	  
different	  colors	  in	  order	  to	  perform	  an	  in	  vivo	  competition	  experiment.	  Cells	  heterozygous	  for	  the	  
Ezh2	   conditional	  allele	  were	  again	  used	   to	  monitor	   the	  Cre-­‐mediated	   toxicity	  as	   in	   the	  previous	  
model.	  To	  check	  for	  any	  possible	  toxicity	  caused	  by	  the	  fluorescent	  proteins,	  I	  decided	  to	  perform	  
infections	  in	  order	  to	  get	  all	  the	  possible	  combinations	  of	  genotypes	  and	  colors,	  as	  listed	  in	  Table	  
12.	  
	  
Table	  12.	  Panel	  of	  genotype/infection	  combinations	  in	  NPs.	  	  
	  
3.3	  Assessing	  the	  role	  of	  EZH2	  in	  tumor	  formation	  
3.3.1	  Deletion	  of	  Ezh2	  by	  administration	  of	  4-­‐hydroxytamoxifen	  
The	  cells	  used	  for	  this	  experiment	  carried	  the	  conditional	  allele	  of	  Ezh2	  (Ezh2flox)	  described	  earlier	  





recombinase	   is	   activated	   upon	   Tamoxifen	   administration.	   Particularly,	   its	   active	   metabolite	   4-­‐
Hydroxytamoxifen	  has	  to	  be	  administered	  in	  cell	  cultures.	  I	  treated	  the	  cells	  with	  1	  µM	  4-­‐OHT	  for	  
4	   days	   starting	   from	   the	   day	   after	   derivation.	   The	   copy	   number	   assay	   demonstrated	   that	   the	  
treatment	  was	  effective	  and	  the	  deletion	  complete	  in	  both	  genotypes	  (Figure	  20).	  
	  
	  
Figure	  20.	  4-­‐OHT	  treatment	  is	  effective	  in	  NPs.	  The	  4-­‐OHT	  treatment	  completely	  deleted	  Ezh2	  SET	  domain	  in	  all	  the	  NP	  
populations	   (expected	   results:	   50%	   and	   0%	   for	   NPdel/+	   and	   NPdel/del,	   respectively).	   Values	   for	   the	   untreated	   samples	  
(NPflox/+	  and	  NPflox/flox)	  are	  reported	  for	  clarity.	  
	  
3.3.2	  Transplantation	  of	  NPs	  into	  C57	  mice	  and	  assessment	  of	  glioma	  formation	  







Table	  13.	  Panel	  of	  injections	  of	  NPs.	  	  
	  
On	   the	   day	   of	   injection,	   cells	   were	   harvested	   and	   counted	   with	   a	   hemocytometer	   both	   in	  
transmitted	  light	  and	  with	  the	  appropriate	  fluorescent	  light	  in	  order	  to	  determine	  the	  percentage	  
of	   infected	   cells	   in	   each	   sample.	   The	   percentage	   of	   infection	   was	   further	   validated	   by	   flow	  
cytometry	  analysis;	  estimated	  percentages	  varied	  among	  5-­‐7%.	  Mice	  were	  injected	  with	  1.5	  ×	  104	  
infected	   cells;	   for	   the	   in	   vivo	   competition	   experiment,	  mice	  were	   injected	  with	   1.5	   ×	   104	   green	  
cells	  +	  1.5	  ×	  104	  red	  cells.	  Stereotaxic	  coordinates	  used	  for	  this	  experiment	  correspond	  to	  a	  more	  
anterior	  part	  of	  the	  caudate,	  compared	  to	  the	  ones	  used	  for	  previous	  experiment	  (1	  mm	  anterior,	  
1.5	  mm	  left	  and	  2.5	  mm	  under	  the	  bregma).	  	  
At	  the	  onset	  of	  neurological	  symptoms,	  mice	  were	  sacrificed	  and	  all	  the	  brains	  were	  imaged	  with	  
a	   fluorescent	   stereomicroscope	   (Figure	   21).	   The	   results	   were	   fully	   consistent	   with	   the	   ones	  
obtained	  with	  the	  previous	  model.	  Cells	  proficient	  for	  EZH2	  (NPsflox/+,	  NPsflox/flox	  and	  NPsdel/+)	  were	  
able	   to	   form	   the	   tumor	   regardless	   of	   the	   fluorescent	   reporter	   and	   all	  mice	   injected	  with	   those	  
cells	   died,	   except	  one.	   This	   is	  most	   probably	  due	   to	   a	   technical	   problem	  during	   injection	   (most	  
likely	  the	  syringe	  was	  not	   loaded	  with	  cells).	  By	  contrast,	  all	  mice	  receiving	  Ezh2del/del	  NPs	  are	  all	  
currently	   alive,	   250	   days	   after	   injection	   (Figure	   22).	   In	   the	   in	   vivo	   competition	   this	   finding	  was	  





trace	   of	   any	  Ezh2del/del	   cell	   in	   both	   combinations	   of	   reporters	   (Figure	   21).	   Therefore,	   I	   conclude	  




Figure	   21.	   Tumor	   is	   formed	   exclusively	   by	   EZH2	   proficient	   cells.	   a-­‐b.	   Brain	   were	   imaged	   under	   a	   fluorescent	  
stereomicroscope	  in	  order	  to	  visualize	  the	  tumor	  mass.	  b.	  In	  the	  in	  vivo	  competition	  experiment,	  the	  mass	  is	  made	  only	  









Figure	  22.	  Ezh2	  deleted	  cells	  are	  prevented	  of	  forming	  a	  tumor.	  Survival	  analysis	  of	  mice	  injected	  with	  tumorigenic	  NPs	  
shows	  that	  all	  the	  mice	  receiving	  NPdel/del	  are	  still	  alive.	  
	  
I	  next	   sought	   to	  determine	   the	   fate	  of	   the	  NPdel/del	  cells.	   I	  dissected	  carefully	   tissues	  around	   the	  
injection	  site	  to	  try	  to	  identify	  the	  injected	  cells,	  i.e.	  if	  the	  NPdel/del	  cells	  are	  able	  to	  engraft	  but	  not	  
to	  survive	  in	  the	  host	  microenvironment	  or	  if	  they	  are	  completely	  prevented	  from	  engrafting	  the	  
host	   brain.	   Three	   new	  mice	  were	   injected	  with	  NPflox/flox	   and	   3	  mice	  with	  NPdel/del,	   both	   the	   cell	  
populations	   being	   dsRED+.	   I	   sacrificed	   one	   mouse	   per	   group	   1	   week	   after	   injection	   and	   the	  
remaining	  2	  mice	  per	  group	  2	  weeks	  after	  injections.	  Brains	  were	  isolated,	  processed	  according	  to	  
normal	  histological	  procedures	  and	   imaged	  under	  a	   fluorescent	  microscope	   in	  order	  to	  see	  how	  
the	   injected	   cells	   were	   performing.	   It	   was	   impossible	   to	   find	   any	   dsRED+	   cell	   in	   brains	   taken	   1	  
week	  after	  injection	  –	  most	  likely	  due	  both	  to	  limited	  microscope	  sensitivity,	  but	  also	  to	  the	  loss	  of	  
cells	  during	  the	  stressful	   injection	  procedure.	  However,	   in	  brains	  taken	  2	  weeks	  after	  injection	  it	  





were	   clearly	   invading	   the	   surrounding	   tissue,	   particularly	   egressing	   along	   the	   corpus	   callosum	  
(Figure	  23,	  a-­‐b).	  Importantly,	  for	  those	  mice	  injected	  with	  NPdel/del	  it	  was	  impossible	  to	  identify	  any	  
dsRED+	  cells	  at	  the	  same	  stage	  of	  tumor	  formation	  (Figure	  23,	  c-­‐d).	  This	  result	  indicates	  that	  EZH2	  
proficient	   cells	   are	   immediately	   enabled	   to	   form	   a	   tumor	   mass	   upon	   transplantation	   whereas	  
those	   lacking	  fail	   to	  engraft	  and	  establish	  masses	  early	  on.	   I	  cannot	  rule	  out	  that	  EZH2	  depleted	  




Figure	  23.	  EZH2	  proficient	  cells	  successfully	  engrafted	  and	  start	  invading	  the	  host	  brain	  2	  weeks	  after	  injection.	  The	  
channel	  of	  injection	  is	  clearly	  traceable	  in	  all	  the	  brains	  but	  dsRED+	  cells	  are	  found	  only	  in	  the	  NPflox//flox	  injected	  animals	  





a	   b	  





3.2	  Assessing	  the	  role	  of	  EZH2	  in	  tumor	  maintenance	  
3.2.1	  Generation	  of	  Ezh2-­‐proficient	  GPCs	  
Also	  in	  this	  second	  model	  it	  is	  possible	  to	  isolate	  GPCs	  from	  the	  tumor	  mass.	  The	  primary	  tumors	  
generated	  with	  Ezh2flox/flox	   cells	  were	  dissected	  and	   the	  allele	  was	  deleted	   in	   the	   resulting	  GPCs	  
before	  injecting	  them	  for	  secondary	  tumorigenesis	  assay,	  following	  the	  same	  scheme	  described	  in	  
the	   previous	   experiment.	   GPCs	   were	   treated	   while	   in	   culture	   with	   1	   µM	   4-­‐OHT	   for	   9	   days	   to	  
remove	   the	   catalytic	   domain	   of	   Ezh2.	   All	   the	   secondary	   hosts	   receiving	   both	   experimental	  




Figure	  24.	  Secondary	  tumors	  are	  formed	  without	  EZH2.	  All	  the	  mice	  transplanted	  with	  primary	  GPCs	  developed	  lethal	  
tumors,	  both	  in	  the	  presence	  (GPCflox/flox)	  or	  absence	  (GPCdel/del)	  of	  EZH2.	  
	  
I	  checked	  for	  Ezh2	  deletion	  using	  the	  copy	  number	  assay	  and	  as	  reported	  for	  the	  previous	  model,	  
no	  counter	  selection	  was	  seen	  in	  GPCs	  derived	  from	  secondary	  tumors	  (Figure	  25).	  GPCdel/del	  were	  
able	  to	  form	  the	  tumor	  to	  the	  as	  the	  GPCflox/flox.	  These	  results	  confirmed	  that	  EZH2	  is	  dispensable	  
for	   secondary	   tumorigenesis,	   thus	   corroborating	  my	   previous	   findings	   and	   indicating	   that	   EZH2	  






Figure	  25.	  Secondary	  GPCs	  are	  Ezh2-­‐deleted.	  As	   in	   the	  previous	  experiment,	   copy	  number	  assay	  on	   secondary	  GPCs	  
showed	  no	  counter	  selection	  for	  Ezh2-­‐deleted	  cells.	  
	  
4.	  Exploring	  the	  transcriptome	  of	  the	  tumor	  –	  relation	  with	  H3K27me3	  mark	  
I	  took	  advantage	  of	  the	  intrinsic	  possibility	  of	  my	  model	  system	  to	  analyze	  various	  cell	  populations	  
with	  different	  tumorigenic	  potential	  (primary	  wild-­‐type	  astrocytes,	  primary	  p16/p19-­‐/-­‐	  astrocytes,	  
transformed	   astrocytes,	   GPCs	   derived	   from	   primary	   tumors,	   GPCs	   derived	   from	   secondary	  
tumors).	   This	   allows	   me	   to	   investigate	   at	   the	   molecular	   level	   how	   the	   H3K27me3	   mark	   is	  
relocated	   during	   tumorigenesis,	   how	   the	   transcriptome	   changes	   and	   which	   is	   the	   possible	  
correlation	  between	  these	  two	  processes.	  So	  far,	  one	  sample	  of	  transformed	  astrocytes	  and	  two	  
samples	   of	   primary	   GPCs	   have	   been	   analyzed	   in	   terms	   of	   transcriptome	   and	   genome-­‐wide	  
H3K27me3	  distribution.	  	  
	  
4.1	  Analysis	  of	  differentially	  expressed	  genes	  (DEGs)	  between	  tumorigenic	  astrocytes	  and	  
primary	  tumors	  
In	  order	  to	  unravel	  the	  transcriptomic	  changes	  that	  occur	  during	  the	  transition	  from	  tumorigenic	  





the	   gene	   expression	   profile	   of	   one	   tumorigenic	   astrocyte	   line	   (“Astro”)	   and	   of	   two	   different	  
samples	  of	  primary	  GPCs	  (Glio1	  and	  Glio2;	  together	  they	  will	  be	  referred	  to	  as	  “Glio”)	  by	  RNA-­‐seq.	  
Through	  the	  direct	  comparison	  of	  the	  expression	  level	  determined	  for	  each	  gene	  in	  each	  sample,	  
we	   found	   that	   the	   2	   GPC	   samples	   are	   globally	   more	   similar	   to	   each	   other	   (correlation	   index	  
r=0.97)	   than	   each	   of	   them	   compared	   to	   “Astro”	   (r=0.83	   for	   Glio1	   and	   r=0.85	   for	   Glio2).	   This	  
suggests	   that	   changes	   in	   the	   transcriptional	  profile	  during	   tumorigenesis	  are	  not	   stochastic,	  but	  
rather	  they	  tend	  to	  converge	  towards	  a	  common	  signature.	  	  
	  
	  
Figure	   26.	   Different	   tumor	   samples	   show	   a	   high	   correlation	   according	   to	   the	   transcriptional	   profile.	   Scatterplots	  
representing	  the	  direct	  comparison	  of	  expression	  levels	  for	  each	  gene.	  Astro	  were	  compared	  to	  Glio1	  (a),	  Glio2	  (b)	  and	  
to	   the	   two	   Glio	   samples	   considered	   together	   (c).	   When	   comparing	   the	   two	   glioma	   samples	   to	   each	   other,	   the	  
correlation	  index	  increased	  substantially	  (d,	  r=0.97).	  
	  
We	  determined	  the	  number	  of	  differentially	  expressed	  genes	   (DEGs)	  comparing	  “Astro”	  to	  each	  
“Glio”	  and	  we	  found	  2396	  DEGs	  for	  Glio1	  and	  2626	  DEGs	  for	  Glio2	   (FDR<0.05).	  Particularly,	  882	  
and	   1235	   genes	  were	   upregulated	   in	   Glio1	   and	   Glio2	   respectively,	   while	   1514	   and	   1391	   genes	  
were	   downregulated	   in	   Glio1	   and	   Glio2	   respectively.	   We	   performed	   a	   Gene	   Ontology	   (GO)	  
analysis	   to	   determine	  which	   are	   the	   biological	   processes	   enriched	   in	   the	   DEGs	   for	   each	   “Glio”	  
sample.	   We	   found	   that	   the	   most	   significantly	   associated	   biological	   processes	   are	   related	   to	  
c	  






classical	   Polycomb	   functions,	   like	   development	   and	   differentiation.	   Intersecting	   the	   2	   sets	   of	  
DEGs,	  we	  found	  that	  about	  70%	  of	  the	  genes	  (1738)	  are	  consistently	  up-­‐	  or	  down-­‐regulated	  in	  the	  
two	   samples.	   If	   we	   restrict	   the	   GO	   analysis	   on	   this	   subset	   of	   genes,	   we	   could	   find	   a	   stronger	  
enrichment	   with	   classical	   Polycomb	   functions,	   suggesting	   that	   this	   epigenetic	   axis	   is	   actively	  
involved	  and	  plays	  an	  important	  role	  in	  gliomagenesis.	  	  
	  
	  
Figure	   27.	   DEGs	   showed	   an	   enrichment	   for	   classical	   Polycomb	   functions.	   GO	   analysis	   of	   the	   biological	   processes	  
associated	  to	  DEGs	  shows	  an	  enrichment	  for	  classical	  Polycomb	  functions,	  like	  development	  and	  differentiation.	  In	  the	  
common	  DEGs	  this	  association	  becomes	  even	  stronger.	  	  
	  
The	  common	  1738	  DEGs	  were	  then	  divided	  into	  up-­‐regulated	  or	  down-­‐regulated	  (i.e.,	  genes	  that	  
are	  up-­‐regulated	  moving	  from	  astrocytes	  towards	  glioma	  or	  down-­‐regulated	  following	  the	  same	  
direction).	   We	   found	   643	   up-­‐regulated	   genes	   and	   1098	   down-­‐regulated	   genes.	   Biological	  
processes	   enriched	   in	   downregulated	   genes	   were	   involved	   in	   tissue	   development	   and	  
differentiation	   while	   those	   associated	   to	   upregulated	   genes	   seemed	   to	   be	   involved	   in	   cell	  
metabolism.	  We	  analyzed	  also	  the	  KEGG	  (Kyoto	  Encyclopedia	  of	  Genes	  and	  Genomes)	  pathways	  
enriched	   in	   each	   gene	   set.	   Interestingly,	   pathways	   associated	   to	   downregulated	   genes	   are	  
involved	   in	   cell	   adhesion	  while	   pathways	   associated	   to	   upregulated	   genes	   are	   again	   related	   to	  
metabolism.	  Taken	   together,	   these	   findings	   fit	  with	   typical	   features	  described	   for	  GPCs.	   Indeed,	  





differentiated	  compared	  to	  astrocytes;	  they	  resemble	  neural	  progenitors	  or	  neural	  stem	  cells	  and	  
it	   has	   already	   been	   shown	   that	   they	   are	   able	   to	   differentiate	   in	   3	   cell	   types,	   namely	   neurons,	  
astrocytes	   and	  oligodendrocytes.	   In	   addition,	   even	   if	   gliomas	  don’t	   form	  metastasis	   in	  different	  
organs,	  cells	  are	  extremely	  invasive	  and	  able	  to	  migrate	  diffusely	  in	  the	  brain.	  	  	  
	  
Figure	  28.	  Up-­‐regulated	  genes	  are	  involved	  in	  metabolism.	  For	  each	  set	  of	  genes,	  we	  defined	  the	  enriched	  biological	  
processes	  and	  KEGG	  pathways.	  Up-­‐regulated	  genes	  are	  related	  to	  metabolism	  and	  particularly	  to	  lipid	  metabolism.	  
Down-­‐regulated	  genes	  are	  involved	  in	  differentiation	  and	  development	  and	  associated	  to	  adhesion	  pathways.	  The	  
associations	  with	  biological	  processes	  and	  KEGG	  pathways	  have	  been	  calculated	  considering	  a	  FDR<0.05.	  	  
	  
Among	  the	  KEGG	  pathways	  enriched	  in	  the	  up-­‐regulated	  gene	  set,	  we	  found	  the	  calcium-­‐signaling	  
and	   the	   MAPK-­‐signaling	   pathways,	   strongly	   associated	   with	   the	   activation	   of	   EGFR	   signaling	  







Figure	   29.	  Up-­‐regulated	   genes	   are	   related	   to	   EGFR	   pathway.	   The	   functional	   annotation	   analysis	   revealed	   that	   up-­‐
regulated	  genes	  are	  enriched	  for	  the	  calcium	  signaling	  and	  the	  MAPK	  signaling	  pathways,	  which	  are	  both	  involved	  in	  the	  
EGFR	  pathway	  (a).	  Indeed,	  EGFR	  is	  overexpressed	  in	  Glio	  compared	  to	  Astro	  (b).	  	  
	  
4.2	  Analysis	  of	  the	  H3K27me3	  distribution	  
In	   the	   same	   samples	   used	   to	   analyze	   the	   transcriptome,	   we	   also	   examined	   the	   distribution	   of	  
H3K27me3	  by	  ChIP-­‐seq.	  We	  divided	  the	  genome	  in	  discrete	  windows	  of	  1	  Mbp	  and	  we	  counted	  
how	  many	  reads	  aligned	  in	  each	  window	  for	  each	  sample.	  By	  comparing	  the	  read	  counts	   in	  two	  
samples,	   we	   were	   able	   to	   define	   the	   similarity	   in	   the	   H3K27me3	   distribution,	   expressed	   as	   a	  
correlation	  index.	  The	  two	  tumor	  samples	  have	  a	  correlation	  index	  of	  0.97,	  while	  when	  comparing	  
each	   Glio	   to	   Astro	   the	   correlation	   index	   decreases	   (r=0.92	   for	   Glio1	   and	   r=0.90	   for	   Glio2),	  
indicating	  that	  the	  deposition	  of	  H3K27me3	  along	  the	  genome	  is	  almost	  identical	  between	  the	  2	  
“Glio”.	  Taken	  together	  these	  results	  seem	  to	  indicate	  that	  the	  relocation	  of	  K27	  trimethylation	  is	  
not	   random	  but	   rather	  happens	  at	  very	  specific	   sites,	   common	  across	  different	  glioma	  samples.	  
Moreover,	  the	  redistribution	  moving	  from	  transformed	  astrocytes	  to	  gliomas	  is	  not	  massive	  but	  is	  








Figure	  30.	  Different	   tumor	   samples	   show	  an	  high	   correlation	  according	   to	   the	  H3K27me3	  distribution.	  Scatterplots	  
representing	  the	  direct	  comparison	  of	  read	  counts	  in	  1	  Mbp	  windows	  on	  the	  genome.	  The	  correlation	  between	  the	  two	  
Glio	  is	  higher	  (r=0.97),	  while	  it	  decreases	  when	  each	  of	  the	  Glio	  is	  compared	  to	  Astro	  (r=0.92	  for	  Astro/Glio1	  comparison	  
and	  r=0.90	  for	  Astro/Glio2	  comparison).	  	  
	  
We	  determined	  the	  number	  of	  genes	  carrying	  the	  trimethylation	  of	  lysine	  27	  for	  each	  sample	  and	  
we	  found	  an	  increase	  in	  both	  tumors	  (3636	  for	  Glio1	  and	  3585	  for	  Glio2)	  compared	  to	  astrocytes	  
(2515).	  The	  overlap	  of	  the	  trimethylated	  genes	  between	  Glio1	  and	  Glio2	  is	  more	  than	  80%	  (3010).	  
We	  analyze	  the	  trend	  of	  this	  histone	  mark	  moving	  from	  tumorigenic	  astrocytes	  to	  gliomas	  and	  we	  
discovered	   that	   of	   the	   3010	   trimethylated	   genes	   found	   in	   the	   tumors,	   1049	   acquired	   the	  mark	  
during	   the	   transition,	   while	   1961	   were	   already	   trimethylated	   in	   the	   tumorigenic	   astrocytes.	  
Interestingly,	  554	  genes	  that	  were	  trimethylated	  in	  astrocytes	  lost	  the	  mark	  in	  the	  tumors	  (Figure	  
31).	  Overall,	  the	  relocation	  of	  the	  H3K27me3	  involved	  almost	  1600	  genes.	  	  
	  
Figure	   31.	   Relocation	   of	   H3K27me3	   during	   tumorigenesis	   involves	   almost	   1600	   genes.	   Analysis	   of	   the	   H3K27me3	  
patterns	  revealed	  that	  the	  two	  Glio	  samples	  shared	  80%	  of	  trimethylated	  genes.	  Moreover,	  of	  these	  genes,	  only	  1049	  






We	  went	   then	  back	   to	  our	  common	  DEG	   list	  and	  we	  defined	  how	  many	  up-­‐regulated	  gene	  and	  
down-­‐regulated	   genes	   retained,	   gained	   or	   lost	   the	   H3K27me3.	   Analyzing	   the	   KEGG	   pathways	  
enriched	  in	  the	  set	  of	  genes	  that	  acquired	  the	  trimethylation	  and	  that	  were	  also	  down-­‐regulated,	  
we	  could	  confirm	  that	  all	  of	  them	  were	  included	  in	  the	  pathways	  enriched	  in	  the	  broader	  down-­‐
regulated	  gene	  set.	  
	  
4.3	  Comparison	  of	  expression	  profile	  data	  with	  known	  human	  molecular	  signatures	  
We	   wanted	   to	   compare	   our	   transcriptional	   profiles	   with	   the	   human	   molecular	   signatures	  
previously	   defined	   by	   3	   different	   groups	   [Phillips	   et	   al.	   2006,	   Carro	   et	   al.	   2010,	   Verhaak	   et	   al.	  
2010]	  in	  order	  to	  determine	  if	  there	  was	  any	  overlap	  between	  our	  data	  and	  their	  classification.	  In	  
their	  study,	  Phillips	  et	  al.	  defined	  a	  list	  of	  254,	  217	  and	  170	  overexpressed	  genes	  that	  characterize	  
the	  proneural	  (PN),	  proliferative	  (PR)	  and	  mesenchymal	  (MES)	  signatures,	  respectively.	  In	  our	  set	  
of	   up-­‐regulated	   genes,	   we	   found	   33	   genes	   shared	   with	   the	   proneural	   signature.	   More	  
interestingly,	   among	   the	   biological	   processes	   enriched	   in	   this	   group	   of	   33	   genes	   we	   found	  
“neurogenesis”	   and	   “Notch	   signaling	   pathway”,	   which	   are	   typically	   features	   of	   the	   proneural	  
tumors	  according	  to	  the	  same	  work	  [Phillips	  et	  al.	  2006].	  In	  our	  set	  of	  down-­‐regulated	  genes,	  22	  
belong	  to	   the	  mesenchymal	  signature;	  also	   in	   this	  case	  one	  biological	  process	  enriched	   in	   these	  










Figure	  32.	  Up-­‐regulated	  genes	  are	  enriched	  for	  Phillips’	  proneural	  signature	  genes.	  Comparing	  our	  set	  of	  genes	  with	  
the	  molecular	   subtypes	  defined	  by	  Phillips	   et	   al.	   in	   their	  work,	  we	   found	   that	   up-­‐regulated	   genes	  were	  enriched	   for	  
genes	  belonging	  to	  the	  proneural	  signature,	  while	  down-­‐regulated	  genes	  were	  enriched	  for	  mesenchymal	  genes.	  	  	  
	  
Carro	  et	  al.	   re-­‐defined	  the	  classification	  proposed	  by	  Phillips	  et	  al.	  analyzing	  a	  broader	  group	  of	  
samples	  (including	  the	  one	  used	  by	  Phillips	  et	  al.).	  They	  reduced	  the	  number	  of	  genes	  associated	  
to	   each	   signature,	   indicating	   244,	   182	   and	   82	   genes	   for	   the	   proneural,	   proliferative	   and	  
mesenchymal	  signature	  respectively.	   In	  our	  up-­‐regulated	  set	  of	  genes,	  35	  overlapped	  again	  with	  
the	   proneural	   signature	   and	   17	   of	   the	   down-­‐regulated	   overlapped	   with	   the	   mesenchymal,	  
confirming	  previous	   results.	  Verhaak	  et	   al.	   introduced	  a	  different	  molecular	   classification	  based	  
on	  4	  signatures.	  They	  maintained	  the	  proneural	  and	  mesenchymal	  subtypes,	  but	  they	  introduced	  
two	  new	   classes,	   called	  neural	   and	   classical.	  When	  we	   compared	  our	   transcriptional	   profiles	   to	  
their	  results,	  our	  common	  up-­‐regulated	  genes	  were	  mostly	  associated	  with	  the	  proneural	  subtype	  
(25	  genes),	  but	  also	  with	  the	  classical	  (13	  genes)	  and	  with	  the	  neural	  (11	  genes).	  Down-­‐regulated	  
genes	   instead	   overlapped	   again	   with	   the	   mesenchymal	   signature	   (43	   genes).	   Taking	   all	   these	  
results	   together,	  we	   can	   then	   conclude	   that	  our	   tumors	   closely	   resemble	   the	  human	  proneural	  









Figure	  33.	  Up-­‐regulated	  genes	  are	  enriched	  for	  Carro’s	  and	  Verhaak’s	  proneural	  signature	  genes.	  Comparison	  of	  our	  
down-­‐	  or	  up-­‐regulated	  genes	  with	  Carro’s	  (upper	  graphs)	  and	  Verhaak’s	  (lower	  graphs)	  signatures.	  In	  both	  cases	  our	  up-­‐
regulated	  genes	  are	  enriched	  for	  genes	  belonging	  to	  the	  proneural	  signature.	  	  	  	  	  	  
	  
4.4	  Transcription	  factor	  binding	  site	  overrepresentation	  analysis	  
We	  examined	  our	  DEGs	   in	  order	   to	  define	  which	  were	   the	   transcription	   factors	   (TFs)	   consensus	  
binding	  sequences	  present	  in	  their	  promoters.	  We	  defined	  overrepresented	  TFs	  in	  order	  to	  find	  a	  
possible	  master	   regulator	   for	   gliomagenesis	  using	   the	  R	  package	  pcaGoPromoter	   [Hansen	  et	   al.	  
2012].	   In	  developmental	  biology,	  a	  master	  regulator	   is	  defined	  as	  a	  gene	  (usually	  a	  transcription	  
factor)	   that	   is	  necessary	  and	  sufficient	   to	  coordinate	  the	  activity	  of	  a	  broader	  group	  of	  genes	   in	  
order	  to	  activate	  a	  developmental	  program	  specific	  for	  a	  certain	  tissue	  or	  organ.	  Since	  the	  process	  





pick	  out	  one	  or	  few	  genes	  that	  carry	  out	  the	  same	  function	  in	  the	  disease	  process.	  Possibly,	  the	  
expression	  of	  our	  master	  regulator	  should	  have	  been	  controlled	  by	  H3K27me3.	  	  
With	   those	   parameters	   we	   found	   one	   TF,	   ZFP423,	   that	   is	   down-­‐regulated	   and	   acquires	   the	  
trimethylation	  of	  lysine	  27	  in	  Glio.	  Based	  on	  the	  consensus	  binding	  site,	  ZFP423	  seems	  to	  control	  
219	   genes	   in	   our	   DEG	   set,	   128	   of	   which	   are	   down-­‐regulated	   and	   81	   up-­‐regulated.	   This	  
transcription	  factor	  is	  known	  to	  activate	  the	  transcription	  of	  BMP	  target	  genes	  by	  associating	  with	  
SMADs	  in	  response	  to	  BMP2/4/7	  [reviewed	  in	  Liu	  et	  al.	  2005].	  Moreover	  it	  can	  act	  as	  repressor	  of	  
the	  olfactory	  neurogenesis	  by	  binding	  to	  EBF1	  and	  preventing	  the	  transcription	  of	  EBF1	  olfactory-­‐
specific	   genes	   [Roby	  et	  al.	   2012].	   Interestingly,	   another	  putative	   target	  of	   ZFP423	   is	  Dll3,	  which	  
seems	   involved	   in	   the	   block	   of	   astrogenesis	   (GO:0048712,	   negative	   regulation	   of	   astrocyte	  
differentiation)	  and	  that	  in	  our	  data	  turned	  out	  to	  be	  up-­‐regulated.	  	  
If	  validated,	  this	  could	  represent	  an	  interesting	  molecular	  mechanism	  through	  which	  one	  or	  few	  
genes	   regulated	  by	  H3K27me3	   can	   in	   turn	   regulate	   several	  molecular	   processes,	   leading	   to	   the	  







Figure	  34.	  ZFP423	  controls	  more	  than	  200	  DEGs.	  The	  transcription	  factor	  ZFP423	  is	  de	  novo	  H3K27	  trimethylated	  during	  
gliomagenesis,	   is	  down-­‐regulated	  and	   is	  overrepresented	   in	  our	  DEG	   list,	   controlling	  219	  genes	   (128	  down-­‐regulated,	  






The	   work	   presented	   in	   this	   thesis	   aimed	   at	   investigating	   the	   functional	   role	   of	   H3K27me3	   in	  
gliomagenesis.	  	  
In	   the	   last	  decade,	  several	  works	  contributed	  to	  change	  the	  general	  view	  of	  cancer	  as	  a	  genetic	  
disease,	  demonstrating	  that	  epigenetics	  is	  deeply	  involved	  in	  the	  transforming	  process	  of	  cells	  and	  
that	  genetics	  and	  epigenetics	  cooperate	  during	  cancer	  development.	  Particularly,	  several	  studies	  
defined	  Polycomb	  group	  (PcG)	  proteins	  as	  key	  players	  in	  this	  process.	  	  
Historically,	   PcG	  were	   shown	   to	   exert	   a	   transcriptional	   repressive	   function	   that	   determines	   the	  
patterned	   expression	   of	   the	   homeotic	   genes	   in	   Drosophila.	   Homeotic	   genes	   (Hox	   genes	   in	  
vertebrates)	   are	   responsible	   for	   the	   specification	   of	   characteristic	   structures	   in	   each	   body	  
segment	  along	  the	  antero-­‐posterior	  axis	  and	  their	  expression	  needs	  to	  be	  tightly	  controlled	  both	  
spatially	   and	   temporally	   (“homeo”	   means	   similar	   and	   homeotic	   mutants	   generally	   show	   a	  
phenotype	   in	  which	  a	  body	  structure	   is	   replaced	  by	  another).	  Mutants	   for	  PcG	  proteins	  showed	  
homeotic	  transformation	  of	  body	  segments	  due	  to	  an	  ectopic	  expression	  of	  homeotic	  genes.	  From	  
this	   evidence,	   it	   was	   demonstrated	   that	   they	   exert	   a	   transcriptional	   repressive	   function.	   PcG	  
proteins	   are	   assembled	   in	   two	   different	   multiproteic	   complexes,	   namely	   Polycomb	   Repressive	  
Complex	  (PRC)	  1	  and	  2.	  The	  current	  model	  proposes	  that	  PRC2	  is	  responsible	  for	  the	  initiation	  of	  
repression	   while	   PRC1	   is	   involved	   in	   its	   maintenance.	   PRC2	   is	   evolutionary	   conserved	   in	  
invertebrates,	   vertebrates	   and	   plants	   and	   in	   mammals	   it	   contains	   four	   core	  members,	   namely	  
EED,	   SUZ12,	   RBAP46/48	   and	   EZH2.	   The	   proposed	   model	   suggests	   that	   PRC2	   recruits	   histone	  
deacetylases	   (HDAC)	   at	   target	   genes,	   causing	   deacetylation	   of	   histones.	   Through	   its	   active	  
subunit,	  EZH2,	   it	   catalyzes	   the	  di-­‐	  and	   tri-­‐methylation	  of	  H3K27	  which	  acts	  as	  a	  docking	   site	   for	  
PRC1,	  that	  in	  turn	  ubiquitilates	  lysine	  119	  of	  histone	  H2A.	  Moreover,	  members	  of	  the	  PRCs	  have	  
been	   shown	   to	   interact	  with	   the	   DNA	  methyl	   transferases	   [Vire	   et	   al.	   2006,	  Mohammad	   et	   al.	  
2009],	   suggesting	   that	   they	   can	   actively	   control	   this	   further	   layer	   of	   epigenetic	   silencing.	   The	  





necessary	   for	   the	   proper	   organism	   development	   by	   controlling	   cell	   growth	   and	   differentiation.	  
Both	   these	   processes	   are	   deregulated	   in	   cancer	   and	   several	   studies	   demonstrated	   that	   this	   is	  
linked	  with	  the	  aberrant	  expression	  of	  PcG	  proteins.	  
	  
In	   my	   work	   I	   wanted	   to	   determine	   whether	   EZH2	   plays	   a	   fundamental	   role	   in	   the	   set	   up	   of	  
gliomas.	  To	  assess	  my	  hypothesis,	   I	  used	  two	  different	  mouse	  model	  systems.	  The	  first	   is	  mainly	  
considered	  as	  an	  astrocytoma	  model	   [Bachoo	  et	   al.	   2002],	   even	   if	   several	   evidences	   from	  mine	  
and	   previous	   studies	   [Bachoo	   et	   al.	   2002,	   Bruggeman	   et	   al.	   2007]	   revealed	   that	   different	  
histotypes	   can	   be	   originated	   with	   the	   same	  model	   (oligodendogliomas,	   oligoastrocytomas	   and	  
gliosarcomas).	  The	  second	   is	  an	  oligodendrocytoma	  model	   [Appolloni	  et	  al.	  2009].	  Regardless	  of	  
the	  histological	  outcome,	  these	  two	  models	  were	  chosen	  to	  assess	  if	  the	  role	  of	  EZH2	  could	  vary	  
according	   to	  different	   tumor-­‐driving	   genetic	   lesions;	   indeed,	  while	   the	   first	  model	   relies	   on	   the	  
loss	  of	   the	   Ink4a/Arf	   locus	   combined	  with	   the	  over-­‐expression	  of	  a	   constitutively	  active	  mutant	  
form	  of	  EGFR,	  EGFRvIII,	  the	  second	  is	  driven	  by	  the	  over-­‐expression	  of	  PDGFB.	  	  
With	  both	  models,	   I	  was	  able	   to	   show	   that	   EZH2	  depleted	   cells	   are	   counterselected	   in	   the	   first	  
steps	  of	  glioma	  formation,	   indicating	  that	  the	  genetic	   lesions	  per	  se	  are	  not	  sufficient	  to	  get	  the	  
tumor.	   Instead,	   they	   have	   to	   be	   accompanied	   by	   a	   re-­‐setting	   of	   the	   epigenome,	   mediated	   by	  
PRC2.	  Moreover,	  this	  appears	  to	  be	  relevant	  only	  in	  the	  earliest	  stages	  of	  cancer	  development.	  	  
It	  has	  been	  shown	  that	  epigenetic	  silencing	   is	  another	  way	  to	  achieve	   loss	  of	  function	  of	  a	  gene	  
and	   sometimes	   this	   accounts	   for	   the	   “second	   hit”,	   the	   first	   being	   a	   genetic	  mutation.	   In	   colon	  
cancer	   and	   in	   other	   cancer	   types	   it	   was	   shown	   that	   some	   genes	   are	   already	   silenced	   in	   pre-­‐
invasive	   stages	   of	   the	   disease	   [reviewed	   in	   Baylin	   and	  Ohm	   2006].	   These	   genes	   are	   defined	   as	  
“epigenetic	   gatekeepers”,	   since	   their	   normal	   epigenetic	   modulation	   activates	   them	   during	  
development	   and	   differentiation	   to	   prevent	   immortalization	   of	   stem	   or	   progenitor	   cells.	   The	  
silencing	   of	   these	   genes	   leads	   to	   extended	   survival	   and	   proliferation	   and	   to	   a	   block	   in	   the	  





malignant	  transformation.	  Interestingly,	  among	  the	  genes	  undergoing	  epigenetic	  silencing	  there	  is	  
HIC1,	   which	   is	   a	   transcription	   factor	   that	   negatively	   modulates	   the	   transcription	   of	   sirtuin	   1	  
(SIRT1),	  a	  NAD-­‐dependent	  histone	  deacetylase	  belonging	  to	  class	  III	  HDACs.	  SIRT1	  is	  often	  found	  in	  
association	  with	  a	  different	  Polycomb	  complex,	  called	  PRC4,	  in	  which	  EED	  isoform	  1	  is	  replaced	  by	  
isoform	   2	   [Kuzmichev	   et	   al.	   2005].	   SIRT1	   deacetylates	   histones,	   thus	   favouring	   PRC4-­‐mediated	  
methylation.	   Interestingly,	   PRC4	   is	   able	   to	  methylate	   lysine	   26	   of	   histone	   H1	   [Kuzmichev	   et	   al.	  
2004],	  which	  in	  turn	  can	  recruit	  heterochromatin	  binding	  protein	  1	  (HP1)	  causing	  a	  remodeling	  in	  
higher	   order	   chromatin	   structure	   [Daujat	   et	   al.	   2005].	   Accumulation	   of	   EZH2	   caused	   by	   over-­‐
expression	  often	  occurs	  in	  cancer	  as	  shown	  in	  prostate	  [Varambally	  et	  al.	  	  2002],	  breast	  [Kleer	  et	  
al.	  2003]	  and	  bladder	  [Arisan	  et	  al.	  2005,	  Raman	  et	  al.	  2005,	  Weikert	  et	  al.	  2005],	  but	  also	  in	  my	  
own	  study.	  The	  different	   stoichiometry	  of	   the	  PRC	  members	  can	   facilitate	   the	   formation	  of	   this	  
alternative	  PRC	  complex	  [Kuzmichev	  et	  al.	  2005],	  adding	  another	   layer	   in	  the	  regulation	  of	  gene	  
expression.	  Epigenetic	   changes	  happening	   in	   the	  early	   stages	  of	  glioma	  development	  may	   favor	  
the	   expansion	   of	   cells	   harbouring	   genetic	   lesions,	   providing	   a	   substrate	   for	   accumulation	   of	  
further	  genomic	  or	  epigenomic	  alterations.	  Furthermore,	  this	  aberrant	  system	  is	  maintained	  once	  
established	   because	   H3K27me3,	   as	   well	   as	   genetic	   mutations,	   is	   mitotically	   inheritable	  
[Margueron	  et	  al.	  2009].	  	  
While	  I	  showed	  that	  EZH2	  is	  necessary	  in	  the	  early	  stage	  of	  glioma	  formation,	  I	  demonstrated	  that	  
it	   is	   dispensable	   in	   later	   phases,	   represented	   here	   by	   secondary	   tumorigenesis	   experiments.	  
Another	  important	  epigenetic	  mark	  that	  is	  modified	  in	  early	  stages	  of	  cancer	  is	  DNA	  methylation.	  
It	   was	   demonstrated	   that	   PcG	   proteins,	   and	   particularly	   EZH2,	   are	   able	   to	   directly	   control	   the	  
deposition	   of	   this	   mark	   by	   interacting	   with	   the	   DNA	   methyl	   transferases	   (DNMTs)	   [Vire	   et	   al.	  
2006].	   Generally,	   in	   normal	   tissues	   pericentromeric	   hetrochromatin	   and	   retrotransposons	  
elements	   are	   hypermethylated,	   while	   CpG	   islands	   at	   gene	   promoters	   are	   hypomethylated.	   In	  
cancer	   this	   paradigm	   is	   subverted	   and	   characterized	   by	   genome-­‐wide	   hypomethylation	   causing	  
genomic	   instability,	   while	   at	   some	   specific	   loci,	   CpG	   islands	   found	   in	   gene	   promoters	   are	  





the	  majority	  of	  genes	  that	  undergo	  de	  novo	  DNA	  hypermethylation	  in	  cancer	  bear	  H3K27me3	  in	  
normal	   tissue	   [Ohm	   et	   al.	   2007,	   Schlesinger	   et	   al.	   2007,	   Widschwendter	   et	   al.	   2007]	   and	   PcG	  
targets	   genes	   are	   preferentially	   methylated	   in	   poorly	   differentiated	   tumors	   [Ben-­‐Porath	   et	   al.	  
2008].	   In	   their	   studies	   Widshwendter	   et	   al.	   and	   Ohm	   et	   al.	   postulated	   also	   that	   the	   DNA	  
methylation	  pattern	   found	   in	   cancer	  might	   reflect	   the	   chromatin	   status	  of	   the	   cells	   from	  which	  
the	   tumor	   developed,	   cells	   in	   which	   a	   reversible	   epigenetic	   repressive	   mark	   as	   H3K27me3	   is	  
replaced	   by	   a	   permanent	   silencing,	   locked	   in	   by	   DNA	   methylation.	   Also	   DNA	   methylation	   is	  
mitotically	  inheritable	  [Hansen	  et	  al.	  2008]	  and	  once	  established	  it	  can	  be	  passed	  over	  subsequent	  
cell	  generations.	  My	  study	  raises	  the	  possibility	  that	  once	  driven	  by	  H3K27me3	  and	  permanently	  
established	  by	  DNMTs,	  DNA	  methylation	  could	  be	  sufficient	  to	  control	  the	  glioma	  gene	  expression	  
pattern	  and	  thus	  no	  longer	  require	  PRC2	  to	  be	  maintained.	  
The	  requirement	  of	  Ezh2	  in	  the	  early	  period	  of	  gliomagenesis	  and	  its	  dispensability	  at	  later	  points	  
was	  confirmed	  in	  both	  the	  systems	  chosen	  for	  this	  study,	  indicating	  that	  the	  critical	  role	  of	  Ezh2	  is	  
independent	  of	  the	  glioma-­‐driving	  mutations.	  This	  finding	  sets	  the	  stage	  for	  further	  investigations	  
aimed	   at	   identifying	   the	   existence	   of	   a	   common	  mechanism	   that	   regulates	   gliomagenesis.	   It	   is	  
possible	   that	   one	   or	   few	   molecular	   pathways	   are	   universally	   altered	   at	   the	   earliest	   stages	   of	  
different	  gliomas,	  either	  through	  genetic	  mutations	  or	  by	  epigenetic	  modification	  (e.g.	  epigenetic	  
silencing,	   which	   is	   an	   alternative	   mechanism	   underlying	   gene	   loss	   of	   function)	   through	   an	  
instructive	   mechanism.	   Once	   the	   common	   axis	   has	   been	   established,	   other	   alterations	   can	  
contribute	   to	   the	   final	  phenotype,	   in	   terms	  of	  histotype,	  gene	  expression	  profile,	  prognosis	  and	  
response	   to	   therapy.	   Those	   alterations	   might	   be	   due	   to	   the	   genomic	   instability	   or	   to	   other	  
mechanisms	   that	   either	   in	   an	   adaptive	   or	   in	   a	   random	   manner,	   selected	   afterwards	   in	   a	  
evolutionary	  fashion,	  hit	  different	  loci	  in	  the	  genome.	  
Taking	   advantage	   of	   the	   intrinsic	   possibility	   of	  my	  model	   systems	   to	   isolate	   homogeneous	   cell	  
populations	  that	  have	  different	  tumorigenic	  potential,	  I	  explored	  the	  relocation	  of	  H3K27me3	  and	  
the	   gene	   expression	   profile	  modifications	   in	   tumorigenic	   astrocytes	   and	   primary	   tumor	   glioma	  





analysis,	   I	   identified	  about	  1700	  genes	  that	  were	  differentially	  expressed	  (i.e.	  consistently	  up-­‐	  or	  
down-­‐	   regulated	   in	   two	   different	   samples)	   between	   tumorigenic	   astrocytes	   and	   primary	   GPCs.	  
The	  transcriptomes	  of	  poorly	  differentiated	  gliomas	  show	  what	  has	  been	  defined	  as	  “embrionyc	  
stem	  cell	  (ESC)-­‐like	  signature”,	  in	  which	  PcG	  targets	  are	  under-­‐expressed	  [Ben-­‐Porath	  et	  al.	  2008];	  
consistent	   with	   this	   finding,	   biological	   processes	   associated	   to	   our	   down-­‐regulated	   gene	   set	  
concern	  typical	  functions	  orchestrated	  by	  PcG,	  namely	  development	  and	  differentiation	  [Bracken	  
et	  al.	  2006].	  The	  analysis	  of	  the	  redistribution	  of	  H3K27me3	  revealed	  that	  almost	  1600	  genes	  are	  
affected	  by	  the	  relocalization.	  Of	  these,	  roughly	  1000	  acquired	  the	  K27	  trimethylation	  while	  about	  
550	  lost	  it	  during	  glioma	  formation.	  Interestingly,	  comparing	  the	  H3K27me3	  occupancy	  data	  with	  
the	  transcriptome	  profiling,	  we	  found	  that	  only	  100	  of	  the	  1098	  down-­‐regulated	  genes	  acquired	  
the	  mark,	  while	  the	  vast	  majority	  genes	  belonging	  to	  this	  subset	  were	  unmethylated	  in	  astrocytes	  
and	   retain	   this	   status	   also	   in	   primary	   GPCs.	   Strikingly,	   a	   small	   portion	   of	   genes	   that	   are	   up-­‐
regulated	   in	   gliomas	  acquired	   the	  H3K27me3;	   from	  previous	   studies	  of	  PcG	   target	   sites	   in	  both	  
Drosophila	  and	  mammals	  it	  has	  already	  been	  shown	  that	  the	  presence	  of	  the	  H3K27me3	  mark	  at	  
gene	  promoters	   is	   compatible	  with	   transcriptional	   activity	   [Ringrose	  et	   al.	   2004,	   Schwartz	  et	   al.	  
2006,	  Pasini	  et	  al.	  2007].	  All	  these	  results	  have	  several	  implication	  for	  the	  biology	  of	  gliomas.	  First,	  
GPCs	  acquire	  and	  maintain	  a	  more	  undifferentiated	  profile,	  compared	  to	  tumorigenic	  astrocytes	  
by	   inhibiting	   pathways	   related	   to	   development	   and	   differentiation;	   this	   is	   consistent	   with	   two	  
major	   findings	   in	   the	   field	   that	   demonstrated	   how	   GPCs	   have	   aberrant	   developmental	   blocks	  
making	   them	  similar	   to	  neural	   stem	  cells	   [Lee	  et	   al.	   2008,	  Abdouh	  et	   al.	   2009]	   and	  how	  poorly	  
differentiated	  tumors	  restore	  an	  ESC-­‐like	  molecular	  signature	  through	  the	  down-­‐regulation	  of	  ESC	  
Polycomb	   targets	   [Ben-­‐Porath	   et	   al.	   2008].	   Second,	   the	   redistribution	   of	   the	   H3K27me3	   mark	  
happens	   at	   about	   6-­‐7%	   of	   genes	   in	   the	   genome;	   roughly	   two	   thirds	   (1049	   out	   of	   1603)	   of	   the	  
involved	   genes	   acquire	   the	  mark,	   but	   only	   one	   tenth	   (100	   out	   1049)	   are	   down-­‐regulated.	   This	  
strengthens	   the	  hypothesis	   that	  PcG	  mediated	   regulation	   requires	  other	  effectors	   to	  be	  unfold,	  
such	  as	  transcriptional	  activator	  or	  repressors,	  and	  that	  histone	  modifications	  can	  have	  different	  





al.	  2012],	  as	  for	  example	  the	  one	  described	  for	  bivalent	  domains	   in	  which	  H3K27me3	  is	  coupled	  
with	   H3K4me3	   and	   results	   in	   low	   expression	   levels	   [Bernstein	   et	   al.	   2006],	   or	   changes	   in	   the	  
“reading	   machinery”	   of	   the	   histone	   code	   can	   affect	   the	   transcriptional	   activity.	   Third,	   in	   my	  
comparative	  analysis	   I	  found	  that	  the	  vast	  majority	  of	  up-­‐	  or	  down-­‐regulated	  genes	  were	  H3K27	  
unmethylated	  in	  astrocytes	  and	  remained	  so	  in	  GPCs,	  suggesting	  that	  the	  regulation	  of	  few	  genes	  
through	  epigenetic	  modifications	  can	   lead	  to	  a	  cascade	  of	  events	  that	   initiate	  circuitry	  effect	  on	  
the	   entire	   transcriptome.	   This	   is	   quite	   well	   exemplified	   by	   the	   case	   of	   ZFP423,	   a	   transcription	  
factor	   that	   is	   found	   to	   be	   H3K27me3	   and	   downregulated	   in	   my	   GPCs	   samples.	  Moreover,	   the	  
transcription	   factor	  binding	  site	  overrepresentation	  analysis	   showed	   that	  more	   than	  10%	  of	   the	  
genes	  among	  our	  DEGs	  (219	  out	  of	  1738)	  has	  a	  consensus	  sequence	  for	  ZFP423.	  This	  TF	  has	  both	  
activating	  and	  repressive	  activity.	  Among	  its	  219	  targets	  in	  our	  DEG	  set,	  I	  identified	  the	  Delta-­‐like	  
protein	   3	   (DLL3)	  which	   is	   thought	   to	   block	   astrocyte	   differentiation.	  Both	  DLL3	   and	   ZFP423	   are	  
involved	   in	   the	  Notch	   signaling	   pathway.	  When	  DLL3	   binds	   to	  Notch	   receptor,	   the	   intracellular	  
domain	   of	   the	   receptor	   is	   cleaved	   [Brou	   et	   al.	   2000,	   Mumm	   et	   al.	   2000]	   and	   induces	   the	  
transcription	   of	   target	   genes	   including	   Hes1	   and	   Hes5,	   two	   basic	   helix-­‐loop-­‐helix	   (bHLH)	  
transcription	   factors	   that	   are	   known	   to	   inhibit	   neuronal	   differentiation	   [Ohtsuka	   et	   al.	   1999,	  
Hatakeyama	   et	   al.	   2004].	   ZFP423	   interacts	  with	   the	   intracellular	   domain	   of	   the	  Notch	   receptor	  
inducing	  the	  transcription	  of	  Hes5;	  moreover	  since	  it	  is	  known	  to	  interact	  with	  SMAD	  proteins	  in	  
response	   to	   BMP	   signaling,	   and	   that	   BMP	   can	   induce	  Hes5	   expression	   in	   neuroepithelial	   cells	  
[Takizawa	  et	  al.	  2003],	  it	  has	  been	  postulated	  that	  ZFP423	  can	  coordinate	  the	  activity	  of	  the	  Notch	  
and	  BMP	  pathways	  by	   regulating	   the	  expression	  of	  Hes5	   [Masserdotti	   et	   al.	   2010].	   If	   validated,	  
this	  could	  be	  a	  clear	  example	  of	  a	  cascade	  mechanism	  by	  which	  the	  methylation	  of	  a	  single	  or	  at	  
most	   few	   genes,	   particularly	   transcription	   factor	   with	   pleiotropic	   effects	   on	   the	   transcriptional	  
activity	  of	  target	  genes,	  entailed	  multiple	  effects,	  including	  a	  differentiation	  block	  that	  helps	  GPCs	  
maintain	  a	  NSC-­‐like	  state.	  	  	  	  
The	   two	   glioma	   samples	   analyzed	   so	   far	   appear	   nearly	   identical	   at	   the	   transcriptional	   level	   but	  





drives	   tumorigenesis,	   at	   least	   in	   the	  early	  phase.	   It	  will	  be	  very	   interesting	  now	   to	  examine	   the	  
same	   properties	   in	   the	   second	   model	   that	   was	   chosen	   to	   probe	   the	   results	   obtained	   in	   the	  
astrocyte-­‐based	   model.	   If	   the	   trimethylation	   of	   H3K27	   will	   hit	   loci	   that	   have	   already	   been	  
identified	   as	  methylated	   in	   this	   preliminary	   analysis,	   it	  will	   be	   a	   further	   step	   in	   order	   to	   find	   a	  
common	   basic	   mechanism	   that	   sets	   in	   to	   drive	   glioma	   formation.	   Also	   the	   comparison	   of	   the	  
transcriptomes	   can	   reveal	   alterations	   that	   are	   taking	   place	   and	   whether	   there	   is	   a	   common	  
underlying	   signature	   or	   pathway	   in	   different	   gliomas.	   Indeed,	  much	  of	   the	  work	   present	   in	   the	  
literature	  of	  the	  last	  years	   is	  aimed	  at	   identifying	  differences,	  rather	  than	  common	  mechanisms,	  
with	   the	  main	   focus	   of	   tailoring	   the	   therapy	   according	   to	  molecular	   alterations.	   The	   caveat	   in	  
these	   studies	   is	   that	   they	   are	   performed	   at	   later	   stages	   of	   the	   disease,	   when	   the	   genomic	  
instability	  and	  other	  processes	  could	  have	  further	  perturbed	  the	  initial	  (common)	  landscape.	  
The	  identification	  of	  a	  molecular	  signature	  in	  order	  to	  define	  molecular	  subclasses	  of	  gliomas	  has	  
been	   strongly	   pursued	   in	   the	   last	   years;	   several	   studies	   tried	   to	   solve	   this	   issue,	   reporting	  
successful	  identification	  of	  glioma	  profiles,	  but	  a	  unified	  picture	  is	  still	  missing	  [Phillips	  et	  al.	  2006,	  
Li	   et	   al.	   2009,	   Verhaak	   et	   al	   2010].	   This	   can	   be	   due	   to	   different	   biases,	   as	   intrinsic	   biological	  
variability,	  abnormal	  data	  distribution	  (e.g.,	  skewed	  distribution	  that	  was	  thought	  to	  be	  Gaussian)	  
in	   the	   tumor	   samples	   compared	   to	   normal	   tissue	   and	   analytical	   factors	   due	   to	   commonly	  
employed	  algorithms	  [Marko	  et	  al.	  2011].	  I	  testified	  the	  lack	  of	  consistency	  among	  different	  data	  
sets	  by	  comparing	  gene	  expression	  profiles	  published	  in	  three	  different	  studies	  [Phillips	  et	  al	  2006,	  
Carro	  et	  al.	  2010,	  Verhaak	  et	  al.	  2010];	  despite	  the	  limited	  overlap	  among	  the	  reported	  signatures,	  
up-­‐regulated	  genes	  in	  my	  DEG	  dataset	  were	  always	  enriched	  for	  genes	  belonging	  to	  the	  proneural	  
subtypes.	  The	  overlap	  of	  the	  three	  proneural	  signatures	  defined	  by	  Phillips,	  Carro	  and	  Verhaak	  is	  
reduced	  to	  21	  genes,	  but	  9	  out	  of	  these	  21	  are	  also	  found	  to	  be	  upregulated	  in	  my	  experiment.	  I	  
can	  then	  argue	  that,	  despite	  the	  weakness	  of	  the	  human	  molecular	  classification,	  my	  data	  seem	  to	  
be	  invariably	  correlated	  with	  the	  human	  proneural	  profile.	  Two	  are	  the	  possible	  scenarios	  at	  this	  
point.	   In	   the	   first,	   there	   is	   a	   correspondence	   between	   the	   mouse	   model	   and	   the	   human	  





two	  systems	  and	  that	  form	  a	  strong	  “core”	  for	  the	  proneural	  signature.	  The	  second	  instead	  is	  that,	  
regardless	  of	  the	  driving	  mutation,	  modeling	  glioma	  in	  the	  mouse	  will	  always	  give	  rise	  to	  tumors	  
belonging	  to	  the	  proneural	  signature.	  It	  has	  already	  been	  published	  that	  glioma	  developed	  using	  
the	   p53-­‐/-­‐/Pten-­‐/-­‐/PDGF	   model	   correspond	   to	   this	   particular	   gene	   expression	   profile	   [Lei	   et	   al.	  
2011].	  To	  partially	  settle	  this	  controversy,	  it	   is	  now	  of	  primary	  importance	  to	  extend	  my	  analysis	  
on	  a	  larger	  cohort	  of	  samples	  and	  see	  if	  the	  relation	  with	  the	  human	  counterpart	  still	  holds.	  Even	  	  
more	  important	  will	  be	  to	  repeat	  the	  same	  screening	  on	  the	  second	  glioma	  model	  I	  adopted.	  
In	   conclusion,	   results	   presented	   in	   this	  work	   revealed	   the	   relevance	   of	   Ezh2	   activity	   during	   the	  
early	  stages	  of	  gliomagenesis,	  which	  on	  the	  contrary	  is	  no	  longer	  required	  for	  the	  maintenance	  of	  
the	   tumor.	   This	   suggests	   that	   there	   is	   a	   narrow	   time	   window	   in	   which	   the	   Polycomb	   axis	   is	  
required	   and	   that	   probably	   this	   happens	   before	   the	   establishment	   of	   other	   molecular	  
mechanisms	  that	  enable	  the	  GPC	  pool	  to	  escape	  from	  this	  dependency.	  Furthermore,	  H3K27me3	  
relocation	   upon	   tumorigenesis	   seems	   to	   happen	   consistently	   in	   different	   glioma	   samples,	  
highlighting	  the	  instructive	  properties	  of	  this	  process	  and	  causing	  almost	  identical	  effects	  on	  the	  
transcriptome,	   suggesting	   the	  existence	  of	  a	   “starting”	  PcG-­‐dependent	  molecular	   signature	   that	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